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Interventional oncology (IO) is a rapidly evolving sub-specialty of interventional ra-
diology with increasing importance in the management of cancer patients. Over the 
past two decades interventional radiologists together with scientists have ridding the 
tidal wave of technological innovation to introduce multiple novel cancer treatments. 
Therapies such as percutaneous ablation, drug-eluting bead trans-arterial chemo-
embolization and radioembolization have found their way to clinical practice and are 
now considered standard of care for various indications. As interventional radiology 
procedures are targeted minimally invasive therapies, complication rates are generally 
low and hospital admissions short. This offers clear advantages over surgical procedures 
and intense chemotherapeutic regimes that put a larger burden on both the health care 
budget and patients.
IO is a relatively new medical specialty compared to other specialties involved in cancer 
care, such as surgery, radiotherapy and medical oncology. Whereas many surgical pro-
cedures and chemotherapeutic therapies have gone through decades of improvements 
and evaluation in clinical research and trials, some of the IO procedures have only been 
introduced in clinical practice over recent years. There is a need for further research to 
optimize novel minimally invasive therapies and to determine the role in the treatment 
algorithms for various cancer types.
LIVeR MALIGnAnCIes
Liver malignancies have been at the center of attention of interventional oncologists. 
The liver has several unique features that can be utilized when performing minimally 
invasive image-guided therapies. It is the largest solid organ in the human body and oc-
cupies much of the right hypochondrial region of the upper abdomen. The location, size 
and texture of the liver allow excellent visualization with ultrasonography. Furthermore, 
the liver has a unique dual blood supply. Most of the blood supply to the hepatocytes 
is derived from the portal vein (70-80%) and the hepatic arteries supply the remaining 
20-30%. In contrast, most hepatic malignancies have a dominant or exclusive vascular 
supply from the hepatic artery. The difference in vascularization between non-tumorous 
liver parenchyma and liver malignancies is utilized in transarterial therapies, such as 




Most patients in this thesis are patients with hepatocellular carcinoma (HCC). Primary 
liver cancer is a rare disease in the Netherlands, but the third most common cause of 
cancer-related death in the world (1). HCC represents more than 90% of primary liver 
tumors and the incidence of HCC in Europe is estimated to increase from 21.000 cases 
in 2008 to 78.000 cases in 2020 (1). Approximately 90% of HCC are associated with an 
underlying liver disease (1). At the time of diagnosis, the majority of patients with HCC 
are not surgical candidates. Surgical resection may not be feasible as a result of tumor 
location, advanced stage of disease or contra-indications such as liver cirrhosis with 
portal hypertension, deranged liver function or co-morbidity. 
For patients who are not surgical candidates, minimally invasive image-guided thera-
pies are often the treatment of choice. In patients with very early stage according to the 
Barcelona Clinic Liver Cancer (BCLC) staging system (HCC <2cm), percutaneous ablation 
is the treatment of choice for patients who are not a candidate for liver transplantation. 
Ablation is the first-line therapy for patients with BCLC early stage (≤3 HCC of ≤3cm 
each), if surgical resection or transplantation is contra-indicated (2). In patients with 
BCLC intermediate stage, the superiority of transarterial chemo-embolization (TACE) 
over best-alternative care has been demonstrated in two randomized controlled trials 
(3,4). The efficacy of transarterial radioembolization has been proven in several phase II 
and retrospective studies in patients with either intermediate or advanced BCLC stage 
(5,6).
secondary liver malignancies
The liver is a predilection site for metastases from various malignancies. The high inci-
dence of liver metastases may be attributed to several factors. First, the likelihood of 
metastatic deposits is increased as a high volume of blood perfuses the liver. The liver 
has an extensive capillary network and therefore blood flow in the liver is relatively slow, 
increasing the likelihood that tumor cells nestle in the liver (7). Second, several organs 
with a high incidence of malignancies, such as the colon and pancreas, drain into the 
portal vein through the splanchnic veins and subsequently into the capillary bed of the 
liver. Finally, the endothelium of the liver sinusoids lacks a basal lamina and endothelial 
fenestration may allow tumor cells to exit the bloodstream more easily (7).
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MInIMALLY InVAsIVe, IMAGe-GUIDeD LIVeR InteRVentIons
Radiofrequency ablation
Radiofrequency ablation (RFA) is the most commonly used ablation technique used for 
the treatment of liver tumors. After placement of a RFA probe into a tumor using a per-
cutaneous or open approach, an alternating electrical current can be delivered through 
the RFA probe. This causes ionic cell agitation that results in heat generation. The heat is 
generated in an active zone around the tip of the RFA probe and more peripheral areas 
receive heat through thermal conduction. RFA is most suitable for tumors smaller than 
3cm as larger tumors are associated with higher local tumor recurrence rates (8-10). 
Much of the research on ablation focuses on ways to reduce recurrence rates. More 
accurate tumor targeting and improved response assessment is essential in achieving 
better outcomes after RFA. Also, on-going trials are analyzing the efficacy of combina-
tion treatment of RFA with either other locoregional therapies or systemic therapy. 
Furthermore, new RFA systems and alternative ablation techniques, such as microwave 
ablation (MWA) and irreversible electroporation (IRE), have been introduced over recent 
years.
transarterial chemoembolization
Transarterial chemoembolization (TACE) was accepted as the first line treatment in 
patients with intermediate stage HCC after two randomized trials showed the superior-
ity of TACE over best alternative care (3,4). TACE has not been widely adopted in the 
Netherlands as a treatment for secondary tumors, but there is growing scientific evi-
dence that TACE offers symptomatic relieve and/or survival benefit in patients with liver 
metastases from various histologic origins (11,12). Over the past decade, there has been 
an increased use of TACE with drug-eluting beads. These embolic beads can be pre-
loaded with a chemotherapeutic agent and allow a sustained, local drug release with 
lower systemic toxicity (13). The availability of smaller micro-catheters, allowing more 
selective hepatic artery catheterization, and better imaging techniques, such as cone-
beam computed tomography (CBCT) and computed tomography hepatic arteriography 
(CTHA), has led to more accurate tumor targeting. Nevertheless, recurrence rates after 
TACE are high and the long-term prognosis remains poor. There is an on-going demand 
for improvements in patient selection, tumor targeting and response assessment.
Radioembolization
The liver has low tolerance to external radiation therapy, and cirrhosis further decreases 
this tolerance. External beam radiation may cause radiation-induced liver disease at a 
whole liver dose exceeding 40 Gray (Gy), but such a dose is generally insufficient to 
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cause necrosis in liver tumors (14). Radioembolization enables delivery of a high radia-
tion dose to a liver tumor with limited radiation injury to the non-tumorous liver tissue. 
Radioembolization is a form of brachytherapy, in which microspheres loaded with a 
radionuclide are delivered to the hepatic tumors by selective hepatic arterial infusion. 
Currently, microspheres loaded with either yttrium-90 (SIR-spheres or Theraspheres) or 
Holmium-166 (QuiremSpheres) are commercially available. The infused microspheres 
lodge permanently within the vascular bed of the tumor to deliver high-energy ß-radi-
ation. Each microsphere has a limited therapeutic range (mean tissue range 2.5-3.2mm; 
maximum 9-11mm), but radiation of the entire tumorous region can be achieved by 
infusion of large numbers of spheres. Radioembolization has been proven to be an ef-
fective treatment for patients with irresectable HCC and is used in clinical practice to 
treat intermediate and advanced stages of this disease (6,15). Also, radioembolization 
has gained acceptance as an effective treatment in patients with liver metastases from 
colorectal carcinoma and other tumors (16).
Percutaneous hepatic perfusion
The unique hepatic anatomy allows vascular isolation of the liver from the systemic 
blood circulation Percutaneous hepatic perfusion (PHP) is a novel minimally invasive 
technique that enables vascular isolation and perfusion of the liver with the use of en-
dovascular techniques (17). This technique allows administration of a very high dose of 
chemotherapy to the liver with limited systemic side effects. This innovative therapy has 
been shown to be effective, especially in patients with hepatic metastases from ocular 
melanoma (17).
AIM AnD oUtLIne oF tHIs tHesIs
The aim of this thesis is to evaluate and advance minimally invasive image-guided liver 
therapies. Current practices and therapies are evaluated and new imaging techniques 
and treatment strategies are analyzed. PART I focuses on image-guided percutaneous 
RFA. In chapter 2, the results are presented of a retrospective study of 279 HCC patients 
treated with percutaneous RFA in either a tertiary referral center in Northern-Europa or 
South-East Asia. The study investigates how differences in base-line patient characteris-
tics may vary per geographical region and influence long-term outcome. Chapter 3 is a 
phantom study that investigates the accuracy of electromagnetic fusion of volumetric 
computed tomography (CT) with real-time ultrasonography (US). Such fusion imaging 
may enable US-guided targeting of tumors, even if lesions are inconspicuous on US. In 
the phantom study, manual fusion of images is compared with automatic and semi-au-
tomatic fusion and the accuracy and errors of fusion imaging are investigated. In chapter 
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4, the efficacy of RFA with adjuvant drug-eluting bead TACE is evaluated in patients with 
HCC >3cm. PART II discusses transarterial liver therapies. The subject of chapter 5 is a 
prospective study comparing catheter-directed contrast-enhanced ultrasound (CCEUS) 
and catheter-directed computed tomography hepatic arteriography (CTHA) as adjuncts 
to digital subtraction angiography (DSA) to guide TACE. Chapter 6 describes the feasibil-
ity and safety of yttrium-90 (Y90) infusion into the right inferior phrenic artery in large 
HCC tumors with extra-hepatic vascular supply, using CTHA in addition to DSA to plan 
and execute therapy.. The superior imaging capabilities of CTHA are also demonstrated 
in Chapter 7. As shown in this chapter, CTHA enables better detection of the falciform 
artery compared to DSA and Tc99m-macroaggregated albumin single photon emission 
computed tomography with integrated computed tomography (Tc99m-MAA SPECT/
CT). The value of CTHA is further illustrated in Chapter 8 that discusses the development 
of personalized predictive dosimetry in radioembolization with the use of artery-specific 
SPECT/CT partition modeling. Chapter 9 is a review of the current literature on PHP. The 
results of a prospective pharmacological study investigating the efficacy and safety of 
the Delcath GEN2 filter are reported in Chapter 10. PART III is a short but indispensible 
part of this thesis. In Chapter 11, a prospective study is presented that evaluates the im-
pact of an outpatient interventional radiology clinic on patient safety and satisfaction. 
Finally, the main conclusions of this thesis are summarized and discussed in Chapter 12.
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Differences in patient characteristics and midterm outcome 
between Asian and European patients treated with 
radiofrequency ablation for hepatocellular carcinoma
Burgmans MC, Too CW, Fiocco M, Kerbert AJC, Lo RH, Schaapman JJ, van Erkel AR, Coenraad 
MJ, Tan BS




The aim of this study was to compare patient characteristics and mid-term outcome 
after RFA for unresectable hepatocellular carcinoma (HCC) in an Asian and European 
cohort
Methods
The study was based on retrospective analysis of 279 patients (mean 64.8 ± 12.1 years; 
208 males) treated with RFA for de novo HCC in tertiary referral centers in Singapore and 
the Netherlands, with median follow-up of 28.2 months (quartiles: 13.1-40.5 months). 
Cumulative incidence of recurrence and death were analyzed using a competing risk 
model.
Results
Age was higher in the Asian group: 66.5 versus 60.1 years (p<0.0001). The most common 
etiology was hepatitis B in the Asian group (48.0%) and alcohol-induced cirrhosis in Eu-
ropeans (54.4%); p<0.001. Asian patients had less advanced disease: 35.5%, 55.0% and 
3.0% respectively had BCLC 0, A and B versus 21.5%, 58.2% and 15.2% in the European 
group (p=0.01). The cumulative incidence of recurrence in the Asian group at 1, 2, 3 
and 5 years was 37.0%, 56.4%, 62.3% and 67.7% respectively compared to 32.6%, 47.2%, 
49.7% and 53.4% in the European group (p=0.474).
At 1, 2, 3 and 5 years the cumulative incidence of death in the Asian group was 2.0%, 
3.9%, 4.9% and 4.9% respectively and 7.7%, 9.2%, 14.1% and 21.0% in the European 
group (p=0.155).
Conclusion
Similar short-term treatment outcomes are achieved with RFA in HCC patients in the 
South-East Asian and Northern-European populations. Midterm recurrence and death 
rates differ between the groups as a result of differences in baseline patient character-
istics and patient selection. Our study provides insight relevant to the design of future 
international studies.
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IntRoDUCtIon
Hepatocellular carcinoma (HCC) is a heterogeneous condition with multiple variables 
affecting the course of the disease. The prognosis is not only determined by the tumor 
burden, but also by the liver function and performance status of a patient. In order to 
have stratification and prognostication ability, most staging systems have incorporated 
various prognostic factors (1-6). The Barcelona Clinic Liver Cancer (BCLC) classification 
system is the most widely adopted staging system for HCC worldwide and is endorsed 
by the European Association for the Study of the Liver (EASL) and American Associa-
tion for the Study of Liver Disease (AASLD) (7,8). The Asian Pacific Association for the 
Study of the Liver (APASL) guidelines are based on results from many of the randomized 
controlled trials and cohort studies that were also used to devise the BCLC schedule, and 
both guidelines use similar eligibility criteria for RFA (9). Despite adherence to similar 
treatment guidelines, outcomes in daily clinical practice are unlikely to be the same in 
different parts of the world as a result of geographical differences in characteristics and 
etiology of HCC. In East-Asia, the incidence rates of HCC are high and most HCC cases are 
attributable to chronic hepatitis B infection (7,10). In Northern-European countries, HCC 
is not prevalent, and chronic hepatitis C and alcohol-induced liver disease are the most 
dominant predisposing risk factors (7,10).
Prospective clinical trials have been essential in the development of treatment guidelines, 
but often only recruit patients from a particular region and according to strict eligibil-
ity criteria. Real-world observational studies are needed to provide insight into how the 
implementation of HCC guidelines has affected patient care in different geographical 
regions. The aim of our descriptive study was to compare the patient characteristics and 
midterm outcome after RFA for unresectable, de novo HCC in an Asian and European pa-
tient cohort. In this retrospective study, the cumulative incidence of recurrence and death 
after RFA were analyzed in large centers both in South-East Asia and Northern Europe.
MetHoDs
Patients
We conducted a retrospective analysis of a patient cohort in a high-volume hospital 
in Singapore and the Netherlands. Both institutions were tertiary referral centers with 
dedicated care for hepato-biliary diseases and liver transplant programs. The local 
medical ethics committee of both institutions approved the retrospective study and 
informed consent was waived for the analysis. Between January 2009 and March 2014, 
442 consecutive patients were treated with percutaneous RFA for unresectable HCC 
22 Chapter 2
in the radiology department of one of the two centers. Of the 442 patients, 163 had 
undergone previous HCC treatment, i.e. ablation, resection, transplantation or transarte-
rial chemoembolization, and these were excluded from the analysis. All remaining 279 
patients (mean age ± standard deviation (SD): 64.8 ± 12.1 years; 208 males) were treated 
with RFA because of newly diagnosed HCC. The diagnosis was based on either tumor 
histology (n=30) or on radiological imaging criteria according to guidelines by the 
EASL or the APASL (n=249) (7,9). For radiological confirmation of the diagnosis, multi-
phase contrast-enhanced computed tomography (CECT) and/or dynamic gadolinium-
enhanced magnetic resonance imaging (GE-MRI) was used. Arterial hyperenhancement 
of a lesion with wash-out in the delayed phase was considered to be diagnostic of HCC 
in patients with liver cirrhosis or chronic hepatitis B/C. 
Similar eligibility criteria were used in both centers for local ablation and these were in 
accordance with the BCLC and APASL treatment guidelines: a single tumor measuring 
≤5 cm or a maximum of 3 HCCs measuring ≤3cm each and Child Pugh A or B status (7,9). 
In exceptional cases, RFA was offered also outside BCLC and APASL criteria. In patients 
with two tumors, RFA was considered if only one HCC measured more than 3cm and 
no more than 5 cm. Patients with Child Pugh C who were on the waiting list for liver 
transplantation could undergo RFA as a bridging therapy to transplantation. Contra-
indications for RFA were: significant and uncorrectable coagulopathy, extrahepatic 
metastasis, or macrovascular invasion, and severe liver dysfunction (Child-Pugh C) in a 
patient not eligible for liver transplantation.
Radiofrequency ablation
All patients gave informed consent prior to treatment. Percutaneous RFA was per-
formed using ultrasound and/or CT guidance. In the European center, procedures were 
performed under general anesthesia. Local anesthesia and conscious sedation with 
midazolam and fentanyl were used in the Asian center.
Both centers used similar RFA equipment: either a single electrode was used (3 cm ex-
posed tip Cooltip (Covidien, Gosport Hamspire, United Kingdom) or multiple electrodes 
with a switch-control system (3 or 4 cm exposed tip Cooltip). Ablation was performed 
for 12 (single Cooltip electrode) or 16-20 minutes (multiple Cooltip electrodes) using 
standard impedance controlled ablation. In the European center, CECT was performed 
immediately after ablation on a spiral CT (Aquilion 16, Toshiba, Tokyo, Japan). If this CT 
showed residual tumor enhancement, immediate re-ablation was performed. In the 
Asian center, CECT was performed 1 day after ablation (Aquillion 64, Toshiba, Tokyo, 
Japan). If the CECT showed residual tumor enhancement, re-ablation was performed 
during the same or subsequent admission, dependent on the patient’s preference.
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Follow-up
All patients were scheduled for follow-up examinations every 3 months after RFA, in-
cluding liver function tests and multiphase CECT or dynamic GE-MRI. In the European 
center, these examinations were also performed at 6 weeks after RFA.
Recurrence was defined as local tumor progression (LTP) and/or a new intrahepatic 
tumor distant from the treated tumor. Recurrence was distinguished from incomplete 
ablation. Tumor enhancement on the CECT performed immediately or 1 day after RFA, 
was classified as incomplete ablation and treated with repeated RFA until complete ra-
diological ablation was achieved. Patients were followed until last follow-up date, death, 
or till the end of the study.
The median follow-up for all patients was 28.2 months (quartiles: 13.1–40.5 months).
statistical analysis
Comparisons between the two groups were done by student t-test for continuous 
variables and Pearson Chi-Square test for categorical variables using two-sided tests. 
A competing risk model with recurrence and death as competing events was used to 
estimate the cumulative incidence of recurrence and death per center. To study the 
impact of prognostic factors on recurrence the cause specific hazard ratios were esti-
mated by employing a Cox proportional hazard regression model with transplantation 
as time-dependent risk factor (11). A Cox’s proportional hazard model was employed 
to study the association between risk factors and overall survival with recurrence and 
transplantation as time-dependent risk factors. A difference was considered significant 
when p< 0.05. The statistical analyses were performed using SPSS 21 (IBM, Armonk, NY, 
USA). The competing risks analysis was performed in the R-software environment with 
the mstate library (12,13).
ResULts
Patient characteristics
Baseline demographics of all patients are shown in Table 1. The median age of patients 
in the Southeast Asian group was slightly higher than that of the Northern European 
patients (p<0.0001). Statistically significant differences between the patient groups 
were also seen in underlying liver disease and BCLC stage (p<0.0001 and p=0.01 re-
spectively). In the European patients, alcoholic liver disease was most prevalent (54.4%) 
followed by hepatitis C (22.7%), whereas the majority of Asian patients suffered from 
chronic hepatitis B (48.0%). The percentage of patients without underlying liver disease 
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was much higher in the Asian group compared to the European group: 19.0% versus 
6.3%. The Asian group had a higher percentage of patients with BCLC very early stage: 
35.5% versus 21.5% in the European group. Both the percentage of patients with BCLC 
early stage and intermediate stage were higher in the European group: 58.2% and 








Age (year), mean ± sD 66.5 ± 10.7 60.1 ± 14.3 64.8 ± 12.1 <0.0001
Male/female 144 / 56 
(72,0 / 28,0)
64 / 15 
(81,0 / 19,0)




HBV 96 (48.0) 7 (8.9) 103 (36.9) 
HCV 26 (13.0) 18 (22.7) 44(15.8) 
Alcohol 21 (10.5) 43 (54.4) 64 (22.9) 
nAsH 11 (5.5) 3 (3.8) 14 (5.0) 
Cryptogenic 38 (19.0) 5 (6.3) 43 (15.4) 
others 8 (4.0) 3 (3.8) 11 (3.9) 
AFP (ng/mL), mean ± sD 141,4 ± 753.3✗ 346.9 ± 1600.6♯ 212.7 ± 1122.7 0.289
Child Pugh class 0.248
A 137 (68.5) 48 (60.8) 185 (66.3) 
B 49 (24.5) 27 (34.2) 77 (27.6) 
C 14 (7.0) 4 (5.0) 17 (6.1) 
number of tumors 0.139
1 154 (77.0) 53 (67.1) 207 (74.2) 
2 39 (19.5) 24 (30.4) 63 (22.6) 
3 7 (3.5) 2 (2.5) 9 (3.2) 
Maximal diameter largest tumor (mm), mean ± sD 23.7 ± 11.3 26.8 ± 12.6 24.9 ± 12.5 0.85
Maximal diameter largest tumor 0.106
<10mm 9 (4.5) 0 (0.0) 9 (3.2) 
10-<20mm 84 (42.0) 26 (31.9) 110 (39.4) 
20-30mm 61 (30.5) 26 (32.9) 87 (31.2) 
>30mm 46 (23.0) 27 (34.2) 73 (26.1) 
BCLC stage 0.01
0 71 (35.5) 17 (21.5) 88 (31.5) 
A 110 (55.0) 46 (58.2) 156 (55.9) 
B 6 (3.0) 12 (15.2) 18 (6.5) 
C 0 (0.0) 0 (0.0) 0 (0.0) 
D 13 (6.5) 4 (5.0) 17 (6.1) 
SD = standard deviation HBV = hepatitis B virus. HCV = hepatitis C virus. NASH = non-alcoholic steatosis 
hepatitis. AFP = alpha-fetoprotein BCLC = Barcelona Clinic Liver Cancer.✗55 missing. ♯2 missing.
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15.2%, respectively, versus 55.0% and 3.0% in the Asian group. These differences in BCLC 
stage may be explained by the dissimilarities in Child Pugh class, number of tumors and 
maximal tumor diameter between the two groups. In the Asian group, a higher percent-
age of patients had Child Pugh A status (68.5% versus 60.8%), a single tumor (77.0% 
versus 67.1%), and the mean maximal diameter of the largest tumor was smaller (23.7 ± 
11.3mm versus 26.8 ± 12.6mm). The differences in Child Pugh status, tumor number and 
tumor size did not reach statistical significance.
treatment outcome
In 269 patients (96.4%) technical success was achieved after a single RFA procedure. In the 
remaining 10 patients a second ablation procedure was needed to achieve technical success. 
The cumulative incidence of recurrence showed a similar trend in both the Asian and 
European groups during the first 1.5 years after RFA (Figure 1). At 6, 12 and 18 months, 
the cumulative incidence rates for recurrence in the Asian group were equal to 25.5% 
(95% CI: 19.5-31.6), 37.0% (95% CI: 30.3-43.8) and 49.1% (95% CI: 41.9-56.2) respectively, 
compared to 24.1% (95% CI: 14.7-33.5), 32.6% (95% CI: 22.0-43.2) and 45.5% (95% CI: 
33.8-57.2), respectively, in the European group. The cumulative incidence of recurrence 
was higher in the Asian group at 2, 3 and 5 years: 56.4% (95% CI: 49.1-63.8), 62.3% (95% 
CI: 54.7-69.8) and 67.7% (95% CI: 58.6-76.7), respectively, compared to 47.2% (95% CI: 
35.4-59.0), 49.7% (95% CI: 37.5- 62.0) and 53.4% (95% CI: 40.2-66.6), respectively, in the 
European group. The difference between the cumulative incidences of recurrence for 
the two groups was not significant (p=0.474).
The cumulative incidence of death was higher in the European population compared to 
the Asian group (Figure 1). At 1, 2, 3 and 5 years, the cumulative incidence rates of death 
were 2.0% (95% CI: 0.06-4.0), 3.9% (1.0-6.7), 4.9% (1.5-8.3) and 4.9% (1.5-8.3), respec-
tively, in the Asian group and 7.7% (1.8-13.6), 9.2% (2.7-15.8), 14.1% (5.1-23.1) and 21.0% 
(9.0-33.1) in the European group. The differences in cumulative death between the two 
groups did not reach statistical significance (p=0.155).
Prognostic factors associated with the risk of recurrence
A maximal tumor diameter >3cm and tumor number >1 were independent risk factors 
for recurrence after RFA (Table 2). The cause-specific hazard ratio (csHR) was equal to 
1.568 (95% CI: 1.083-2.271) for patients with HCCs >3cm. Patients with more than 1 
tumor were 1.5 times more like to develop recurrence than patients with a single tumor 
(HRc 1.494 (95% CI: 1.031-2.163). Liver transplantation had a significant protective effect 
on tumor recurrence (HRc 0.065; 95% CI: 0.009-0.480).
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Cox regression model for overall survival
Child Pugh B/C status and recurrence were independent risk factors for death after RFA 
(Table 3). The hazard ratios (HRs) for Child Pugh B and C were equal to 2.924 (95% CI: 
1.582-5.404) and 4.824 (95% CI: 2.100-11.083), respectively, with Child Pugh A status 
as reference category. The HR was almost 5 times increased in patients with recurrence 
compared to patients without recurrence (HR 4.524; 95% CI: 2.438-8.395). An increased 
table 2. Cause-specific hazard ratios to evaluate the effect of prognostic factors on risk of recurrence (mul-
tivariate analysis)
csHR 95.0% CI for HR p-value
Lower Upper
Female (reference male) .844 .567 1.256 0.403
Child Pugh A (reference) 0.480
Child Pugh B .795 .535 1.181 0.256
Child Pugh C .810 .412 1.591 0.540
Largest tumor diameter >3cm 1.568 1.083 2.271 0.017
Tumor number >1 1.494 1.031 2.163 0.034
Hepatitis B (reference) 0.739
Hepatitis C .857 .497 1.477 0.578
Alcohol-induced 1.175 .702 1.967 0.538
Other 1.100 .692 1.750 0.686
South-East Asian center✗ .978 .609 1.568 0.925
Liver transplantation .065 .009 .480 0.007
Statistical significant p values are given in bold p < 0.05. csHR = cause-specific hazard ratio. CI = confidence 
interval. ✗The Northern-European Center was used as the reference center
Figure 1. Cumulative incidence of recurrence and death in the South-East Asian and Northern European 
patient group
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HR of death was found in patients with either hepatitis C or alcohol-induced liver disease 
compared to hepatitis B, but the differences were not statistically significant.
Liver transplantation had a protective effect, though not statistically significant (HR 
0.805; 95% CI: 0.318-2.036).
Further treatment
Table 4 provides an overview of consecutive treatments that were administered in 
patients with recurrent disease. No significant differences were seen between the two 
groups other than the higher proportion of patients in the European group receiving 
a liver transplantation. In the European group, 44.3% (n=35) of patients eventually 
underwent liver transplantation compared to 3.0% in the Asian group (n=6) (p<0.0001).
table 3. Hazard ratios to evaluate the effect of prognostic factors on overall survival (multivariate analysis)
HR 95.0% CI for HR p-value
Lower Upper
Female (reference male) .968 .491 1.911 0.926
Child Pugh A (reference) 0.000
Child Pugh B 2.924 1.582 5.404 0.001
Child Pugh C 4.824 2.100 11.083 0.000
Largest tumor diameter >3cm 1.326 .714 2.462 0.372
Tumor number >1 .679 .355 1.299 0.242
Hepatitis B (reference) 0.399
Hepatitis C 1.573 .697 3.549 0.275
Alcohol-induced 1.234 .554 2.747 0.607
Other .776 .326 1.845 0.566
South-East Asian center .531 .269 1.049 0.068
Recurrence (time-dependent) 4.524 2.438 8.395 0.000
Liver transplantation .805 .318 2.036 0.647
Statistical significant p values are given in bold p < 0.05. HR = hazard ratio. CI = confidence interval
table 4. Summary of second line treatment in the South-East Asian and Northern-European patient cohort
Second line treatment Asian group; n=97 (48.5%) European group; n=54 (68.4%) p-value
Resection 8 (4.0) 2 (2.5) 0.552
RFA 68 (34.0) 21 (26.6) 0.231
TACE/TARE 35 (17.5) 13 (16.5) 0.835
Liver transplantation 5 (2.5) 35 (44.3) <0.0001
Sorafenib 3 (1.5) 4 (5.1) 0.89




Our study provides insight in the differences in baseline characteristics and treatment 
outcome between a South East Asian and Northern European cohort of patients under-
going RFA for de novo HCC. The differences observed may have implications for clinical 
management and the design of large multicenter, international studies.
Our study confirms that hepatitis B is the leading cause of HCC in South-East Asia, 
whereas most HCC cases in Northern Europe are related to alcohol or hepatitis C. This is 
well known from the literature (7,10). The higher percentage of patients without known 
risk factors in the Asian study group is also consistent with previous reports (14).
In the Asian group, the number of tumors as well as Child Pugh score was lower compared 
to the European group. These observed dissimilarities between the two groups may, in 
part, reflect differences in patient selection. First of all, differences in screening between 
the Netherlands and Singapore may have resulted in detection of tumors at an early 
stage in the Asian group. In both countries, six monthly screening with ultrasonography 
was common practice during the study period, but the higher incidence of HCC in Asia 
is likely to results in higher awareness and better adherence to the screening program 
by Singaporean doctors and patients. Secondly, differences in baseline characteristics 
may be a result of differences in the EASL and APASL guidelines. According to the APASL 
guidelines, the diagnosis of HCC can be made regardless of the size of a lesion, if a lesion 
has typical arterial enhancement and portovenous ‘wash-out’ on diagnostic imaging. 
This is different from the EASL guidelines that state that non-invasive criteria only apply 
in patients with typical lesions >1cm. The difference in diagnostic criteria between the 
APASL and EASL guidelines explains the difference in baseline tumor size between the 
Asian and European group in our study. In the Asian group, 9 patients had a maximal 
tumor diameter of <1cm, whereas all European patients had a tumor larger than 1 cm. 
This is also reflected by the smaller mean tumor diameter of patients in the Asian group 
compared to that of the European patients (23.7 ± 11.3 versus 26.8 ± 12.6 respectively). 
As the noninvasive diagnostic accuracy is lower in lesions <1cm, there is an increased risk 
of a false-positive diagnosis of HCC in the Asian group in our study. It is unlikely though 
that this had a significant impact on the results of our study, as only 4.5% of patients in 
the Asian group had lesions <1cm. There is considerable overlap between the BCLC and 
APASL treatment algorithms with regards to selection of patients for RFA. According to 
both algorithms, eligible candidates are Child Pugh A/B patients with a single tumor 
≤ 5cm or up to 3 nodules of ≤3cm each and the absence of vascular invasion or extra-
hepatic disease (the EASL guidelines do not clearly give a maximal diameter for a solitary 
tumor, but 5cm is generally considered the limit beyond which RFA is associated with 
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unacceptable high recurrence rates). The EASL and APASL guidelines both recommend 
RFA as an alternative to resection for patients not suitable for surgery, but do not use the 
same criteria to select surgical candidates (15). The EASL guidelines recommend resec-
tion for patients with a single tumor with very well preserved liver function, defined as 
normal bilirubin with either hepatic vein pressure gradient <10mmHg or platelet count 
≥100x 109/L. According to the APASL guidelines, surgical resection should be considered 
for single or multifocal disease, anatomically resectable, and with satisfactory liver func-
tion reserve without strict cut-off values. As a result of the more conservative criteria 
for resection in the EASL guidelines, patients may have been referred for ablation in the 
European center, whereas the same patients may still have been surgical candidates 
in the Asian institution. This may have contributed to a higher percentage of patients 
in the European group with Child Pugh B status and >1 tumor. Following the APASL 
guidelines, decisions on resectability in South-East Asia are more contingent on age and 
functional capacity of a patient. This may also explain the significantly higher age of 
patients in the Asian cohort. 
The differences in cumulative incidence of recurrence and death between the Asian and 
European group are likely related to a multitude of variables, such as patient selection, 
baseline patient characteristics, pathogenesis and histopathology of tumors, differences 
in clinical management and treatment of underlying liver disease. Patients in the Euro-
pean group had an insignificant higher midterm cumulative incidence of death. As the 
recurrence rate in the European patients was not higher than in the Asian patients, the 
poorer survival rate is probably attributable to factors other than disease progression. 
It is likely that the significantly higher baseline Child Pugh score had a negative impact 
on survival. A higher Child Pugh score has been shown to be associated with poorer 
overall survival in previous studies (16-23). The lower Child Pugh score may also reflect 
a difference between the two groups in the proportion of patients with cirrhosis, as the 
development of HCC in the absence of cirrhosis tends to be more common in Asian pa-
tients. Another factor could be the differences in therapeutic options for the underlying 
liver disease. Anti-viral agents such as lamivudine, adefovir dipivoxil or entecavir may 
improve overall survival after RFA in hepatitis B patients, whereas therapeutic options 
for hepatitis C and alcohol-induced liver cirrhosis were limited during the study period 
(24,25). Finally, differences in molecular pathogenesis of HCC between regions and races 
may result in differences in outcome (26).
Although previous studies have shown that liver transplantation improves survival in 
patients with HCC, such a survival benefit was not found in our study (27). Transplan-
tation did have a significant protective effect on tumor recurrence, but the protective 
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effect on survival did not reach statistical significance. This is likely to be related to the 
relatively small number of patients that were transplanted in our study (14.3%). 
Our study findings are of importance when interpreting published studies on RFA in 
HCC patients. Comparison of studies that have been conducted in different parts of the 
world is complicated by the differences in patient characteristics, selection and clini-
cal management. Results obtained in an Asian population cannot be extrapolated to a 
European population without notion of these differences, and vice versa. Our results 
may also have important implications for the design of new international studies. Based 
on our results, the impact of RFA on survival may be more difficult to determine in a 
Northern-European population than in a South-East Asian cohort as factors other than 
tumor progression play a more important role in the first group of patients. European 
patients eligible for RFA are likely to have risk factors other than tumor recurrence that 
are associated with poorer survival, such as hepatitis C or alcohol-induced liver cirrhosis, 
and higher BCLC stage. To demonstrate survival benefit of RFA in a group of European 
patients with unresectable HCC, one may thus need a larger sample size than in an Asian 
patient group. 
Our descriptive study has several limitations. The first limitation is the retrospective 
design of the study. Secondly, the numbers of centers included in our analysis is limited 
and therefore the data may not be representative for all centers in the geographical re-
gions that were compared. Thirdly, some predicting factors that may have been different 
between the two cohorts were not analyzed, for example co-morbidity, tumor histol-
ogy, and anti-viral treatment of hepatitis. Fourthly, a small numbers of patients in the 
Asian and European group were treated outside APASL and EASL criteria respectively. 
This may have resulted in differences between the groups that are not attributable to 
differences in the regional guidelines. Finally, we did not analyze the cause of death. The 
poorer survival rate in the European patients may have been related to causes other that 
progression of tumor or underlying liver disease. It is not unlikely that the proportion 
of patients with tobacco abuse and poor nutritional status was higher in the European 
group given the higher prevalence of alcohol abuse.
In conclusion, the baseline characteristics of patients treated with RFA for de novo 
HCC differ between Northern-European and South-East Asian patients. Despite these 
differences similar short and midterm treatment outcomes are achieved by applying 
regional recommendations for RFA in HCC patients. Midterm recurrence and death rates 
differ between the two groups and this may be explained by differences in underlying 
liver disease, screening, and the more conservative approach to resection in European 
countries.
Geographical differences in baseline characteristics and outcomes in HCC patients undergoing RFA 31
ReFeRenCes
 1. Okuda K, Ohtsuki T, Obata H, Tomimatsu 
M, Okazaki N, Hasegawa H, Nakajima Y, 
Ohnishi K. Natural history of hepatocel-
lular carcinoma and prognosis in relation 
to treatment. Study of 850 patients. Cancer 
1985;56:918-28.
 2. Llovet JM, Brú C, Bruix J. Prognosis of 
hepatocellular carcinoma: the BCLC staging 
classification. Semin Liver Dis 1999;19:329-
38.
 3. A new prognostic system for hepatocellular 
carcinoma: a retrospective study of 435 
patients: the Cancer of the Liver Italian 
Program (CLIP) investigators. Hepatology 
1998;28:751-5.
 4. Kudo M, Chung H, Osaki Y. Prognostic stag-
ing system for hepatocellular carcinoma 
(CLIP score): its value and limitations, and 
a proposal for a new staging system, the 
Japan Integrated Staging Score (JIS score). 
J Gastroenterol 2003;38:207-15.
 5. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, 
Leung KL, Lau JT, Yu SC, Johnson PJ. Con-
struction of the Chinese University Prog-
nostic Index for hepatocellular carcinoma 
and comparison with the TNM staging 
system, the Okuda staging system, and the 
Cancer of the Liver Italian Program staging 
system: a study based on 926 patients. 
Cancer 2002;94:1760-9.
 6. Chevret S, Trinchet JC, Mathieu D, Rached 
AA, Beaugrand M, Chastang C.. A new 
prognostic classification for predicting 
survival in patients with hepatocellular car-
cinoma. Groupe d’Etude et de Traitement 
du Carcinome Hépatocellulaire. J Hepatol 
1999;31:133-41.
 7. European Association For The Study Of The 
Liver; European Organisation For Research 
And Treatment Of Cancer. EASL-EORTC 
clinical practice guidelines: management of 
hepatocellular carcinoma. J Hepatol 2012. 
Apr;56(4):908-43.
 8. Bruix J, Sherman M, American Association 
for Study of Liver Diseases. Management 
of Hepatocellular Carcinoma: An Update. 
Hepatology 2011. Mar;53(3):1020-22.
 9. Omata M, Lesmana LA, Tateishi R, Chen PJ, 
Lin SM, Yoshida H, Kudo M, Lee JM, Choi 
BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi 
S, Han KH, Jafri W, Chow P, Lim SG, Chawla 
YK, Budihusodo U, Gani RA, Lesmana CR, 
Putranto TA, Liaw YF, Sarin SK. Asian Pacific 
Association for the Study of the Liver con-
sensus recommendations on hepatocellular 
carcinoma. Hepatol Int. 2010;4:439–474
 10. Parkin DM, Bray F, Ferlay J, Pisani P. Global 
cancer statistics, 2002. CA Cancer J Clin 
2005;55:74–108
 11. Putter H, Fiocco M, Geskus RB. Tutorial in 
biostatistics: Competing risks and multi-
state models. Stat Med 2007 May 20: 26 
(11): 2389–2430
 12. De Wreede LC, Fiocco M, Putter H. Mstate: 
an R package for the analysis of competing 
risks and multi-state models. J. Stat. Softw 
2011;38:1-30.
 13. De Wreede LC, Fiocco M, Putter H. The 
mstate package for the estimation and 
prediction in non and semi-parametric 
multi-state and competing risks models. 
Comput Methods Programs Biomed 2010 
Sep;99(3):261-74 
 14. Bruix J, Sherman M, Llovet JM, Beaugrand 
M, Lencioni R, Burroughs AK, Christensen E, 
Pagliaro L, Colombo M, Rodés J; EASL Panel 
of Experts on HCC.. Clinical management 
of hepatocellular carcinoma. Conclusions 
of the Barcelona-2000 EASL conference. 
European Association for the Study of the 
Liver. J Hepatol 2001;35:421– 430
 15. Chow PK. Resection  for hepatocellular 
carcinoma: is it justifiable to restrict this to 
32 Chapter 2
the American Association for the Study of 
the  Liver/Barcelona Clinic for  Liver  Cancer 
criteria? J Gastroenterol Hepatol.  2012 
Mar;27(3):452-7.
 16. Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, 
Paik SW, Koh KC, Lee JH, Choi MS, Yoo BC. 
Percutaneous radiofrequency ablation for 
early-stage hepatocellular carcinoma as a 
first-line treatment: long-term results and 
prognostic factors in a large single-institu-
tion series. Eur Radiol 2007;17(3):684–692.
 17. Shiina S, Tateishi R, Arano T, Uchino K, 
Enooku K, Nakagawa H, Asaoka Y, Sato T, 
Masuzaki R, Kondo Y, Goto T, Yoshida H, 
Omata M, Koike K. Radiofrequency abla-
tion for hepatocellular carcinoma: 10-year 
outcome and prognostic factors. Am J 
Gastroenterol 2012;107(4):569–577.
 18. Tateishi R, Shiina S, Teratani T, Obi S, 
Sato S, Koike Y, Fujishima T, Yoshida H, 
Kawabe T, Omata M. Percutaneous radio-
frequency ablation for hepatocellular car-
cinoma: an analysis of 1000 cases. Cancer 
2005;103(6):1201–1209.
 19. Raut CP, Izzo F, Marra P, Ellis LM, Vauthey 
JN, Cremona F, Vallone P, Mastro A, For-
nage BD, Curley SA. Significant long-term 
survival after radiofrequency ablation of 
unresectable hepatocellular carcinoma 
in patients with cirrhosis. Ann Surg Oncol 
2005;12(8):616–628.
 20. Lencioni R, Cioni D, Crocetti L, Franchini C, 
Pina CD, Lera J, Bartolozzi C.. Early stage 
hepatocellular carcinoma in patients with 
cirrhosis: long-term results of percutaneous 
image-guided radiofrequency ablation. 
Radiology 2005;234(3):961–967.
 21. Lam VW, Ng KK, Chok KS, Cheung TT, Yuen 
J, Tung H, Tso WK, Fan ST, Poon RT. Risk 
factors and prognostic factors of local 
recurrence after radiofrequency ablation 
of hepatocellular carcinoma. J Am Coll Surg 
2008;207(1):20–29.
 22. Xu HX, Lu MD, Xie XY, Yin XY, Kuang M, 
Chen JW, Xu ZF, Liu GJ. Prognostic factors 
for long-term outcome after percutaneous 
thermal ablation for hepatocellular carci-
noma: a survival analysis of 137 consecutive 
patients. Clin Radiol 2005;60(9):1018–1025.
 23. Guglielmi A, Ruzzenente A, Battocchia 
A, Tonon A, Fracastoro G, Cordiano C. 
Radiofrequency ablation of hepatocellular 
carcinoma in cirrhotic patients. Hepatogas-
troenterology 2003;50(50):480–484.
 24. Chuma M, Hige S, Kamiyama T, Meguro 
T, Nagasaka A, Nakanishi K, Yamamoto Y, 
Nakanishi M, Kohara T, Sho T, Yamamoto 
K, Horimoto H, Kobayashi T, Yokoo H, 
Matsushita M, Todo S, Asaka M. The influ-
ence of hepatitis B DNA level and antiviral 
therapy on recurrence after initial curative 
treatment in patients with hepatocellular 
carcinoma. J Gastroenterol 2009;44: 991-
999.
 25. Hann HW, Coben R, Brown D, Needleman 
L, Rosato E, Min A, Hann RS, Park KB, Dunn 
S, DiMarino AJ. A long-term study of the 
effects of antiviral therapy on survival of 
patients with HBV-associated hepatocel-
lular carcinoma (HCC) following local tumor 
ablation. Cancer Med 2014;3: 390-396.
 26. Song TJ, Fong Y, Cho SJ, Gönen M, Hezel 
M, Tuorto S, Choi SY, Kim YC, Suh SO, Koo 
BH, Chae YS, Jarnagin WR, Klimstra DS. 
Comparison of hepatocellular carcinoma in 
American and Asian patients by tissue array 
analysis. J Surg Oncol. 2012 Jul 1;106(1):84-
88.
 27. Mazzaferro V, Regalia E, Doci R, Andreola 
S, Pulvirenti A, Bozzetti F, Montalto F, Am-
matuna M, Morabito A, Gennari L. Liver 
transplantation for the treatment of small 
hepatocellular carcinomas in patients 





Phantom study investigating the accuracy of manual and 
automatic image fusion with the General Electric Logiq E9: 
implications for use in percutaneous liver interventions
Burgmans MC, Harder JM, P. Meershoek P, Chan SXJM, van de Berg NS, van Leeuwen FWB, 
van Erkel AR 




To determine the accuracy of automatic and manual co-registration methods for image 
fusion of three-dimensional computed tomography (CT) with real-time ultrasonography 
(US) for image-guided liver interventions. 
Methods
CT images of a multi-modality skills phantom with lesions were acquired and co-
registered to real-time US using GE Logiq E9 navigation software. Manual co-registration 
was compared to automatic and semi-automatic co-registration using an active tracker. 
Also, manual point registration was compared to plane registration with and without 
an additional translation point. Finally, a comparison was made between manual and 
automatic selection of reference points. The residual displacement was measured in 
phantom lesions to determine the registration accuracy of different methods. In each 
experiment the accuracy of the co-registration method was determined by measure-
ment of the residual displacement in phantom lesions by two independent observers.
Results
Mean displacements for a superficial and deep liver lesion were comparable after 
manual and semi-automatic co-registration: 2.4mm and 2.0mm vs. 2.0mm and 2.5mm, 
respectively. Both methods were significantly better than automatic co-registration: 
5.9mm and 5.2mm residual displacement (p<0.001 and p<0.01). The accuracy of manual 
point registration was higher than that of plane registration, the latter being heavily 
dependent on accurate matching of axial CT and US images by the operator. Automatic 
reference point selection resulted in significantly lower registration accuracy compared 
to manual point selection despite lower root mean square deviation (RSMD) values.
Conclusion
The accuracy of manual and semi-automatic co-registration is better than that of au-
tomatic co-registration. For manual co-registration using a plane, choosing the correct 
plane orientation is an essential first step in the registration process. Automatic refer-
ence point selection based on RSMD values is error-prone.
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IntRoDUCtIon
Image guidance using ultrasonography (US) offers important advantages over computed 
tomography (CT) guidance for targeting of liver lesions during minimally invasive proce-
dures such as biopsies and percutaneous ablations (1). US allows real-time imaging, is not 
associated with radiation, and offers the interventional radiologist a free choice of plane 
for needle placement. However, up to one fifth of liver lesions are inconspicuous on US (2). 
US systems with fusion imaging are commercially available from different vendors 
(3,4,5,6). Three dimensional (3D) computed tomography (CT) or magnetic resonance 
(MR) image data can be acquired before the intervention and uploaded onto these US 
systems for image fusion with real-time US images, using an electromagnetic transmit-
ter and electromagnetic sensors attached to the transducer (7,8). To the interventional 
radiologist, the fusion-imaging technology may be of great value as it allows targeting 
of lesions that are inconspicuous on US with reduced radiation exposure. Several clinical 
studies have demonstrated the usefulness of US-CT/MRI image fusion in targeting liver 
tumors that are inconspicuous on US (1-6).
For safe and accurate use of these navigation systems, accurate matching (co-registra-
tion) of the 3D image datasets with the real-time US images is essential. Inaccuracies 
in co-registration may lead to technical failure or inadvertent ablation of healthy liver 
tissue. Co-registration can be performed either manually or automatically. Manual co-
registration requires indication of reference points or planes by the operator in the 
real-time US data and their corresponding positions or planes in the 3D dataset (9,10). 
It can be challenging, requires experience and does not compensate for patient move-
ment. A variable learning curve is experienced for obtaining consistent and accurate 
manual co-registration. Automatic co-registration by the ultrasound machine on the 
other hand either makes use of automatic image recognition or of a frame with fiducial 
markers, attached to the patient’s body (11,12). Automatic co-registration saves time, 
can compensate for patient movement and is feasible even if ultrasonographic visualiza-
tion of the liver is compromised, due to e.g. obesity, overlying air, steatosis or cirrhosis. 
Though automatic co-registration offers an easier to use and learn platform than manual 
co-registration, the accuracy of automatic registration has not been determined.
In this study we compared the accuracy of manual and automatic co-registration for 
liver lesions in a phantom using the General Electric Logiq E9 system (General Electric 
(GE) Healthcare, Wauwatosa, WI, USA). Additional experiments demonstrate the benefits 
and caveats of different manual co-registration methods. Based on these experiments 




A General Electric Logiq E9 ultrasound system with XDclear platform (General Electric 
(GE) Healthcare, Wauwatosa, WI, USA) and multi-modality abdominal CIRS model 057 
phantom (CIRS, Norfolk, VA, USA) were used to conduct the experiments. GE Volume 
Navigation software, a C1-6-D convex transducer and an electromagnetic signal trans-
mitter (Ascension Technology, Shelburne, VT, USA) were used to allow fusion of US 
and CT images (Figure 1 and 2). An omniTRAXTM Active Patient Tracker (CIVCO Medical 
Solutions, Kalona, IA, USA) was fixed on the anterolateral side of the phantom (Figure 
1). CT of the phantom was acquired using a Toshiba Aquilion 64 scanner (Toshiba Medi-
cal Systems, Otawara, Japan) with the following scanning parameters: tube voltage of 
120 kVp, 1.0 mm slice thickness and in-plane resolution of 0.78 mm × 0.78 mm. The CT 
data was uploaded to a GE Logiq E9 ultrasound system (Figure 1) prior to image fusion. 
Measurement of co-registration accuracy
Several phantom experiments were conducted (see below). In each experiment the 
accuracy of the co-registration method was determined. Accuracy was determined by 
measurement of the residual displacement by two independent observers (PM and CH). 
High accuracy corresponded to low residual displacement, i.e. low registration mismatch 
between the US and CT images. Inaccuracy referred to high residual displacement, i.e. 
large discrepancies between US and CT images. To measure the residual displacement, a 
marker was placed in the center of a lesion on the US images, i.e. centerUS. Then, the cen-
ter of the lesion was identified on the CT images, i.e. centerCT, and the distance between 
centerUS and centerCT was measured in millimeters. 
For manual co-registration methods, the root mean square deviation (RSMD) was re-
corded. The RSMD is an established method to quantify the reliability of image fusion, as 
it is the standard deviation of the mean distance between the corresponding registration 
points on CT and US. The RSMD for a set of n reference points is given by the formula:
where  and  are the position of the reference point i on CT and US respectively
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experiments
Experiment A. Manual versus automatic versus semi-automatic co-registration
In the first experiment, the registration accuracy of manual point co-registration was 
compared with that of automatic co-registration and semi-automatic co-registration. 
Figure 3A provides a graphical overview of the different co-registration methods used 
in this experiment.
For manual point co-registration, three reference points were selected manually on both 
the US and CT images using the “point/all” registration option of the GE Logiq E9 system. 
The center of each kidney and a well identifiable point of the left hepatic vein were 
chosen as reference points. Automatic co-registration was established using automatic 
detection of the active tracker within the electromagnetic field by the US system. Semi-
automatic co-registration was realized by automatic co-registration and an additional 
Figure 1. Volume navigation system and phantom setup: (a) GE Logiq E9 US system with volume naviga-
tion module (dashed arrow). (b) C1-6-D convex transducer equipped with two electromagnetic sensors 
(solid yellow arrows). The electromagnetic transmitter is positioned next to the phantom (yellow dashed 
arrow) and the active tracker with four radio-opaque fiducial markers and an additional electromagnetic 
sensor is attached to the phantom (red dashed arrow). (c) omniTRAXTM Active Patient Tracker with electro-
magnetic sensor 
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translation correction by manual indication of a well identifiable point in the left hepatic 
vein. Thus, automatic and semi-automatic co-registration are similar except for the fol-
lowing: in semi-automatic co-registration an additional reference point is placed manu-
ally after the automatic registration process to optimize the co-registration.
To compare the accuracy of the three different registration techniques, the residual 
displacement was measured for two different lesions in the phantom: a superficial 
target lesion at 50 mm from the surface and a target lesion at 80 mm from the surface. 
The co-registrations and measurements were repeated twenty times by each of the two 
observers.
Experiment B. Manual point-registration versus plane-registration
In the second experiment, two methods of manual co-registration were compared 
(Figure 3B). The first method was manual co-registration using three reference points as 
described above. In the second method, manual co-registration was established by so-
called ‘plane registration’. After choosing an axial CT image, the phantom was scanned 
with the ultrasound probe in axial plane to find a matching US image. By pressing the 
‘lock plane’ button on the US machine, the US image was fused to the corresponding CT 
image. After this, correction of the image fusion was restricted to translational correc-
tions. Then, a translation point was placed in order to optimize the co-registration.
Figure 2. Example of automatic co-registration of US and CT images in a 65-year old male with colorectal 
liver metastases. Two sub-centimeter lesions were characterized as metastases with the use of MRI (not 
shown), but were not found on pre-procedural ultrasonographic examination. The patient was scheduled 
to undergo ablation using the GE Logiq E9 navigation system. CT with intravenous contrast was obtained 
with the omniTRAXTM Active Patient Tracker attached to the patient. The images show adequate co-regis-
tration of US (left) and CT (right) with matching position of a portal vein branch (dotted arrows) and liver 
cyst (black arrows). After image fusion, the liver metastases were vaguely seen (white arrow; second lesion 
not shown) and could be targeted with a radiofrequency probe. Post-ablation CT showed a good location 
of the ablation zone and no recurrence has occurred during follow-up.
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The co-registrations and measurements were repeated five times by each of the two 
observers.
Experiment C. Pitfalls of co-registration, part I
The third experiment further examined co-registration using a plane (Figure 3C). In this 
experiment a deliberate mismatch was created between the CT and US plane. The trans-
ducer was positioned at an angle of roughly twenty degrees to the axial plane around 
the left-right axis, while the CT images were maintained axial without angulation. Then, 
subsequent translation points were set to try to correct the registration mismatch: first 
at a well-identifiable point in the left hepatic vein and then in the center of the right 
kidney.
As the last part of this experiment, the transducer was carefully positioned axially on the 
phantom, but at an in-plane rotation of roughly twenty degrees around the feet-head 
axis. The same two subsequent translation points were set as described above trying to 
correct the registration mismatch. 
Each step of the experiment was repeated five times by each of the two observers with 
measurement of the registration accuracy for the superficial lesion and the center of the 
right kidney during each step.
Experiment D. Pitfalls of co-registration, part II 
The last experiment examined manual co-registration using the “Point/best3” option of 
the GE Logiq E9 system (Figure 3D). This option allows automatic selection of reference 
points by the US system: when more than three reference points are manually selected 
by the operator, the US system automatically selects the three reference points that 
result in the lowest RSMD. 
In the first step of this experiment, reference points were manually selected in the center 
of each kidney and at a well identifiable point of the left hepatic vein The left hepatic 
vein reference point was deliberately displaced 8 mm too far anteriorly in the sonogram 
to test a clinical scenario of operator-dependent misregistration. The second step was to 
evaluate whether the addition of a fourth reference would improve the co-registration 
accuracy. A fourth reference point was placed on the left edge of the spine, in line with 
the reference points in the kidneys. Finally, the “Point/best3” option was selected on the 
US system to activate selection of the best three out of the four reference points by the 
US system based on RSMD calculations. As a result of the displacement of the middle 
hepatic vein reference point, a preference was enforced for automatic selection by the 
system of the three reference points that were in line. 
42 Chapter 3
Figure 3. Graphical overview of the phantom experiments. A. Comparison of manual point co-registration 
(left), automatic co-registration (middle) and semi-automatic co-registration (right). B. Comparison of two 
manual co-registration methods: point co-registration (not shown; see A, left) and plane-registration. Prior 
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After each step the reported RMSD was recorded and the residual displacement was 
measured in the superficial lesion. All steps and measurements were repeated five times 
by each of the two observers.
statistical analysis
Statistical analyses were performed using SPSS version 23.0 (IBM, Armonk, NY, USA). For 
all measurements, mean and standard deviation were derived as well as 95% confidence 
intervals (CI) of the mean. Using a 2-way analysis of variance (ANOVA) the dependency 
of the accuracy on the position of the lesion and the co-registration method (manual 
using reference points, automatic, and semi-automatic) was determined. Additionally, a 
one-way ANOVA was used to analyze the dependency of the accuracy on the position of 
the lesion for each of these co-registration methods separately. A one-way ANOVA was 
also used to determine the dependency of the registration accuracy on the number of 
reference points. A p-value < 0.05 was considered statistically significant.
ResULts
For all co-registration experiments, measurements are listed in Table 1.
Experiment A. Manual versus automatic versus semi-automatic co-registration
A significantly higher mean residual displacement was found with automatic co-
registration compared to manual co-registration: 5.9 mm and 5.2 mm for the superficial 
and deep liver lesion respectively, compared to 2.4 mm and 2.0 mm (Figure 4). The ac-
curacy of automatic co-registration improved significantly after applying a translation 
correction, i.e. semi-automatic co-registration (p<0.0005). The residual displacement 
to plane-registration, the orientation of the ultrasound plane could be changed by both rotation (Rx, Ry 
and/or Rz) and translation (Tx, Ty and/or Tz) (left). After fusion of the CT and US image by pressing the ‘lock 
plane’ button on the US machine, correction of the image fusion was restricted to translational movements 
(middle). A single translation point was placed to optimize the co-registration (right) C. Plane-registration 
was conducted with deliberate mismatch between the CT and US plane. The US transducer was positioned 
at an angle of roughly twenty degrees to the axial plane around the left-right axis (above) or at an in-plane 
rotation of roughly twenty degrees around the feet-head axis (below). The angulated US plane was fused to 
an axial CT image. After this, correction of the co-registration was attempted by placing a well-identifiable 
point in the left hepatic vein (middle) and then in the center of the right kidney (right). D. Comparison of 
manual selection of three reference points (left) or four reference points (middle) and automatic selection 
of three out of four reference points (right). As the left hepatic vein reference point (a) was deliberately 
placed 8mm anteriorly, a system preference was enforced for the three reference points that were in line 
(as these resulted in the lowest RSMD). Rotation of the registration plane was restricted by the triangular 
orientation of the reference points (middle) in the experiments with operator-dependent point selection, 
whereas rotational errors around the blue line (right) occurred with automatic point selection
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table 1. Reported RMSD and residual displacement for different co-registration methods: mean, standard 
deviation and 95%CI of the mean.
Measure target mean ± std.dev. (mm) 95%CI (mm)
experiment A
Manual point
RMSD 1.0 ± 0.4 0.8 - 1.1
Residual displacement
Superficial lesion 2.4 ± 0.5 2.2 - 2.5
Deep lesion 2.0 ± 0.6 1.9 - 2.2
Automatic Residual displacement
Superficial lesion 5.9 ± 0.7 5.7 - 6.1
Deep lesion 5.2 ± 0.6 5.0 - 5.4
Semi - automatic Residual displacement
Superficial lesion 2.0 ± 0.7 1.8 - 2.3
Deep lesion 2.5 ± 0.7 2.2 - 2.7
experiment B
Plane only Residual displacement
Superficial lesion 13 ± 3 11 - 15
Left kidney 13 ± 3 11 - 16
TP1: superficial Residual displacement
Superficial lesion 1.9 ± 0.8 1.4 - 2.5
Left kidney 4.5 ± 1.8 3.2 - 5.7
experiment C
200 angulation around L-R axis
Plane only Residual displacement
Superficial lesion 17 ± 11 9 - 26
Left kidney 33 ± 4 30 - 36
TP1: superficial Residual displacement
Superficial lesion 4.7 ± 2.6 2.8 - 6.6
Left kidney 34 ± 3 32 - 36
TP2: deep Residual displacement
Superficial lesion 34 ± 3 32 - 36
Left kidney 5.9 ± 1.8 4.6 - 7.2
200 rotation around F-H axis
Plane only Residual displacement
Superficial lesion 35 ± 5 31 - 38
Left kidney 54 ± 8 49 - 60
TP1: superficial Residual displacement
Superficial lesion 18 ± 4 15 - 21
Left kidney 26 ± 5 23 - 30
TP2: deep Residual displacement
Superficial lesion 28 ± 6 24 - 32
Left kidney 35 ± 7 30 - 40
experiment D
Three
RMSD 2.5 ± 0.5 2.1 - 2.8
Residual displacement Superficial lesion 6.2 ± 1.1 5.5 - 7.0
Four
RMSD 2.4 ± 0.5 2.0 - 2.7
Residual displacement Superficial lesion 5.5 ± 1.3 4.5 - 6.4
Best three of four
RMSD 0.9 ± 0.4 0.6 - 1.1
Residual displacement Superficial lesion 40 ± 26 21 - 58
TP = translation point; L-R = left-right; F-H = feet-head; RSMD = root mean square deviation
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of semi-automatic co-registration was similar to the displacement found after manual 
co-registration: 2.0mm and 2.5mm for the superficial and deep lesion, respectively. 
The accuracy depended on both the co-registration method and the position of the 
lesion. After manual co-registration, the mean displacement was significantly larger for 
the superficial lesion than for the deep lesion (p=0.027). Conversely, the semi-automatic 
co-registration resulted in a larger displacement for the deep lesion than for the super-
ficial lesion (p=0.002). 
Experiment B. Manual point-registration versus plane-registration
After manual co-registration using a plane, a high residual displacement was found for 
both the superficial lesion and the left kidney (13.3 ± 3mm for both). Upon placing a 
translation point, this accuracy improved to 1.9 ± 0.8mm and 4.5 ± 1.8mm respectively 
(Figure 5A).
Experiment C. Pitfalls of co-registration, part I
Manual co-registration using a deliberately angulated plane resulted in poor registra-
tion accuracy with a wide range (Figure 5). 
Placement of a translation point did improve registration accuracy, but only for one of 
the two points of measurement (Figure 5B). If the translation point was placed in the left 
hepatic vein, registration accuracy improved for the liver lesion but not for the center of 
the right kidney. If the translation point was placed in the right kidney, only the registra-


























Superficial lesion Deep lesion
Figure 4. Comparison of manual, automatic and 
semi-automatic co-registration. Accuracy is ex-
pressed as residual displacement between US 
and CT measured for a superficial lesion (blue) 
and a deep lesion (red). Centerlines in boxplots 
indicate the median, box edges indicate the 
25th and 75th percentile. Uninterrupted brackets 
indicate comparisons between co-registration 
methods. Dotted brackets indicate compari-
son between lesions for a single co-registration 
method. *p<0.05, **p<0.01,***p<0.001.
46 Chapter 3
After deliberate in-plane rotation of the US transducer around the feet-head axis, 
a substantial in-plane displacement was measured at both the superficial lesion and 
the right kidney (Figure 5C). Again, assigning translation points led to an acceptable 
	 39	
After manual co-registration using a plane, a high residual displacement was found for both the superficial 
lesion and the left kidney (13.3 ± 3mm for both). Upon placing a translation point, this accuracy improved to 
1.9 ± 0.8mm and 4.5 ± 1.8mm respectively (Figure 5A). 
 
Figure 5. 
A. Comparison of plane co-registration without (right) and with (left) additional translation point. Registration accuracy was measured 
for a superficial lesion (blue) and deep lesion (red). B. Plane co-registration using a plane deliberately angulated around the left-right 
axis (left) resulted in poor registration accuracy with a wide range. Placement of a superficial translation point (TP1) resulted in 
improved registration accuracy for the superficial lesion, but not for the deep lesion (middle). Placement of a deep translation point 
(TP2) resulted in high registration accuracy for the deep lesion, but not for the superficial lesion (right). C. Plane co-registration with a 
plane deliberately rotated around the feet-head axis resulted in poor registration accuracy with a wide range (left). Placement of a 
superficial translation point (TP1) or deep translation point (TP2) did not result in acceptable registration accuracies (middle and 
right). 
Experiment C. Pitfalls of co-registration, part I 
Manual co-registration using a deliberately angulated plane resulted in poor registration accuracy with a wide 
range (Figure 5).  
Placement of a translation point did improve registration accuracy, but only for one of the two points of 
measurement (Figure 5B). If the translation point was placed in the left hepatic vein, registration accuracy 
improved for the liver lesion but not for the center of the right kidney. If the translation point was placed in the 
right kidney, only the registration accuracy for center of the right kidney improved substantially. 
After deliberate in-plane rotation of the US transducer around the feet-head axis, a substantial in-plane 
displacement was measured at both the superficial lesion and the right kidney (Figure 5C). Again, assigning 
translation points led to an acceptable co-registration only near the most recently chosen translation point. 
Objects at other locations remained misaligned. 






































Figure 5. A. Comparison of plane co-registration without (right) and with (left) additional translation point. 
Registration accuracy was measured for a superficial lesion (blue) and deep lesion (red). B. Plane co-reg-
istration using a plane deliberately angulated around the left-right axis (left) resulted in poor registration 
accuracy with a wide range. Placement of a superficial translation point (TP1) resulted in improved registra-
tion accuracy for the superficial lesion, but not for the deep lesion (middle). Placement of a deep transla-
tion point (TP2) resulted in high registration accuracy for the deep lesion, but not for the superficial lesion 
(right). C. Plane co-registration with a plane d liberately rota ed around the feet-head axis resulted in poor 
registration accuracy with a wide r nge (left). Placement of a superficial translation point (T 1) or deep 
translation point (TP2) did not result in acceptable registration accuracies (middle and right).
Deliberate misplacement of one of the reference points during manual co-registration led to a high residual 
significant (p=0.91) improvement in registration disp
system of the best three of four reference points resulted in a significantly worse residual displacement 
compared to either using three or four reference points (p<0.0005, Figure 6). The mean reported RMSD, 
how ver, was significantly smaller in this case compared t  the two co-registration methods with operator-




Comparison of manual point registration using three reference points (left), four reference points (middle) and software-based 
selection of three out of four reference points based on root mean square deviation (RMSD) (right). The registration error ex
RMSD (red) doe
indicate the 25th and 75th 
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Figure 6. Comparison of manual 
point registration using three ref-
erence points (left), four reference 
points (middle) and software-based 
selection of three out of four refer-
ence points based on root mean 
square deviation (RMSD) (right). 
The registration error expressed as 
RMSD (red) does not correspond 
with the actual residual displace-
ment (blue). Centerlines in boxplots 
indicate the median, box edges in-
dicate the 25th and 75th percentile. 
Unin erupted bracke s ind cate 
comparison of measured residual 
displacement for different co-reg-
istration methods. Dotted brackets 
indicate comparisons between re-
ported RSMD. *p<0.05, **p<0.01, 
***p<0.001.
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co-registration only near the most recently chosen translation point. Objects at other 
locations remained misaligned.
Experiment D. Pitfalls of co-registration, part II 
Deliberate misplacement of one of the reference points during manual co-registration 
led to a high residual displacement in the superficial lesion (6.2 ± 1.1mm) (Figure 6). 
Adding a fourth reference point led to a non-significant (p=0.91) improvement in reg-
istration displacement (5.5 ± 1.3mm) (Figure 6). Selection by the US system of the best 
three of four reference points resulted in a significantly worse residual displacement 
compared to either using three or four reference points (p<0.0005, Figure 6). The mean 
reported RMSD, however, was significantly smaller in this case compared to the two co-
registration methods with operator-dependent selection of reference points (p<0.0005).
DIsCUssIon
Basic knowledge of fusion technology and potential pitfalls is essential when using US 
systems with fusion imaging. We did not investigate the GE Logiq E9 navigation system 
in a clinical setting, so the implications of our phantom study for use of the system in 
patients are open to discussion. Nevertheless, it is likely that many of our study findings 
also apply in a clinical system. A co-registration method that is inaccurate in a phantom 
study is likely to have a higher co-registration mismatch in patients. 
Our results demonstrate that automatic co-registration is significantly less accurate 
than manual co-registration when using the GE Logiq E9 navigation system (p<0.0005). 
Based on our findings we consider this registration method insufficient for routine use in 
clinical practice. The residual displacement of automatic co-registration was >5mm. This 
increases the risk of technical failure (i.e. incomplete treatment or insufficient margins) in 
liver tumor ablation or of a sampling error in a percutaneous biopsy of a liver lesion. We 
therefore consider manual co-registration to be the preferred registration method. The 
accuracy of manual co-registration with the GE Logiq E9 has also been demonstrated in 
previous experiments, both in phantom studies as in healthy volunteers (2-10). 
Semi-automatic co-registration is a valuable alternative in patients where manual reg-
istration is complicated by compromised ultrasonographic visibility and difficulties in 
identification of reference points. In our phantom study, the registration accuracy of 
semi-automatic co-registration was comparable to that of manual co-registration. Semi-
automatic has an important disadvantage over manual co-registration. It requires ac-
quisition of a contrast-enhanced CT or MRI just prior to the intervention with the tracker 
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attached to the patient (same applies to automatic co-registration). This increases the 
procedure time as well as the radiation dose and contrast volume for the patient. 
Based on our study findings, manual selection of reference points using the “Point/
all” mode offers the most accurate and reliable co-registration of the different manual 
co-registration methods of the GE Logiq E9 navigation system. Co-registration using a 
plane depends on the operator’s ability to identify an identical axial plane on the US im-
ages and the pre-intervention data. In clinical practice, matching the plane orientations 
in the first step of the registration process may be prone to errors as the positioning of 
the patient during the intervention may be different from that during the acquisition of 
the CT or MRI. As shown in our study, an initial mismatch between the CT and US plane 
cannot be sufficiently corrected by adding translation points. The addition of a transla-
tion point does shift the plane in the X-, Y- and/or Z-axis, but does not allow rotation of 
the plane. The registration accuracy may thus only be sufficient close to the intersection 
line between the US and CT plane. We therefore advise to use co-registration with plane 
registration with caution and only if placement of a translation point close to the target 
lesion is feasible.
From the current study it was also found that assignment of reference points by the 
operator was more accurate than automatic selection of three reference points by the 
US system. The system’s selection algorithm is based on the lowest RSMD, which does 
not necessarily result in the best registration accuracy. 
Similar to previous study findings, the current study shows that the accuracy is depen-
dent on the position of the target lesion (9). After manual co-registration, the residual 
displacement was slightly larger for the superficial target lesion than for the deep lesion. 
This is expected to be a direct consequence of the compression of the phantom by the 
transducer, which influences the position of a superficial lesion more than that of a deep 
lesion (13). Conversely, semi-automatic co-registration was found to be less accurate for 
the deep target lesion than for the superficial lesion, which suggests that the accuracy 
decreases with increasing distance between the lesion and the active tracker. Preferably, 
both the active tracker and the translation point are placed close to the target lesion for 
improved accuracy.
Our study has several limitations. The performance of the US system in clinical practice 
may differ from the results obtained in our phantom study. Registration inaccuracies are 
expected to be greater in patients for all co-registration methods as motion, breathing 
and tissue compressibility may induce registration errors (14,15). Furthermore, patient 
positioning may have a negative impact on registration accuracy, as it may lead to 
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increased mismatches due to deformation of tissue (13,16,17). Another limitation of the 
study is that we only investigated the performance of the GE Logiq E9 and study find-
ings may thus not be extrapolated to other systems and registration methods. Finally, 
reference points were chosen within the phantom kidneys for manual co-registration, 
because these could be identified more easily than other landmarks due to the limited 
anatomical detail in our phantom. In patients, reference points are preferentially placed 
within the liver when performing percutaneous liver interventions.
In conclusion, manual and semi-automatic co-registration result in low registration 
inaccuracies in a phantom model and are preferred over fully automatic co-registration. 
Point-registration is preferentially performed using all operator-assigned reference 
points rather than using automatic point selection by the US system. Plane registration 
is an alternative method, provided that the plane orientation is correctly chosen during 
the first step of the registration process.
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Local tumor progression and survival rates after 
combined radiofrequency ablation and drug-eluting 
bead chemoembolization in unresectable hepatocellular 
carcinoma






Local tumor progression (LTP) rates after radiofrequency ablation (RFA) are higher in 
hepatocellular carcinoma (HCC) >3cm compared to HCCs ≤3cm. Combined RFA and 
drug-eluting-bead transarterial chemoembolization (DEBTACE) can achieve larger 
ablation zones compared to RFA alone. This retrospective study describes 3-year LTP 
free-survival (LTPFS) and overall survival (OS) after RFA and combined RFA-DEBTACE for 
HCC ≤3 cm and >3cm respectively.
Methods
Local medical ethics committee approved the study. 54 patients (42 males; median 66 
years (range: 29-82 years)) were treated with RFA for de novo unresectable HCC. Thirty-
nine patients received RFA only. Fifteen patients with HCC >3-7cm underwent RFA-
DEBTACE. LTPFS and OS were analyzed using Kaplan-Meier and Cox regression analysis.
Results
In the RFA-group, LTPFS and OS rates at 1-, 2- and 3-years were 81.4%, 66.0% and 59.4% 
and 87.2%, 81,6% and 69.8% respectively. The LTPFS and OS rates were lower in the 
RFA-DEBTACE-group: 26.9%, 17.9% and 17.9% and 73.3%, 66.7% and 53.3% respectively. 
Conclusion
LTPFS rates after RFA-DEBTACE for HCC >3-7cm are low compared to the results reported 
after combination therapy of conventional TACE followed by RFA for HCC with similar 
size.
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IntRoDUCtIon
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death 
in the world (1,2). Surgical resection is the first line treatment for patients with solitary 
HCC and a well-preserved liver function (1,2). Unfortunately, many patients with HCC 
are not eligible for surgical resection due to underlying liver disease, i.e. cirrhosis with 
portal hypertension. Liver transplantation is the preferred treatment for patients with 
liver cirrhosis and tumors within Milan criteria (single tumor <5cm or up to 3 tumors 
<3cm) who are unsuitable for resection (1,2). Radiofrequency ablation (RFA) is an ef-
fective alternative for surgical resection and may be used as a ‘bridge-to-transplant’ for 
patients on the waiting list for liver transplantation (1,2). 
Local tumor progression rates after RFA are significantly higher in tumors >3 cm com-
pared to smaller tumors (1-5). Different strategies have been advocated to reduce local 
tumor progression rates after RFA in tumors >3cm. Several Asian studies have shown 
promising results of conventional transarterial chemoembolization (cTACE) as a neo-
adjuvant treatment preceding RFA. Yet, cTACE has been abandoned in many European 
centers after a prospective randomized trial (Precision V) comparing cTACE and TACE 
with doxorubicin-eluting beads (DEBTACE) (6). This trial showed a better safety profile 
and favorable response rates of DEBTACE compared to cTACE.
There is a paucity of publications on combined treatment with RFA and DEBTACE. In 
a pilot study, it has been shown that RFA followed by DEBTACE resulted in significant 
increase in the volume of ablation necrosis compared to RFA alone (7). However, data on 
long-term results for combined RFA and DEBTACE is absent. 
In our institution, a treatment protocol was implemented in January 2009 whereby 
patients with HCC >3cm were treated with combined RFA-DEBTACE and patients with 
HCC ≤3 cm were treated with RFA only. The objective of the study was to analyze three 
year local tumor progression free-survival and overall survival data of patients treated 
by RFA and combined RFA-DEBTACE for HCC ≤3 cm and >3-7cm respectively.
MetHoDs
Patients
The institutional review board (IRB) approved the study and informed consent was 
waived for the retrospective analysis. All patients gave informed consent to undergo 
treatment. Between January 2009 and July 2012, 54 consecutive patients (42 males; 
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median age 66 years (range: 29-82 years)) were treated in our institution with RFA for de 
novo unresectable HCC. The diagnosis was based either on tumor histology or on radio-
logical imaging criteria, according to guidelines by the European Association for Study of 
the Liver (8). For radiological confirmation of the diagnosis, 4-phase contrast-enhanced 
computed tomography (CECT) and/or dynamic gadolinium-enhanced magnetic reso-
nance imaging (GE-MRI) was used. All patients were discussed in a multi-disciplinary 
meeting of hepatologists, surgeons, radiologists and oncologists and consensus about 
the given treatment was reached in all cases. 
Eligibility criteria for local ablation were: Child Pugh A or B, Child Pugh C in a patient 
eligible to undergo liver transplant, Eastern Cooperation Oncology Group performance 
status (ECOG) <2, single tumor measuring <7 cm or a maximum of 3 HCCs measuring 
≤3cm. Ineligibility criteria were: radiologic evidence of vascular invasion into portal/
hepatic vein branches, extrahepatic metastases, severe liver dysfunction (Child-Pugh C) 
and no eligibility for liver transplantation, significant and uncorrectable coagulopathy 
(International Normalized Ratio (INR) >1.7, platelet count <50x 109/mm3). Patients with a 
HCC >3cm were scheduled to undergo RFA followed by DEBTACE the next day. All other 
patients underwent RFA only.
The following baseline information was retrieved from the electronic patient records 
and Picture and Archiving Computer System (Sectra, Linköping, Sweden): (a) age, (b) 
gender, (c) size of lesion, (d) number of lesions, (e) baseline serum albumin, (f ) baseline 
serum bilirubin, (g) baseline INR, (h) etiology cirrhosis, (i) Child Pugh status, (j) tumor 
stage according to Barcelona Clinic Liver Cancer (BCLC) criteria.
The median follow-up for all patients was 23.8 months (quartiles: 15.5-36.9 months).
Radiofrequency ablation
Percutaneous RFA was performed under general anesthesia under ultrasound and/or 
CT guidance. A single electrode was used (3 cm exposed tip Cooltip (Covidien, Gosport 
Hamspire, United Kingdom) or StarBurst XL (AngioDynamics, Amsterdam, Netherlands) 
or multiple electrodes with a switch-control system (3 or 4 cm exposed tip Cooltip). 
Ablation was performed for 12 (single Cooltip electrode) or 16 minutes (multiple Cooltip 
electrodes) using standard impedance controlled ablation. Temperature-based ablation 
was accomplished with the StarBurst XL electrode. CECT was performed immediately af-
ter ablation on a 16-slice spiral CT (Toshiba, Tokyo, Japan). Technical success was defined 
as absence of tumor enhancement after ablation. If the CECT showed residual tumor 
enhancement, re-ablation was performed in the same session.
Combined RFA and DEB-TACE for HCC >3cm 57
transarterial chemoembolization
TACE was scheduled 1 day after RFA. After introduction of a 5F/6F vascular sheath in the 
common femoral artery, angiography was performed from the common, lobar and (sub)
segmental hepatic arteries. Cone-beam CT (CBCT) was performed in individual cases to 
better delineate vascular tumor supply (XperCT, Philips Healthcare, Best, Netherlands). 
TACE was performed as selective as possible using 100-300 micrometer and 300-500 
micrometer DC Bead® with a total of 100mg doxorubicin (Biocompatibles UK Limited, 
Surrey, United Kingdom). Endpoints for embolization were complete administration of 2 
vials of DC Bead® or arterial flow stasis. Hepatic angiography was performed immediately 
after embolization. Technical success was defined as successful delivery of DC Bead® into 
the tumor feeding artery with absence of tumor blush on the completion angiogram.
Complications
Complications were evaluated according to the Common Terminology Criteria for Ad-
verse Effects version 4.0 (CTCAE 4.0).
Follow-up
Four-phase CECT or dynamic GE-MRI was performed 6 weeks after treatment and re-
peated every 3 months thereafter. Local tumor progression was defined as the presence 
of tumor enhancement on a follow-up scan at the location of the treated tumor. Local 
tumor progression was distinguished from distant recurrence (i.e. a new intrahepatic 
tumor distant from the treated tumor). Patients were followed until last follow-up date, 
death or the end of the study. The endpoints were local tumor progression-free survival 
and overall survival.
statistical analysis
The statistical analyses were performed using SPSS 21 (IBM, Armonk, NY, USA). Com-
parisons between the two groups were done by student t-test for continuous variables 
and the Chi-square test for categorical variables. Survival curves for overall survival and 
local tumor progression-free survival were constructed by the Kaplan-Meier method 
and compared with the Cox regression analysis. The impact of liver transplantation on 
overall survival was assessed using a time-dependant covariate with a log-rank test. All 





Baseline demographics of all patients are shown in Table 1. All patients had hepatocellu-
lar carcinoma in the setting of liver cirrhosis. Of the 54 patients, 39 patients were treated 
with RFA and 15 with RFA-DEBTACE. 
Baseline parameters per group are described in Table 2. The mean maximal diameter of 
tumors at baseline was 45.7 mm in the combined RFA-DEBTACE group and 21.5 mm in 
the RFA group. In one patient in the RFA-DEBTACE group the maximal diameter of the 
largest tumor was <3cm. This patient had two tumors in segment 6 of respectively 24 
mm and 22 mm that were in close relation to each other. It had been decided to consider 
the two tumors as one larger tumor area and perform RFA combined with DEB-TACE. In 
the RFA-DEBTACE group, the percentage of patients with multifocal disease (>1 lesion) 
table 1. Baseline patient and tumor characteristics of 54 patients.
Characteristic Value
Median age (range) 66 years (29-82 years)
Male gender 42
ECOG 
 0 53 (98.1)
 1 1 (1.9)
Cause of cirrhosis (n (%))
 Hepatitis B 6 (11.1)
 Hepatitis C 14 (25.9)
 Alcohol 31 (57.4)
 Other 11 (20.4)
Child Pugh score (n (%))
 A 48 (88.9)
 B 4 (7.4)
 C 2 (3.7)
No. nodules per patient (n (%))
 1 40 (74.1)
 2 11 (20.3)
 3 3 (5.6)
Maximal tumor diameter in mm (n=71) Median 22.0
Range 8-69
* The sum of percentages is >100% as the etiology of cirrhosis may be multifactorial. ECOG = Eastern Co-
operative Oncology Group
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was 40.0%. In the RFA group, 20.5% of patients had multifocal disease. The difference 
between the two groups was not statistically significant (p=0.175).
treatment outcome
Technical success was achieved in 98.1% (n=53) of RFA procedures and 100% (n=15) of 
TACE procedures. 
Figure 1 shows the local tumor progression-free survival of the RFA and RFA-DEBTACE 
group. The mean local tumor progression-free survival for all patients was 30.7 months 
(95% CI: 23.9-37.5 months). Patients in the RFA group had a mean local tumor progres-
sion free-survival of 36.9 months (95% CI: 29.6-44.3 months). Mean local tumor progres-
sion free-survival in the RFA-DEBTACE group was 11.0 months (95% CI: 2.8-19.4 months). 
The difference between the two groups was statistically significant: HR 0.211; 95% CI: 
0.094-0.471. In the RFA group, the local tumor progression free-survival rates at 1-, 2- 
and 3-years were 81.4%, 66.0% and 59.4% respectively. These rates were 26.9%, 17.9% 
table 2. Baseline patient and tumor characteristics per treatment group. 
RFA (n=39) RFA and TACE (n=15)
Median age (range) 62.5 years (29-79 years) 65.2 years (47-82 years)
Male gender (%) 30 (76.9) 12 (80.0)
ECOG (n (%))
 0 38 (97.4) 15 (100)
 1 1 (2.6) 0 (0)
Cause of cirrhosis in (n (%))*
 Hepatitis B 3 (7.7) 3 (20.0)
 Hepatitis C 10 (25.6) 4 (26.7)
 Alcohol 23 (59.0) 8 (53.3)
 Other 9 (23.1) 2 (13.3)
Child Pugh score (n (%))
 A 34 (87.2) 14 (93.3)
 B 3 (7.7) 1 (6.7)
 C 2 (5.5) 0 (0)
Nodules per patient 
(no. of patients per arm (%))
 1 31 (79.5) 9 (60.0)
 2 6 (15.4) 6 (33.3)
 3 2 (5.1) 1 (6,7)






* The sum of percentages is >100% as the etiology of cirrhosis may be multifactorial. ECOG = Eastern Co-
operative Oncology Group
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Figure 1. Overall survival rate per treatment group
Figure 2. Local tumor progression-free survival rate per treatment group
Combined RFA and DEB-TACE for HCC >3cm 61
and 17.9% respectively in the RFA-DEBTACE group. The differences in local tumor pro-
gression free-survival rates at 1-, 2- and 3-years were statistically significant (p=0.0001, 
p=0.0004 and p=0.0045 respectively).
Figure 2 shows the overall survival of the RFA and RFA-DEBTACE group. The mean overall 
survival of all patients was 40.4 months (95% CI: 34.5-46.2 months). The mean overall 
survival in the RFA group was 41.6 months (95% CI: 34.6-48.6 months) and 34.8 months 
(95% CI: 23.5-46.1 months) in the RFA-DEBTACE. The overall survival at 1-, 2- and 3-years 
was 87.2%, 81,6% and 69.8% respectively in the RFA group. In the RFA-DEBTACE group, 
these rates were 73.3%, 66.7% and 53.3%. The difference in overall survival between 
the two groups at 1-, 2- and 3-years was not statistically significant (p=0.27, p=0.28 and 
p=0.36 respectively).
Complications
CTCAE grade 3-4 complications occurred in one patient in the RFA group (2.6%) and 2 
patients in the RFA-DEBTACE group (13.3%). The patient in the RFA group had a punc-
ture site bleeding, which was treated successfully with transarterial embolization. One 
patient in the RFA-DEBTACE group developed a liver abscess 6 days after the ablation 
and was successfully treated with percutaneous drainage and antibiotics. The other 
patient in the DEBTACE group had a 47mm HCC high up in the dome of the liver. The 
RFA procedure was complicated by a right-sided pneumothorax for which a chest-tube 
was inserted. The next day, TACE of the liver dome tumor was performed. Five days after 
the TACE, the patient developed sepsis as result of Escherichia coli peritonitis. Despite 
treatment with percutaneous drainage of the ascites and intravenous antibiotics, the 
patient passed away 23 days after RFA as a result of sepsis and hepatorenal syndrome.
Consecutive treatment
Twenty-two patients (40.7%) underwent liver transplantation with a median of 7.0 
months (range 0.3-28.6 months) after the first RFA treatment. The transplant rate for pa-
tients in the RFA group was 43.6% and 33.3% in the RFA-DEBTACE group. The difference 
in transplantation rate between the groups was not statistically significant (p=0.551). 
None of the patients that were transplanted had recurrent HCC. Liver transplantation 
resulted in a non-significant increase in survival with a hazard ratio of 0.452 in favor of 
transplantation (95% CI: 0.116-1.768).
Nineteen out of 54 patients (35.2%) received additional loco-regional treatment after 
the initial RFA or RFA-DEBTACE. In the RFA group, 28.2% patients underwent further loco-
regional treatment after the initial RFA compared to 53.3% in the RFA-DEBTACE group 
(table 3). The difference between the two groups was statistically significant (p=0.022).
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DIsCUssIon
To our best knowledge, this is the first reported study on the long-term efficacy of 
combined treatment with RFA and DEBTACE in patients with unresectable HCC. In 
our institution, we performed RFA for HCCs ≤3cm with a maximum of 3 tumors and 
combined treatment for HCCs >3-7cm. This treatment strategy was adopted on the 
premise that adjuvant DEBTACE would result in similar outcomes in patients with larger 
tumors compared to those with tumors ≤3cm. Despite the additional treatment with 
DEBTACE however, patients in the combined treatment group had significantly lower 
mean local tumor progression free-survival rates compared to the RFA-only group at 
1, 2 and 3-years: 81.4%, 66.0% and 59.4% versus 26.9%, 17.9% and 17.9% respectively. 
The overall survival rate at 1, 2 and 3-years was also lower in the RFA-DEBTACE group 
compared to the RFA group, but the difference between the two groups did not reach 
statistical significance.
Clearly, direct comparison between the two groups in our study is flawed because of 
selection bias. Treatment selection was dependent on tumor size and as a result the 
mean maximal tumor diameter in the RFA-DEBTACE group was significantly larger than 
in the RFA group. Tumor size >3cm is a known risk factor for tumor recurrence after 
RFA and this is confirmed by our study (1-5). Different strategies are have been studied 
trying to reduce HCC recurrence rates after RFA and the debate is still open on what 
the best strategy is. Most studies have used a combination of RFA and TACE, but others 
have combined RFA with ethanol injection or sorafenib (9-12). In our study, RFA was 
performed first followed by DEBTACE the next day. After RFA-DEBTACE, the local tumor 
progression-free survival at 3 years was 17.9%. This compares favorable to previous 
studies that have reported 3-year recurrence free-survival rates of only around 10% after 
RFA for HCC >3cm (13,14). Yet, our results are poorer than those reported in studies that 
used a sequence whereby cTACE was performed prior to RFA (4,15-19). In a randomized 
controlled trial by Peng et al. in patients with unresectable HCC with ≤3 nodules smaller 
table 3. Additional treatment during follow-up per treatment group
RFA n (%) RFA-TACE n (%) Overall n (%)
Transplantation 17 (43.6) 5 (33.3) 22 (40.7)
Resection only 1 (2.6) 0 (0) 1 (1.9)
Resection and RFA and TACE 1 (2.6) 0 (0) 1 (1.9)
RFA only 3 (7.7) 3 (20.0) 6 (11.1)
RFA and TACE 3 (7.7) 2 (13.3) 5 (9.3)
TACE only 3 (7.7) 3 (20.0) 6 (11.1)
RFA = radiofrequency ablation. TACE = transarterial chemotherapy 
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than 7cm, cTACE followed by RFA (n = 94) was significantly better than RFA alone (n = 95) 
(15). For patients with tumor diameters of 3.1–5.0 cm, the 3-year recurrence free survival 
rate was 40% for the combined treatment group (compared to 10% for the RFA group). 
In a smaller randomized controlled study by Morimoto et al. (4), patients with solitary 
HCC of >3-5cm were allocated to treatment with either cTACE followed by RFA (n=19) or 
RFA only (n=18). Local tumor progression at the end of the third year in the cTACE-RFA 
group was 6% compared to 39% in the RFA group (p = 0.012). 
Comparison of the results of the studies by Peng and Morimoto with our study results 
suggests that better outcomes may be achieved with a sequence of cTACE followed by 
RFA rather that with RFA followed by DEBTACE. It can be debated whether the better 
outcome after cTACE-RFA is a result of the difference in the type of TACE or of the differ-
ence in the treatment sequence. 
In our opinion, the type of TACE is less likely to have significant impact on treatment 
outcome. In the Precision V trial, the objective response rate after DEBTACE was higher 
than after cTACE, but the difference between the two treatments did not reach statisti-
cally significance (6). We believe that differences in efficacy between cTACE-RFA and 
RFA-DEBTACE are more likely due to the difference in treatment sequence. It has been a 
long lasting debate in the interventional radiology community whether TACE should be 
performed before or after RFA when combining both treatments. The rationale for one 
or the other sequence is different. RFA induces hyperemia in a marginal zone between 
the ablated area and surrounding tissue. This marginal zone encompasses the periphery 
of the tumor in which viable tumor cells may be present as well as the area where most 
satellite nodules tend to be (20). When TACE is performed within several days after RFA, 
the hyperemia can be used to deliver a high dose of the chemotherapeutic agent to this 
marginal zone. This marginal zone is not specifically targeted when TACE precedes RFA. 
The most important theoretical advantage of this sequence is that it may reduce local 
tumor progression caused by heat sink. Embolization of the hepatic arteries feeding the 
tumor will result in reduced intra- and perilesional blood flow during the ablation. When 
TACE is performed after RFA, nothing is done to prevent heat-sink during the ablation. 
Our study results now allow comparison of long-term results of RFA-DEBTACE with those 
of cTACE-RFA. Local tumor progression free-survival rates in our study were lower com-
pared to those reported in studies on cTACE-RFA. The most likely explanation for this 
would be that cTACE-RFA reduces the risk of tumor recurrence due to heat-sink, whereas 
RFA-DEBTACE does not prevent this type of recurrence. To date, there is limited data 
on the efficacy of combined RFA and TACE for inoperable HCC. The optimal treatment 
strategy in HCCs >3cm is yet to be determined and further studies are warranted. Based 
on a comparison of our results with results of studies using cTACE-RFA, we would argue 
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that a sequence of TACE followed by RFA should be the preferred sequence in further 
studies combining both treatments.
The retrospective nature of our study and the relatively small number of patients are 
limitations of this study. We did not randomize patients to treatment with either RFA 
or RFA-DEBTACE and therefore direct comparison between the two treatments is not 
possible. Furthermore, we were only able to compare our results of RFA-DEBTACE with 
historical data on cTACE-RFA.
In conclusion, local tumor progression free-survival rates for HCC >3cm-7cm are low 
compared to those after RFA for smaller tumors. The 3-year local tumor progression 
free-survival rate after RFA-DEBTACE was 17.9% in our study and this is low compared to 
results reported after cTACE-RFA for HCC with similar size.
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Pilot study evaluating catheter-directed contrast-
enhanced ultrasound compared to catheter-directed 
computed tomography hepatic arteriography as adjuncts 
to digital subtraction angiography to guide transarterial 
chemoembolization
Burgmans MC, van Erkel AR, Too CW, Coenraad MJ, Lo RHG, Tan BS. 




To investigate the feasibility and procedural value of catheter-directed contrast-
enhanced ultrasound (CCEUS) compared with catheter-directed computed tomography 
hepatic arteriography (CTHA) in patients undergoing transarterial chemoembolization 
(TACE) guided by digital subtraction angiography (DSA).
Methods
From December 2010 to December 2011, a pilot study was conducted including 9 
patients (mean age 66.6 years; SD 8.3 years; seven men) undergoing TACE with drug-
eluting beads for unresectable hepatocellular carcinoma (HCC). Both CCEUS and CTHA 
were performed in addition to DSA. Alterations of treatment plan based on CCEUS were 
recorded and compared with CTHA.
Results
CCEUS provided additional information to DSA altering the treatment plan in 4 out of 
9 patients (44.4%). In these four patients, CCEUS helped to identify additional tumor 
feeders (n=2) or led to a change in catheter position (n=2). The information provided by 
CCEUS was similar to that provided by CTHA. 
Conclusion
CCEUS is a potentially valuable imaging tool in adjunction to DSA when performing 
TACE and may provide similar information as CTHA.
Catheter-directed contrast-enhanced ultrasound-guided TACE 73
IntRoDUCtIon
Transarterial chemoembolization (TACE) improves survival in patients with intermedi-
ate stage hepatocellular carcinoma (HCC) (1-3). Traditionally, TACE is guided by digital 
subtraction angiography (DSA). Yet the information obtained with DSA is limited as 
DSA only allows two-dimensional imaging. Different studies have shown the value of 
catheter-directed computed tomography hepatic arteriography (CTHA) and cone-beam 
computed tomography (CBCT) when performing transarterial liver therapies (4-8). 
These techniques allow accurate multi-planar visualization of tumor enhancement and 
improve identification of tumor-feeding arteries. The image quality of CTHA is superior 
to CBCT as a result of higher soft tissue contrast resolution and CTHA allows imaging 
with a larger field of view (9). 
Contrast-enhanced ultrasound with catheter-directed intra-arterial injection (CCEUS) 
may potentially be a good alternative to CTHA or CBCT. CCEUS enables real-time visu-
alization of tumor enhancement in multiple directions. Moreover, it is widely available 
and does not expose the patient to radiation. The aim of this prospective pilot study 
was to evaluate the procedural impact of CCEUS when used in addition to DSA to guide 
TACE with drug-eluting beads (DEB-TACE) in patients with intermediate stage HCC and 
to compare CCEUS with CTHA.
MetHoDs
Patients
The study was approved by the local ethics committee. Informed consent was obtained 
for all study patients. From December 2010 to December 2011, nine consecutive patients 
with HCC were included in the study (mean age 66.6 years; SD 8.3 years; seven men). 
Inclusion criteria for the study were: unresectable HCC, Child-Pugh A or B and ECOG 
performance status <2. The diagnosis of HCC was confirmed according to American As-
sociation for the Study of Liver Diseases (AASLD) practice guidelines criteria (10). Exclu-
sion criteria were age < 18 years, diffuse HCC or more than 5 lesions, previous treatment 
with TACE or radioembolization, advanced stage disease according to Barcelona Clinic 
Liver Cancer (BCLC) criteria (11), total bilirubin >3 mg/dL, uncorrectable coagulopathy, 
end-stage renal failure, any contra-indication for doxorubicin, known hypersensitivity 
to sulphur hexafluoride (SF6) micro-bubbles, known right-to-left intra-cardiac shunts, 
severe pulmonary hypertension, pregnancy.
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All patients provided written informed consent. The study was performed in accordance 
with the Declaration of Helsinki, the International Conference on Harmonization Guide-
line on Good Clinical Practice and relevant local laws and regulations.
Design and procedures
All patients enrolled in the study underwent grey-scale ultrasonography in the an-
giography room prior to TACE. In addition to this, contrast enhanced ultrasound was 
performed with injection of 2.4ml SF6 microbubbles (SonoVue, Bracco International, 
Amsterdam, The Netherlands) through a cannula in the median cubital vein (IVCEUS). 
Additional boluses of 2.4ml of microbubbles were given, if the distance between dif-
ferent tumors was such that the enhancement of each tumor could not be analyzed 
optimally during a single injection. Sufficient time was allowed in between injections for 
the first bolus of microbubbles to be cleared from the body.
The right groin and upper abdomen were cleansed with iodine and the patient was 
draped under sterile cloths with exposure of the right groin and upper abdomen. Vas-
cular access was created through the right common femoral artery using a 6F vascular 
sheath. Using a 5F C2 catheter (Terumo, Tokyo, Japan) selective DSA from the celiac axis 
(CA), common hepatic artery (CHA) and proper hepatic artery (PHA) was performed with 
pump injection of a contrast agent (Omnipaque 300; GE Healthcare, Shanghai, China). 
Angiography from the superior mesenteric artery (SMA) was performed in individual 
cases when hepatic tumor supply from an aberrant right hepatic artery or other SMA 
branches was expected based on pre-procedural CT or magnetic resonance imaging 
(MRI). Immediately after DSA from the PHA and using the same catheter position, CCEUS 
was performed followed by CTHA. A 2.2F or 2.7F Progreat catheter (Terumo, Tokyo, 
Japan) was then used to catheterize the lobar artery of the tumor bearing lobe(s) and se-
lective DSA was performed. Again, this was followed by CCEUS and then CTHA with the 
micro-catheter in the same position. Finally, the (sub)segmental arteries were catheter-
ized using the micro-catheter and sequential DSA, CCEUS and CTHA were performed. 
In patients with bilobar disease, imaging at a lobar and (sub)segmental level was first 
performed on one side followed by TACE of the tumors in that lobe. After that, images 
were obtained at a lobar and (sub)segmental level on the other side and the tumors in 
the other lobe were treated.
DSA images were obtained with breath-hold, 3 frames/sec and 50mAs/120kV for antero-
posterior projections. Using a Mark V ProVis injector (Medrad Inc, Warrendale, PA, USA), 
contrast medium was injected at 6ml/sec for 25ml for the CA, 5ml/sec for 15ml for the 
PHA, 3ml/sec for 12ml for lobar injections and 1-2ml/sec for 6-10 ml for (sub)segmental 
injections. CCEUS was performed using contrast harmonic imaging on a high-perfor-
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mance processor (Aplio, Toshiba Medical Systems, Tokyo, Japan) with a multifrequency 
curved-array probe (2–5 MHz). SF6 micro-bubbles were slowly hand-injected. Injections 
of 1ml were used for the PHA, 0.5ml for the lobar artery and 0.3-0.5ml for (sub)segmen-
tal arteries. During the injection, the entire tumor volume was scanned to assess the 
presence of unenhancing areas. CTHA was performed using a hybrid 16-slice Aquilion 
CT/ Infinix VC-1 angiography system (Toshiba Medical Systems, Tokyo, Japan). Pump-
injections were used with an injection rate similar to that used for DSA. The injected 
contrast volume for CTHA was calculated using the equation: 
volume = (scan delay + scan time) x flow rate
with the scan delay being the time between the start of injection and enhancement of 
the region of interest at DSA. CTHA images were acquired using the following param-
eters: collimation 16x1.0, pitch factor 15, helical pitch 0.938, 120kV and 160 effective 
mAs. The radiation dose used to perform CTHA was recorded as dose length product 
(DLP) per patient.
All patients underwent super-selective TACE with the micro-catheter placed as selec-
tively as possible. TACE was performed with DC-Bead (Biocompatibles, Surrey, UK). First 
1 vial of 100-300 µm beads was injected, followed by 1 vial of 300-500 µm beads. The 
beads were loaded with a total of 150mg of doxorubicin (75mg per vial) and mixed with 
contrast medium prior to injection.
All patients underwent repeated IVCEUS immediately after TACE. Both IVCEUS and 
CCEUS were performed by the interventional radiologist performing the procedure. All 
IVCEUS and CCEUS images were archived digitally for review as cine loops in Windows 
Media Videos (Microsoft, Redmont, WA, USA).
Imaging analysis
At the time of the procedure, DSA images were analyzed by the interventional radiologist 
performing the procedure and a treatment plan was formulated. Then CCEUS images 
were analyzed to see if CCEUS provided additional information to DSA. CCEUS images 
were compared to pre-procedural IVCEUS images. If incomplete tumor enhancement 
was seen at CCEUS from the hepatic arteries, this prompted a search for extra-hepatic 
feeding arteries. If tumor enhancement was incomplete upon CCEUS from a lobar or 
(sub)segmental artery, but not upon CCEUS from a more proximal hepatic artery injec-
tion, the catheter was repositioned more proximally prior to injection of DC-Bead. The 
information obtained with CCEUS was classified into three categories: 1. no change in 
treatment plan; 2. identification of additional tumor feeding arteries; 3. alteration in 
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location of injection of the drug-eluting beads. After this, CTHA images were analyzed to 
see if CTHA provided information not evident on DSA and CCEUS.
IVCEUS images obtained before and after TACE were retrospectively compared to see if 
complete devascularization of tumors was achieved.
ResULts
Patient and tumor characteristics are summarized in Table 1. Nineteen HCCs were identi-
fied on pre-procedural cross-sectional imaging (CT and/or MRI) with an average of 2.1 
(range 1-5) tumor per patient. The mean maximal tumor size was 45.3 mm (range 10-145 
mm). 
table 1. Baseline patient and tumor characteristics.
Patient and tumor characteristics Value




 0 8 (88.9)
 1 1 (11.1)
Cause of cirrhosis (n=9)
 Hepatitis B 6 (66.7)
 Alcohol 2 (22.2)
 NASH 1 (11.1)
Child Pugh score (n=9)
 A 8 (88.9)
 B 1 (11.1)
Tumor burden (n=9)
 Unilobar 6 (66.7)
 Bilobar 3 (33.3)
No. nodules (n=9)
 1-3 8 (88.9)
 >3 1 (11.1)
Tumor diameter (n=19)
 1-3cm 10 (52.6)
 3-5cm 2 (10.5)
 5-10cm 3 (15.8)
 >10cm 4 (21.1)
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In four patients (44.4%), the information provided by CCEUS was not evident at DSA and 
led to a change of treatment plan. In two of these four patients (22.2% of total) CCEUS 
led to identification of additional tumor feeding arteries. Both patients had a right liver 
lobe tumor with a dominant vascular supply from the right hepatic artery. At DSA from 
the right hepatic artery, incomplete tumor enhancement was not evident. Yet, at CCEUS, 
there was incomplete enhancement of the tumor and this eventually helped in identify-
ing additional tumor supply from the middle hepatic artery (Figure 1). In the two other 
patients (22.2%), CCEUS provided information that led to a change in the decision on 
where to inject the DC Bead. In these cases CCEUS allowed a more selective chemo-
embolization while ensuring that the entire tumor was accurately targeted (Figure 2). 
In four patients where CCEUS provided information that led to a change in treatment, 
CTHA provided the same information (Figure 1 and 2). CTHA did not provide additional 
information that led to a change in treatment plan.
Figure 1. 58-yearr-old male with right liver lobe HCC with a maximal diameter of 12 cm. (a) DSA from the 
celiac axis (CA) shows tumor enhancement (asterix) through the right hepatic artery (RHA) (arrow). There 
is a left hepatic artery (LHA) that originates from the left gastric artery (arrowhead). No middle hepatic 
artery (MHA) is seen. (b) CCEUS (left) and B-mode (right) image during injection of SF6 microbubbles into 
the RHA. Marked arterial enhancement of the tumor (arrowheads) is seen compared to the non-tumorous 
liver parenchyma (cross-mark). Absent enhancement is seen in part of the tumor (asterix) (c) CTHA from the 
RHA also shows absent enhancement in part of the tumor (asterix). (d) DSA from the superior mesenteric 
artery shows retrograde flow through the gastroduodenal artery (GDA) (arrow) and opacification of the 
MHA (black arrowhead) and a second LHA (white arrowhead). This MHA and LHA have an origin from the 
CA that was not opacified at DSA from the CA due to the reversed flow through the GDA. (e) CCEUS (left 
image) from the MHA shows tumor supply (asterix) through the MHA with absent enhancement in the rest 
of the tumor (cross-mark). (f ) CTHA from the MHA also shows enhancement of part of the tumor through 
the MHA.
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The use of CTHA did result in additional information on extra-hepatic enhancement that 
was not provided by DSA and CCEUS. In four patients (44.4%), CTHA revealed enhance-
ment of the gallbladder (GB) (n=1), the hepatic falciform artery (HFA) (n=2) or both the 
GB and HFA (n=1) when contrast was injected from the intended location of release of 
the drug-eluting beads. This information did not alter the treatment plan. None of these 
4 patients developed complications related to injection of drug-eluting beads into the 
cystic artery or HFA.
Figure 2. 79-year-old man with a 4.5 cm HCC at the border of segment 6 and the caudate lobe. (a-b) DSA 
from the common hepatic artery (black arrow) in arterial (a) and parenchymal (b) phase with opacification 
of the tumor (white arrow). (c) CCEUS from the subsegmental artery showed complete tumor enhancement 
(white arrow) with enhancement of a small portion of non-tumorous liver parenchyma (arrowhead) and 
no enhancement of most of the right liver lobe (asterisk). (d) CTHA confirmed enhancement of the entire 
tumor upon injection of contrast into the subsegmental artery. CCEUS and CTHA thus ensured complete 
tumor targeting by injection of drug-eluting beads into the subsegmental artery. IVCEUS directly after 
treatment and CT at 6 weeks showed complete devascularization of the tumor (not shown).
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IVCEUS immediately after TACE showed complete devascularization of liver tumors in 5 
patients (55.6%). The 4 patients with residual enhancement at IVCEUS all had large liver 
tumors (>10cm). In these patients, vascular stasis was not achieved after delivery of the 
full dose of drug-eluting beads and the decision was made to treat the remaining viable 
tumor during a second TACE procedure. The area of residual enhancement on IVCEUS 
corresponded to the vascular territory of the supplying artery that was not completely 
embolized, indicating that residual enhancement was not a result of failure to detect 
additional tumor feeding arteries. 
The mean DLP per patient was 921.5 mGy•cm (SD 371.7 mGy•cm) 
DIsCUssIon
The objective of TACE is to accurately target the entire tumor while preserving the non-
tumorous liver parenchyma and extra-hepatic organs. To achieve this, it is generally rec-
ommended to deliver the beads as selective as possible (12). Super-selective injection, 
i.e. into the segmental or sub-segmental arteries, is associated with better treatment 
outcomes compared to lobar or whole liver chemo-embolization (13). 
DSA is used to guide the delivery of the drug-eluting beads. Yet, DSA only enables two-
dimensional imaging. As a result, incomplete tumor enhancement may not be detected 
during hepatic DSA. This is especially true if the non-enhancing tumor parts are located 
anterior or posterior as hepatic DSA images are usually obtained in posterior-anterior or 
moderately oblique projections. 
There are two important causes for incomplete tumor enhancement during hepatic DSA. 
The most important cause is the presence of extra-hepatic feeding arteries. Unfortunately, 
up to 37% of patients with HCC may have a collateral tumor supply through extra-hepatic 
arteries (5). Second, incomplete tumor enhancement may be due to a highly selective 
catheter position. Treatment at a (sub)segmental level carries the risk that the catheter 
is placed distally to additional hepatic feeders. Failure to detect absent enhancement of 
tumor parts during hepatic DSA may thus result in incomplete tumor treatment. 
Different studies have shown that catheter-directed cross-sectional imaging such as 
CTHA and CBCT allow accurate multi-planar visualization of tumor enhancement and may 
improve tumor targeting (4-8). In the present study we compared CCEUS and CTHA as an 
adjunct to DSA to guide TACE. CCEUS proved to be safe and feasible. In 44.4% of patients, 
CCEUS provided information that was not evident on DSA and altered the treatment ap-
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proach. The additional information provided by CCEUS was similar to that provided by 
CTHA. Although the number of patients in our study is limited, the findings suggest that 
CCEUS may improve trans-arterial liver tumor targeting, as does CTHA. In a viable tumor 
incomplete enhancement upon contrast injection from the hepatic arteries may indicate 
extra-hepatic tumor supply. Complete tumor enhancement upon contrast injection from 
a super-selective hepatic artery position allows the operator to feel confident that the 
entire tumor is targeted, whereas incomplete enhancement may prompt the search for 
additional feeding hepatic arteries. CCEUS offers an important advantage over CTHA. It 
can be repeated multiple times without increasing iodinated contrast volume or radiation, 
whereas computed tomographic imaging during TACE results in significant increase of the 
radiation dose to both the patient and operating staff (14,15). 
Few centers have access to a hybrid CT/angiography system that allows CTHA images 
to be obtained without moving a patient between rooms. CBCT is available to many 
more interventional radiologists and is much more frequently used as an adjunct to DSA 
during TACE. CCEUS and CBCT were not compared in the present study. Yet, CCEUS may 
offer several additional advantages over CBCT. CBCT has a relatively long acquisition 
time (8-20sec) making this technique more susceptible to breathing artifacts, whereas 
breathing is not an issue in CCEUS. Another drawback of CBCT is the limited field of view 
(FOV). CCEUS is less hindered by limitations in the FOV as it can be repeated multiple 
times to cover larger areas without radiation or risk of contrast-induced nephropathy. 
The standard volume of SF6 microbubbles of hepatic IVCEUS in our institution at the 
time of the study was 2.4ml. Modern high-end ultrasound machines enable good qual-
ity IVCEUS imaging with lower dosages and may therefore also allow the use of lower 
volumes of microbubbles for CCEUS then those used in this study.
The main limitation of our study is the limited number of patients. Second, the useful-
ness of CCEUS was not compared with CBCT, which is more widely used than CTHA. 
Yet, CTHA was used as the gold standard in the present study as this technique has 
better image quality and a larger field of view compared to CBCT. Furthermore, CCEUS 
was inferior to CTHA in providing information on extra-hepatic enhancement. Yet, the 
information provided by CCTA did not alter the treatment strategy and no extra-hepatic 
organ injury was seen. 
In conclusion, CCEUS is a potentially useful imaging tool in adjunction to DSA when 
performing TACE. It may provide similar multi-planar information on tumor enhance-
ment as CTHA without increasing iodinated contrast volume or radiation, yet further 
studies are warranted to determine the role of CCEUS.
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Radioembolization with infusion of Y90 microspheres into 
a right inferior phrenic artery with hepatic tumor supply is 
feasible and safe
Burgmans MC, Kao YH, Irani FG, Dames E, Teo TK, Goh ASW, Chow PKH, Tay KH, 
Lo RHG




To evaluate the feasibility and safety of yttrium-90 (Y90) radioembolization through the 
inferior phrenic arteries (IPAs).
Methods
Retrospective analysis of 108 patients referred for radioembolization to treat primary 
(n=103) or secondary (n=5) liver malignancy was performed. Five patients had their 
hepatic malignant tumors supplied by the IPA and met the inclusion criteria for infu-
sion of Y90 spheres into the IPA. DSA, catheter-directed computer tomography hepatic 
angiography (CTHA) and technetium-99m macroaggregated albumin (Tc-99m MAA) 
SPECT/CT were used to plan treatment. Bremsstrahlung SPECT/CT was performed 1 day 
after radioembolization. Follow-up included clinical and biochemical tests and cross-
sectional CT or MRI.
Results
Parasitized extra-hepatic arteries were detected in 37.0% (n=40) of patients. Of these, 
62.5% (n=25) had tumor supply through an IPA. Of the patients with IPA supply, 20% 
(n=5) underwent infusion of Y90 into the right IPA. Reasons for disqualifying patients for 
infusion into the IPA were less than 10% tumor supply (n=11), failed catheterization of 
IPA (n=3), arterioportovenous shunt (n=2), failed identification of IPA at pre-treatment 
angiography (n=1), and gastric or esophageal enhancement on CTHA (n=3). In all 
5 patients technical success was demonstrated on Y90 imaging, with no significant 
extra-hepatic radionuclide activity. No adverse events related to IPA radioembolization 
occurred at mean follow-up of 4.5 months (range 2.2-10.1 months).
Conclusions
Delivery of Y90 microspheres through the right IPA is feasible and safe with the use 
of CTHA in addition to DSA and Tc-99m MAA SPECT/CT in patients with tumors with 
greater than 10% IPA supply.
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IntRoDUCtIon
Radioembolization with yttrium-90 (Y90) microspheres is an effective treatment for pa-
tients with unresectable primary and secondary liver malignancy (1, 2). Microspheres are 
delivered to the hepatic tumors by selective hepatic arterial infusion. The infused micro-
spheres lodge permanently within the vascular bed of the tumor to deliver high-energy 
ß-radiation (3). As each microsphere has a limited therapeutic range (mean tissue range 
2.5mm; maximum 11mm), adequate deposition of microspheres throughout the entire 
tumorous region is essential to achieve optimal treatment results. This may be difficult 
or impossible to achieve in patients with tumors supplied by parasitized extra-hepatic 
arteries (PEAs). Unfortunately, 17-30.8% of patient with liver malignancies may have 
tumor supply through PEAs (4-7). The inferior phrenic arteries (IPAs) are responsible for 
the extra-hepatic supply in the vast majority of cases (4,6,8). Infusion of Y90 into the IPAs 
is generally considered not to be feasible because of the risks of non-target radiation 
injury (6,9).
We hypothesized that selective radioembolization into the IPAs is feasible and safe in 
selected patients when using a combination of digital subtraction angiography (DSA), 
catheter-directed computed tomography hepatic angiography (CTHA) and technetium-
99m macroaggregated albumin (Tc-99m MAA) single photon emission computed 
tomography with integrated low-dose computed tomography (SPECT/CT) to plan and 
guide treatment. We retrospectively reviewed the feasibility and safety of infusion of Y90 
microspheres directly into the IPAs.
MetHoDs
Approval by the Institutional Review Board (IRB) of our institution was obtained for this 
retrospective study.
Patients
We retrospectively reviewed reports and images of all pre-treatment and treatment 
angiograms performed between May 2010 and December 2011. In this period, pre-
treatment angiography with Tc-99m MAA injections were performed in 108 patients for 
the following indications: hepatocellular carcinoma (HCC) in 99 patients (91.7%), metas-
tasis from colorectal carcinoma in 4 patients (3.7%), cholangiocarcinoma in 2 patients 
(1.9%), hepatic angiosarcoma in 2 patients (1.9%) and metastasis from adrenocortical 
carcinoma in 1 patient (0.9%). Patient age ranged from 36-85 years (mean, 63.1 years) 
and 90 patients were male. 
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Among the 108 patients, 81 patients (75.0%) proceeded to have at least one treatment 
session with radioembolization. Seven patients underwent a second radioembolization 
treatment during the study period. All radioembolization procedures were performed 
with Y90 resin microspheres with a diameter of 20-60 µm (SIR-Spheres®, Sirtex Medical 
Limited, New South Wales, Australia).
Pre-treatment angiography and tc-99m MAA
In all patients cross-sectional images obtained with either computed tomography (CT) 
and/or magnetic resonance imaging (MRI) were available and reviewed before the pro-
cedure. The angiographic protocol included selective DSA from the superior mesenteric 
artery, the celiac axis and hepatic arteries. All patients underwent CTHA using a hybrid 
16-slice CT/angiography system (Toshiba, Tokyo, Japan). Selective inferior phrenic DSA 
and CTHA were performed in cases where tumor supply from the IPAs was suspected 
based on the pre-procedural cross-sectional imaging or if incomplete tumor enhance-
ment was seen on DSA and/or CTHA from the hepatic arteries.
Selective DSA of the IPA was performed with a 5F Cobra catheter (Terumo, Tokyo, Japan) 
or 4F Sidewinder catheter (Terumo or Cordis, Miami Lakes, FL, USA). Subsequently, a 
2.2F or 2.7F Progreat catheter (Terumo) was introduced co-axially through the 4F/5F 
catheter and DSA and CTHA were performed. CTHA from the IPA was performed using 
an injection rate of 1-3 ml/sec. The injected contrast volume for CTHA was calculated by 
adding the scan delay and scan time and multiplying the sum by the flowrate, with the 
scan delay being the time between the start of injection and enhancement of the region 
of interest at angiography.
Patients underwent standard coil embolization of hepaticoenteric anastomoses either 
on the day of the pre-treatment angiography or the day of radioembolizaton. In patients 
in whom radioembolization from the IPA was considered, angiography and CTHA im-
ages were carefully reviewed to identify the presence of IPA branches such as inferior 
vena cava, adrenal, esophageal, gastric and diaphragmatic arteries. If feasible, coil em-
bolization of such arteries was performed with 0.018-inch coils (2mm Figure-8 or 3mm 
Diamond-shaped VortX, Boston Scientific, Natick, Massachusetts, USA).
At the end of the procedure, CTHA images were reviewed to visually estimate the con-
tribution to tumor perfusion for each supplying artery as a percentage of total tumor 
perfusion. The Tc-99m MAA (total 5mCi in 3ml; particle size of 10-90µm) was then di-
vided into corresponding portions and slowly hand-injected into each supplying artery. 
For the IPA, the injected volume of Tc-99m MAA ranged between 0.5-1ml (0.8-1.7mCi). 
All patients underwent Tc-99m MAA planar scintigraphy and SPECT/CT using a hybrid 
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SPECT/CT scanner (Philips Precedence, Amsterdam, Netherlands) for calculation of liver-
to-lung shunt fraction and tumor-to-normal liver ratio and to exclude any non-target 
extrahepatic shunting of Tc-99m MAA. Predictive radiation dosimetry was performed by 
Medical Internal Radiation Dose (MIRD) macrodosimetry (ie, ‘partition model’).
Infusion of microspheres into IPA
Before infusion of Y90 microspheres, hepatic angiography and CTHA were repeated. 
Moderate enhancement of the adrenal gland or IVC was not considered to be a contra-
indication for infusion of Y90 microspheres into the IPA. The activity of Y90 microspheres 
injected into the IPA was determined by Tc-99m MAA SPECT/CT predictive dosimetry, in 
accordance with target tissue masses determined by CT volumetry guided by CTHA of 
the IPA. Y90 microspheres were manually infused until the entire calculated dose was 
delivered or angiographic stasis was reached.
safety assessment and follow-up
All patients underwent Y90 imaging one day after radioembolization. Y90 imaging of 
the abdomen was performed by bremsstrahlung SPECT/CT alone or in combination 
with Y90 internal pair production time-of-flight (TOF) positron emission tomography 
with integrated CT (PET/CT) as part of an unrelated research project. Also, planar liver-
to-lung bremsstrahlung scintigraphy was performed. Special attention was paid to Y90 
activity in the tumor area supplied by the IPA versus the rest of the tumor. Liver and renal 
function tests were routinely performed before discharge for all patients. Follow-up 
cross-sectional imaging by CT or MRI was routinely planned 3 months after treatment 
and approximately every 3 months thereafter. Adverse effects were classified into grade 
1 to 5 in accordance with the common terminology criteria for adverse events version 
3.0 (CTCAE v3) (10).
ResULts
Identification of PeAs
Vascular tumor supply through PEAs was detected in 40 of 108 patients (37.0%) who 
underwent preparatory hepatic angiography with Tc-99m MAA injection. Of these 40 
patients, 37 (92.5%) had HCC. Most patients (65.0%) were found to have only one PEA 
(Table 1). A total of 71 PEAs were detected. The IPAs were the most common source of 
extra-hepatic blood supply, seen in 38% of all PEAs (Table 1). Twenty-five patients (62.5% 
of patients with PEAs) had blood supply through one or both IPAs.
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Parasitized extra-hepatic supply through the IPA
The demographics of the 25 patients with tumor supply through an IPA are given in 
Table 2. The mean maximum diameter of liver tumors supplied by the IPA was 13.5cm 
(range 5.8- 20.0 cm). Tumor supply through the right IPA was detected in 19 of the 25 
patients (76.0%), through the left IPA in four patients (16.0%) and through both the right 
and left IPA in two patients (8.0%). Five patients with right IPA supply (26.3%) had a right 
liver lobe tumor with extension to the diaphragm, three (15.8%) had tumor extension to 
the bare area, and 11 (57.9%) had tumor extending to both the diaphragm and the bare 
area. All patients with left or bilateral IPA supply had a liver tumor extending to both the 
diaphragm and the bare area. In 11 (44.0%) patients there was vascular tumor supply 
through at least one other PEA in addition to the IPA supply.
treatment IPA
In 17 of the 25 patients with blood supply through one or both IPAs (68.0%), the option 
of infusion of radioactive microspheres through the IPA was rejected without perform-
ing CTHA from the IPA (Table 3). The feasibility of performing radioembolization from 
table 1. Parasitized extra-hepatic arteries (PEAs): number per patient and types
Number of PEAs per patient n (total = 40) %
 1 artery 26 65.0
 2 arteries 8 20.0
 >2 arteries 6 15.0
Identified PEAs n (total = 71) %
Inferior phrenic 27 38.0
 Right 21 29.6
 Left 6 8.5
Right middle and/or inferior adrenal 7 9.9
Pancreaticoduodenal arcade 6 8.5
Right renal capsular 6 8.5
Right gastro-epiploic 5 7.0
Cystic 4 5.6
Right gastric 4 5.6
Gastroduodenal branch 3 4.2
Superior mesenteric branch 3 4.2
Intercostal 2 2.8
Superior phrenic 1 1.4
Supraduodenal 1 1.4
Left gastroepiploic 1 1.4
Splenic artery branch 1 1.4
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the IPA was not further evaluated in these patients because of IPA supply less than 10% 
(n=11), failed catheterization of the IPA (n=3), arterioportovenous shunting (n=2), or 
failed identification of the IPA supply at the time of pre-treatment angiography (n=1). 
Eight patients did undergo CTHA from the IPA to evaluate the safety of microsphere 
infusion into the IPA. 
In three of the eight patients who underwent CTHA from the IPA, Y90 microspheres infu-
sion into the IPA was not considered safe based on imaging findings and Tc-99m MAA was 
therefore not injected into the IPA. In one patient, CTHA from the left IPA showed marked 
gastric enhancement through several small IPA branches. There was also tumor supply 
seen through the right IPA, but this was estimated to be less than 10% of the overall tumor 
table 2. Demographics patients with inferior phrenic artery (IPA) supply (n=25)
Characteristic Value
Age mean 62.4 yrs 
range 39-83 yrs
Sex n (total =25) %
 Male 22
 Female 3
Tumor type n %
 HCC 25 100
Tumor distribution n %
 Bilobar 16 64.0
 Unilobar 9
Child-Pugh score n %
 A 20 80.0
 B 5 20.0
Vascular invasion 16 64%
Lymph node metastasis 2 8%
Distant metastasis 0 0%
BCLC stage
 A 7 28.0%
 B 2 8.0%
 C 16 64%
BCLC stage = Barcelona Clinic Liver Cancer staging system, HCC = hepatocellular carcinoma
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burden. Transarterial embolization (TAE) of both the right and left IPA was performed us-
ing 250-355 µm polyvinyl alcohol (PVA) particles (Contour; Boston Scientific) in the same 
setting as radioembolization through the hepatic arteries. In another patient, CTHA from 
the right IPA showed a small area of esophageal enhancement and marked enhancement 
of the right adrenal gland. In the third patient, reflux with enhancement of the adrenal 
glands and esophagus was seen at catheter-directed cross-sectional imaging from the 
right IPA. In the second and third patients, coil embolization of the IPA was performed 
in order to re-establish intrahepatic antegrade flow to the tumor area supplied by the 
IPA. Yet, in both patients we failed to demonstrate satisfactory re-establishment of flow 
table 3. Tumor characteristics, IPA supply and treatment of IPA territory
Parameter Value
Diameter of tumor with IPA supply Mean 13.5cm (range 5.8 to 20.0 cm) 
Location of tumor supplied by IPA n (total =25) %
 In contact with diaphragm 5 20.0
 Bare area 3 12.0
 In contact with diaphragm and bare area 17 68.0
Area supplied by IPA
 <10% of entire tumor volume 11 44%
 10-20% 7 28.0%
 20-30% 4 16.0%
 30-40% 3 12.0%
Treatment IPA territory per patient n (total =25) % (of total) Rationale not to attempt RE through 
IPA 
 No treatment 15 60.0%
11 44.0% <10% supply
3 12.0% Failed catheterization IPA
1 4.0% Large APV shunt
 TACE 1 4.0% IPA supply not identified at preparatory 
DSA. Disqualified from RE because of 
lung shunt
 TAE 2 8.0%
1 4.0% Shunt IPA to PV
1 4.0% Gastric enhancement on CCTA
 Coil-embolization 2 8.0%
2 8.0% Esophageal enhancement on CCTA
 Radioembolization 5 20%
RE = radioembolization; TACE = trans-arterial chemo-embolisation; TAE = transarterial embolisation; PV = 
portal vein; CCTA = catheter-directed computer tomography angiography
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through intra-hepatic collaterals to the IPA territory using DSA, CTHA and SPECT/CT. In five 
of the 25 patients (20%), Y90 microspheres were infused directly into the right IPA.
Infusion of Y90 microspheres into the IPA
Y90 microspheres were infused into the right IPA in all five cases with radioembolization 
through the hepatic arteries in the same session. Two patients had been treated with ra-
dioembolization once before, but without infusion of microspheres into the IPA. In one 
patient, the IPA supply was not identified during the first treatment. The other patient 
had undergone treatment twice with conventional TACE prior to the first radioemboliza-
tion. Uncomplicated TACE had been performed from the right IPA during the second 
TACE session.
All 5 patients had large hypervascular right liver lobe tumors (mean diameter 18.2 cm; 
range 15.1-20.0 cm). Selective angiography and CTHA showed good forward flow and 
absence of reflux in all 5 cases. The mean activity of Y90 microspheres infused into the 





Figure 1. Images from a 64-year-old male with a large HCC. (a) DSA from the right hepatic artery (RHA) 
(white arrow) shows enhancement tumor (arrowheads). CTHA from the RHA showed absent enhancement 
of the posterior portion of the tumor (not shown). (b) DSA from the right IPA shows tumor supply (arrow-
heads) through the descending branch of the IPA (black arrow) and no obvious tumor supply from the 
ascending IPA branch (white arrow). (c+d). CTHA from the IPA shows enhancement of the posterior portion 
of the tumor (arrows) and the diaphragmatic crus (arrowheads) (c). The ascending IPA branch (arrowheads) 
does not supply the tumor (d). (e) Coils (black arrows) have been placed in the ascending IPA branch before 
infusion of Y90 microspheres into the RHA and right IPA. (f ) Bremsstralung scan shows Y90 activity in the 
entire tumor, including the IPA territory (arrowheads).
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performed of a diaphragmatic branch that was shown to supply the diaphragm and no 
tumor (Figure 1).
In one of the five patients, a small adrenal artery with tumor supply was seen to origi-
nate from the right IPA branch (Figure 2). TAE of this adrenal artery was performed with 
150-250 µm PVA particles (Contour, Boston Scientific, Natick, MA, USA), and Y90 micro-
spheres were infused into the IPA from a more distal position. In three of the five patients 
(60.0%), CTHA from the IPA showed mild to moderate enhancement of the right adrenal 








Figure 2. Images from 52-year-old male with a HCC in segment 4, 5, 6, 7 and 8. (a) DSA from the proper 
hepatic artery shows the large hypervascular tumor. Poor enhancement of the cranio-medial area is seen 
(asterix). Embolization of the gastroduodenal artery and right gastric artery has been performed with re-
spectively an Amplatzer vascular plug 4 and microcoils (black arrow). (b) DSA from the right IPA (small 
black arrow) shows enhancement of the cranial portion of the tumor and supply to a small tumor area 
(large black arrow) through a proximal adrenal artery branch (white arrow). (c). CTHA from the IPA shows 
enhancement of the cranial tumor part (arrowheads). (d) DSA from the adrenal artery through a micro-
catheter (arrowheads) shows the small area of tumor enhancement (arrow). The adrenal artery was embo-
lized using PVA particles. (e) After placement of the microcatheter (arrowheads) more distally into the IPA, 
Y90 microspheres were infused. This was followed by infusion into the proper hepatic artery. (f ) PET/CT 
performed 1 day after radioembolization shows higher Y90 activity in the IPA territory (arrow) compared 
to the rest of the tumor. 
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Y90 activity in IPA territory
All five patients who underwent infusion of microspheres into the IPA showed Y90 activ-
ity in the IPA territory on bremsstralung SPECT/CT. In three patients, homogenous activ-
ity was seen in the entire IPA territory. In the patient who underwent TAE of the adrenal 
artery, the small area supplied by this artery did not show Y90 activity. In another patient 
there was good Y90 activity in the medial portion of the IPA territory, but unsatisfactory 
activity in the lateral portion. Before infusion of microspheres, TAE of a right renal cap-
sular artery was performed with 355-500 µm PVA particles (Contour, Boston Scientific). 
This capsular artery also showed competing supply to the lateral area of the IPA territory 
and the lack of Y90 activity was thought to be a result of the TAE.
safety of radioembolization into IPA
One of the five patients who underwent radioembolization into the IPA developed a 
small puncture site hematoma during the procedure. No other intra-procedural com-
plications were encountered in these five patients. In all five patients radioembolization 
was performed under local anesthesia and none of the patients required additional 
administration of analgesics during or after the procedure.
The mean follow-up duration for the five patients was 4.5 months (range, 2.2-10.1 
months). One patient who had come from overseas for medical treatment in our in-
stitution was lost to follow-up. He was well at the time of discharge from the hospital 
and returned to his home country 7 days after radioembolization. None of the patients 
developed adverse effects attributable to radioembolization into the IPA.
DIsCUssIon
Radioembolization through PEAs is generally considered to be contraindicated because 
of the high risk of non-target radiation (6,9). Unfortunately, up to 30.8% of patients with 
a hepatic malignancy will have vascular tumor supply through one or more PEAs (4-7). 
In our study, 37.0% of patients had one or more PEAs supplying part of their hepatic 
neoplasms. The IPAs are the most frequent source of extrahepatic collateral blood sup-
ply to hepatic tumors (4-6,8). In the present study, 62.5% of patients with PEAs had 
tumor supply through one or both IPAs. Particular risk factors for parasitized supply 
through the IPAs are a tumor location in the bare area and contact of the tumor with the 
diaphragm (11).
The right and left IPA divide into an ascending and descending branch and give rise 
to superior suprarenal and middle suprarenal branches. The right IPA may give rise to 
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arteries to the IVC, whereas the left IPA can give rise to accessory splenic, gastric and 
esophageal branches (11, 12). Potentially, the IPA can communicate with systemic arter-
ies such as the internal mammary, intercostal, musculophrenic and pericardiophrenic 
arteries (12,13). Transpleural intercommunication with the pulmonary arteries can also 
exist, usually in patients with underlying chronic lung inflammation (14).
Administration of Y90 microspheres into the IPAs has been deemed unsafe because of 
the potential risks of radiation injury to the diaphragm and adrenal glands (6,9). In ad-
dition to this, spheres that are infusion into the right IPA could theoretically find their 
way through branches supplying the IVC, causing radiation injury to the IVC. Infusion of 
Y90 into the left IPA could theoretically result in radiation injury to the spleen, stomach 
or distal esophagus. In addition, reflux could occur into the communicating systemic 
arteries or into the vessel from which the IPA originates. Patients with intercommunica-
tion of the IPA and pulmonary vessels are at risk of radiation pneumonitis or even diffuse 
systemic irradiation if the microspheres shunt into the pulmonary veins (6).
Different strategies can be adopted in patients with PEAs. TAE and TACE have been 
successfully performed through different PEAs, although TACE from the IPA may be 
complicated by pleural effusion and atelectasis (7,11,15-22). Although TAE and TACE are 
feasible treatments to address parts of the hepatic malignancy supplied by PEAs, they 
are not the preferred option. Those patients that are assessed to undergo radioemboli-
zation, often have been selected either because of disease progression after TACE or a 
contra-indication to TACE such as portal vein embolization. Another option to address 
parasitized extra-hepatic supply was recently reported by Abdelmaksoud et al. in a study 
including 35 patients with 73 PEAs (6). Prior to Y90 microspheres infusion, the authors 
attempted to eliminate parasitic perfusion and restore intrahepatic blood supply to liver 
tumors by embolizing the PEAs with large particles and coils. After this method had 
been employed, successful re-establishment of antegrade flow through intra-hepatic 
collateral vessels into tumor areas previously supplied by PEAs was confirmed by both 
DSA and C-arm CT in 94% of territories and by scintigraphy in 96%. They also observed 
symmetric regional tumor response in 94% of patients and this was inferred as success-
fully delivery of microspheres to the territories previously supplied by PEAs. The method 
of embolization of PEAs offers an important advantage, as the risk of nontarget radia-
tion is substantially lower when Y90 microspheres are infused into the hepatic arteries 
instead of into a PEA. However, there are uncertainties with regards to the approach 
of coilembolization. In the study of Abdelmaksoud et al., there was no histological 
confirmation of successful delivery of microspheres in the areas supplied by the PEAs. 
Only surrogates to measure microspheres implantation were used, such as contrast 
enhancement, Tc-99m MAA uptake, and tumor response. Furthermore, many patients 
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in the study by Abdelmaksoud et al. had also received adjuvant systemic therapy after 
radioembolization. Tumor response may therefore not only be a result of successful 
implantation of Y90 microspheres in the PEA territories. The biggest disadvantage of the 
method of embolizing the PEAs is that the success of microspheres delivery to the PEA 
territories remains unpredictable and accurate predictive radiation dosimetry for the 
PEA territories is therefore difficult.
In our study, five patients underwent radioembolization with direct infusion into the IPA. 
In all 5 cases infusion of microspheres was performed from the right IPA. None of the 
five patients experienced serious adverse events at a mean follow-up of 4.5 months. The 
use of CTHA was considered to be crucial in selecting patients for radioembolization via 
the IPA. CTHA provides the necessary complementary information to DSA with better 
image quality and spatial resolution than cone-beam CT and Tc-99m MAA scintigraphy. 
Furthermore, CTHA enables the vascular territory of a particular artery to be accurately 
delineated. Artery-specific CT volumetry guided by CTHA achieves accurate tissue mass 
estimates for improved radiation dosimetry to the IPA territory – a current practice at 
our institution (23).
Limitations of our study are the retrospective nature and the small number of patients. 
Further studies are needed to confirm the safety of infusion of radioactive microspheres 
into the IPA.
In conclusion, this study shows that the delivery of beta-emitting microspheres through 
the right IPA is feasible and safe in selected patients. The use of CTHA in addition to DSA 
and Tc-99m MAA scintigraphy is crucial in minimizing the risk of non-target radiation 
injury. The study does not support any conclusions on the infusion of Y90 microspheres 
into the left IPA or other PEAs. The risk of radiation injury to the esophagus or stomach is 
likely to be significantly higher when infusion of spheres would be performed from the 
left IPA versus the right IPA.
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Chapter 7
Computed tomography hepatic arteriography has a hepatic 
falciform artery detection rate that is much higher than that 
of digital subtraction angiography and 99mTc-MAA SPECT/
CT: implications for planning Y90 radioembolization
Burgmans MC, Too CW, Kao YH, Goh ASW, Chow PKH, Tan BS, Tay KH, Lo RHG. 




To compare the hepatic falciform artery (HFA) detection rates of digital subtraction 
angiography (DSA), computed tomography hepatic arteriography (CTHA) and 99mTc-
macroaggregated albumin (99mTc-MAA) single photon emission computed tomogra-
phy with integrated CT (SPECT/CT) and to correlate HFA patency with complication rates 
of yttrium-90 (Y90) radioembolization.
Methods
From August 2008 to November 2010, 79 patients (range 23-83 years, mean 62.3 years; 
67 male) underwent pre-treatment DSA, CTHA and 99mTc-MAA scintigraphy (planar, 
SPECT/CT) to assess suitability for radioembolization with Y90 resin microspheres. 
Thirty-seven patients were excluded from the study, because CTHA was performed with 
a catheter position that did not result in opacification of the liver parenchyma adjacent 
to the falciform ligament. DSA, CTHA and 99mTc-MAA SPECT/CT images and medical 
records were retrospectively reviewed.
Results
A patent HFA was detected in 22 of 42 patients (52.3%). The HFA detection rates of DSA, 
CTHA and 99mTc-MAA SPECT/CT were 11.9%, 52.3% and 13.3% respectively (p<0.0001). 
An origin from the segment 4 artery was seen in 51.7% of HFAs. Prophylactic HFA coil-
embolization prior to Y90 microspheres infusion was performed in 2 patients. Of the 
patients who underwent radioembolization with a patent HFA, none developed supra-
umbilical radiation dermatitis. One patient experienced epigastric pain attributed to 
post-embolization syndrome and was managed conservatively.
Conculsions
The HFA detection rate of CTHA is superior to that of DSA and 99mTc-MAA SPECT/CT. 
Complications related to non-target radiation of the HFA vascular territory rarely occur, 
even in patients undergoing radioembolization with a patent HFA.
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IntRoDUCtIon
Radioembolization with yttrium-90 (Y90) microspheres is an effective locoregional 
treatment for patients with unresectable primary or secondary liver malignancies (1). 
The microspheres are delivered by selective trans-arterial catheter-directed infusion. 
The microspheres lodge permanently within the vascular bed of the tumor and deliver 
high-energy ß-radiation over a limited range (mean tissue penetration 2.5mm; maxi-
mum 11mm). Non-target radiation to the lungs or gastro-intestinal tract may result in 
severe complications (2-4). To minimize the risk of such complications, all patients will 
undergo pre-treatment hepatic angiography with a test injection of 99mTc-macroag-
gregated albumin (99mTc-MAA) prior to the actual treatment. During the angiography, 
the vascular liver anatomy is meticulously skeletonized to identify hepatico-enteric 
anastomoses. If present, coil embolization of such anastomoses is performed in order 
to prevent inadvertent flow of microspheres to the gastro-intestinal tract. A test injec-
tion of 99mTc-MAA and subsequent planar scintigraphy and/or single photon emission 
computed tomography with integrated low-dose computed tomography (SPECT/CT) of 
the abdomen and lungs are then used to estimate the lung shunt fraction as a result of 
tumor-related pathological arteriovenous shunting. 99mTc-MAA SPECT/CT of the abdo-
men can also accurately detect inadvertent extrahepatic deposition of 99mTc-MAA, 
prompting additional coil embolization during the radioembolization session (2-4).
An uncommon form of non-target radiation injury can result from the flow of Y90 
microspheres into the hepatic falciform artery (HFA) (5). Through the HFA, the micro-
spheres may deposit along the anterior abdominal wall, causing supra-umbilical skin 
rash, epigastric pain and skin necrosis. Although this complication is rare, prophylactic 
coiling of the HFA generally is recommended if the HFA is identified at angiography or if 
deposition of 99mTc-MAA in the HFA trajectory is detected on SPECT/CT (2-4,6). 
However, the reported prevalence of the HFA is much lower in most angiographic and 
99mTc-MAA studies compared to anatomical studies (7-11). This suggests that the HFA 
may remain undetected by digital subtraction angiography (DSA) and 99mTc-MAA 
scintigraphy in a large number of patients. These patients would potentially be at risk of 
non-target radiation injury to the vascular territory of the HFA.
Cone-beam computed tomography (CBCT) and computed tomography hepatic ar-
teriography (CTHA) are increasingly used in addition to DSA to perform transarterial 
liver therapies. In both imaging modalities, cross-sectional images are obtained during 
catheter-injection of a contrast medium into the hepatic arteries. Both CBCT and CTHA 
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allow detection of extra-hepatic perfusion with high sensitivity and specificity, but CTHA 
is the modality with higher resolution and less artefacts (12,13).       
The aim of our study was to compare the HFA detection rate of CTHA with that of DSA 
and 99mTc-MAA SPECT/CT of the abdomen, and to correlate the detection rates with 
clinical outcomes.
MetHoDs
Approval by the Institutional Review Board (IRB) of our institution was obtained for this 
retrospective study.
Patients
From August 2008 to November 2010, 79 patients were referred to the Interventional 
Radiology department of our institution for a pre-treatment angiogram and 99mTc-MAA 
simulation to evaluate suitability for radioembolization. Patient age ranged from 23 to 
83 years (mean, 62.3 +/- 11.7 years) and 67 patients were male. In 78 patients (98.7%), 
the indication for referral was hepatocellular carcinoma (HCC). One patient (1.3%) was 
referred for metastasis from colorectal carcinoma. Thirty-seven patients were excluded 
from the study, because CTHA was performed with a catheter position that did not result 
in opacification of the liver parenchyma bordering the falciform ligament.
Pre-treatment angiography, CtHA and tc99m-MAA test injection
The angiographic protocol included selective DSA with pump injection of a contrast 
agent (Omnipaque 300; GE Healthcare, Shanghai, China or Visipaque 270; GE Healthcare, 
Shanghai, China) from the superior mesenteric artery (SMA), the celiac axis (CA), proper 
hepatic artery (PHA), left hepatic artery (LHA), right hepatic artery (RHA) and, if present, 
middle hepatic artery (MHA). Angiographic images were obtained with breath-hold, 3 
frames/sec and 50mAs/120kV for antero-posterior projections. Using a Mark V ProVis 
injector (MEDRAD INC, Warrendale, PA, USA), contrast medium was injected at 6ml/sec 
for 25ml for the SMA and CA, 5ml/sec for 15ml for the PHA and 3ml/sec for 12ml for lobar 
injections.
Patients underwent CTHA using a hybrid 16-slice Aquilion CT/ Infinix VC-1 angiography 
system (Toshiba, Tokyo, Japan) and pump injections with a Stellant CT injector system 
(MEDRAD INC, Warrendale, PA, USA). Dependent on the treatment plan, CTHA was per-
formed either with super-selective lobar or segmental contrast injections using a 2.2F 
or 2.7F Progreat catheter (Terumo, Tokyo, Japan) or from the PHA using a 5F C2 catheter 
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(Terumo, Tokyo, Japan). CTHA with super-selective lobar or segmental contrast injection 
was performed with an injection rate of 1-3 ml/sec. CTHA from the PHA was performed 
with an injection rate of 3-5 ml/sec. The injected contrast volume for CTHA was calcu-
lated using the equation “volume = (scan delay + scan time) x flow rate” with the scan 
delay being the time between the start of injection and enhancement of the region of 
interest at angiography. CTHA images were acquired using the following parameters: 
collimation 16x1.0, pitch factor 15, helical pitch 0.938, 120kV and 160 effective mAs. 
In all patients included in the study, CTHA showed opacification of the liver segments 
bordering the falciform ligament.
All patient would undergo standard coil embolization of hepaticoenteric anastomoses 
if deemed necessary to avoid non-target embolization, either on the day of the pre-
treatment angiography or on the day of radioembolization. Coil embolization was 
performed using pushable coils (Boston Scientific, Natick, MA, USA) or an Amplatzer 4 
vascular plug (AGA Medical, Golden Valley, MN, USA) for the gastroduodenal artery.
At the end of the procedure, the microcatheter was placed in a position corresponding 
to the intended location of future Y90 microsphere infusion. A total of 5mCi (185MBq) in 
3ml 99mTc-MAA was then injected into the LHA, MHA and/or RHA, or alternatively into 
the PHA. All patients underwent 99mTc-MAA scintigraphy within 1 hour of 99mTc-MAA 
injection. Prior to September 2009, patients underwent only planar scintigraphy. After 
this date, 99mTc-MAA SPECT/CT of the abdomen was also performed, using a hybrid 
SPECT/CT scanner with a dual-head gamma camera integrated with a 16-slice multi-
detector CT (Philips Precedence; Philips, Amsterdam, Netherlands). The lung shunt frac-
tion was calculated by planar scintigraphy, whereas SPECT/CT of the abdomen was used 
for tumor-to-normal liver ratio (T/N ratio) calculation and to exclude any non-target 
extra-hepatic shunting of 99mTc-MAA. Predictive radiation dosimetry was performed by 
Medical Internal Radiation Dose (MIRD) macrodosimetry (i.e. ‘partition model’). Patient 
suitability for radioembolization was decided in a multi-disciplinary manner, taking into 
account the potential risk-benefit based on patient-specific clinical, angiographic, CTHA 
and dosimetric factors.
Radioemboliation
Prior to radioembolization, hepatic angiography and CTHA were repeated. If repeated 
DSA or CTHA showed extrahepatic enhancement or if extrahepatic 99mTc-MAA activ-
ity was detected, additional coil-embolization was performed to prevent non-target 
radioembolization. If the 99mTc-MAA scan showed marked 99mTc-MAA activity in the 
trajectory of the HFA, identification and subsequent embolization was attempted prior 
to radioembolization. The infusion of Y90 microspheres was performed with the catheter 
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placed in an identical position as was used to infuse 99mTc-MAA. Minor changes of cath-
eter position would be made if this would reduce the risk of non-target embolization 
based on DSA, CTHA and/or SPECT/CT findings. All radioembolization procedures were 
performed using SIR-Spheres® (Sirtex Medical Limited; New South Wales, Australia).
Bremsstrahlung scan
All patients underwent Y90 bremsstrahlung scintigraphy one day after radioemboliza-
tion to assess the intrahepatic microsphere biodistribution and to exclude inadvertent 
extrahepatic shunting of microspheres. Planar liver-to-lung bremsstrahlung scintigra-
phy was performed in all patients for qualitative assessment of pulmonary Y90 activity. 
After September 2009, additional Y90 bremsstrahlung SPECT/CT of the abdomen was 
also performed.
Image interpretation
DSA and CTHA images were independently reviewed for the presence of a HFA by two 
interventional radiologists (MCB and RHGL), with respectively 4 and 17 years of experi-
ence with transarterial hepatic therapies. The reviewers were blinded for patient details 
and DSA and CTHA images were reviewed separately without cross-reference. DSA 
images were reviewed using an Amalga Picture Archive and Communication System 
(Microsoft, Redmont, WA, USA). CTHA images were reviewed using imaging software 
Vitrea 2 version 4.1.2.0 (Vital Images Inc, Minnetonka, MN, USA), allowing multi-planar 
reconstruction (MPR) and maximal intensity projection (MIP). The number of HFAs per 
patient and origin of the HFA was recorded for both DSA and CTHA images. Discrepan-
cies between the two reviewers were resolved by consensus reading. 
The 99mTc-MAA and Y90 bremsstrahlung scintigraphy (planar, SPECT/CT) were reviewed 
by a nuclear medicine physician with three years of experience in radioembolization. 
Clinical correlation
Clinical follow-up including physical examination and laboratory testing was performed 
in all patients on days 2 and prior to discharge. Patients were routinely scheduled for 
clinical review at approximately 2, 6 and 12 weeks and, depending on survival, every 
3 months thereafter. Contrast-enhanced 4-phase CT or MRI for patients with primary 
liver carcinoma and contrast-enhanced CT and/or F-18 fluorodeoxyglucose PET/CT for 
patients with secondary liver tumors were routinely planned at 3 months intervals. 
The medical records of all patients were retrospectively reviewed for any signs of epigas-
tric pain or discomfort, anterior abdominal wall skin rash or any other signs that could 
indicate non-target radiation as a result of microsphere infusion into the HFA.
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statistical analysis
The statistical significance of the HFA detection rate between DSA and CTHA and 
between CTHA and 99mTc-MAA was evaluated using McNemar’s test. Results were 
considered significant when a p-value of less than 0.05 was obtained. Data analysis was 
performed using SPSS software version 17.
ResULts
A patent HFA was identified in 22 (52.3%) of the 42 patients included in the study across 
all modalities: DSA, CTHA or 99mTc-MAA SPECT/CT. The demographics of these 22 
patients are listed in Table 1.
A patent HFA was detected in 5 (11.9%) of the 42 patients with DSA (Figure 1). CTHA was 
positive for the presence of a patent HFA in all 5 patients in whom a HFA was detected on 
DSA, and further detected a patent HFA in 17 additional patients. The HFA detection rate with 
CTHA (52.3%) was significantly better than the detection rate with DSA (11.9%) (p<0.0001).
table 1. Demographics of patients with a patent hepatic falciform artery
Characteristic Value
Age mean 63.2 yrs (range 45-80 yrs)
Sex n (total = 22) %
 Male 19 86.4
 Female 3 13.6
Tumor type
 HCC 22 100
Tumor distribution
 Bilobar 11 50
 Unilobar 11 50
Child-Pugh score n %
 A 13 59.1
 B 9 40.9
Vascular invasion/ EHD
 Vascular invasion 7 31.9
 Lymph node metastasis 2 9.1
 Distant metastasis 1 4.5
BCLC stage
 A 1 4.5
 B 13 59.1
 C 8 36.4
BCLC stage = Barcelona Clinic Liver Cancer staging system; EHD = extra-hepatic disease
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In none of the patients, coil embolization of the HFA was performed at the time of 
99mTc-MAA injection. In 6 of the 42 patients, 99mTc-MAA was injected only into the 
right hepatic artery and accumulation into the HFA trajectory would therefore be highly 
unlikely. In 6 (16.6%) of the remaining 36 patients, only 99mTc-MAA planar scintigraphy 
was performed. Thirty patients (83.3%) underwent both 99mTc-MAA planar scintigraphy 
and SPECT/CT. No HFA was detected by planar scintigraphy. With SPECT/CT, 99mTc-MAA 
accumulation in the trajectory of the HFA was detected in 4 (13.3%) of the 30 patients. In 
all 4 patients, a HFA was also detected on CTHA. In 2 of the 4 patients, DSA also detected 
the patent HFA. CTHA had a higher HFA detection rate than 99mTc-MAA SPECT/CT 
(p<0.0001). There was no statistically significant difference between the HFA detection 
rates of DSA versus 99mTc-MAA SPECT/CT.
A total of 29 HFAs were detected across 22 patients: 2 HFAs in 3 patients (13.6%); 3 HFAs 
in 2 patients (9.1%). In all patients, the HFAs originated from either the LHA or MHA. An 
origin from the segment 4 artery was seen in 15 (51.7%) of the 29 HFAs (Figure 2).
Of the 22 patients with a patent HFA, 3 patients (13.6%) did not proceed with radioembo-
lization for the following reasons: high lung shunt fraction (n=1), unfavorable T/N ratio 
(n=1) and a combination of high lung shunt fraction and arterioportovenous shunting 
with unfavorable T/N ratio (n=1). The mean activity of Y90 infused in the remaining 19 
patients was 2.1 + 0.8 GBq (range 0.9 - 4.0 GBq). In the 2 patients where a patent HFA was 
detected on all modalities (DSA, CTHA, 99mTc-MAA SPECT/CT), coil-embolization of the 
A B
Figure 1. Patency of the hepatic falciform artery (HFA) in a 67-year old male with multifocal bilobar hepa-
tocellular carcinoma (HCC) demonstrated on both digital subtraction angiography (DSA) and computed 
tomography hepatic arteriography (CTHA). a) Selective DSA from the middle hepatic artery (MHA). The 
MHA (black arrow) gives rise to the HFA (arrowheads). Reflux is seen into the left hepatic artery (small white 
arrow) with early tumor enhancement of tumors in segments 2 and 3 (large white arrows). b) CTHA also 
shows the HFA (arrow) to be patent. The patient was not considered to be at risk of non-target radiation to 
the HFA vascular territory as Y90 microspheres were infused super-selectively into the left and right hepatic 
artery and not the MHA. 
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HFA was performed using 2x5 mm Figure-8 micro-coils (Boston Scientific, Natick, MA, 
USA) just prior to selective bilobar Y90 microspheres infusion (Figure 3). Three patients 
had infusion of Y90 into the RHA only and were therefore not considered to be at risk 
of non-target irradiation of the HFA vascular territory. Therefore, 14 patients underwent 
radioembolization where Y90 microspheres were released proximal to a patent HFA.
Of these 14 patients, 4 patients underwent planar Y90 bremsstralung scintigraphy and 
the other 10 patients had additional Y90 bremsstrahlung SPECT/CT of the abdomen. 
None of the 14 patients had detectable non-target Y90 bremsstrahlung activity or 
developed anterior abdominal wall radiation dermatitis. One patient experienced epi-
gastric pain, nausea and sub-febrile temperature following Y90 microspheres infusion. 
This patient was treated with bilobar infusion of spheres with a total activity of 2.5GBq 
for extensive bilobar HCC. The symptoms were thought to be due to post-embolization 
syndrome, not HFA vascular territory irradiation. The symptoms were managed conser-
vatively and subsided after 24 hours.
Figure 2. Schematic drawings of the origin of the 29 HFAs detected in 22 patients: a) origin from the seg-
ment 4 artery (S4) or MHA; b) origin from the segment 3 artery (S3); c) origin from a S3/S4 artery bifurcation; 
d) origin from the bifurcation of the segment 2 artery (S2) and S3 near the umbilical point; e) origin from S2.
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DIsCUssIon
There is a discrepancy in the reported prevalence of the HFA between anatomical stud-
ies and most angiographic studies. In an anatomic study by Michels, the HFA was found 
to be present in nearly 70% of cadaveric dissections (7). In a single study, Song et al. 




Figure 3. Patency and coil embolization of 
the HFA in a 74-year old male with multifo-
cal bilobar HCC. a) Selective DSA from the 
left hepatic artery shows a small HFA (arrow-
heads) originating from a segment 4 artery 
(white arrow); b) CTHA performed with the 
same catheter position shows opacification 
of an anastomotic network of arteries (arrow) 
via the HFA. Branches of this network lead to 
the anterior abdominal wall (not shown); c) 
After injection of 99mTc-MAA into the left 
and right hepatic artery, SPECT/CT detected 
99mTc-MAA activity in the trajectory of the 
HFA and the anastomotic network (arrow). 
At the time of actual treatment, the HFA was 
selectively catheterized and embolized with 
micro-coils prior to infusion of Y90 micro-
spheres into the left and right hepatic artery. 
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angiographic studies have reported a prevalence ranging from only 2 to 7.6% (8-11). 
This suggests that a prevalent HFA often remains undetected using DSA. Similarly, the 
reported prevalence of the HFA is low in 99mTc-MAA SPECT/CT studies compared to the 
study by Michels. In a study by Ahmadzadehfar et al., tracer accumulation in the anterior 
abdominal wall, indicating a patent HFA, was present in pre-radioembolization 99mTc-
MAA SPECT/CT images in 9.3% of patients (11). In our study, the HFA detection rate of 
DSA and 99mTc-MAA SPECT/CT was 11.9% and 13.3%, respectively. Yet, we were able 
to demonstrate a patent HFA on CTHA in 52.3% of patients. Our findings are consistent 
with a study by Tajima et al., who found an evidently superior HFA detection rate for 
CTHA compared to DSA in patients undergoing transarterial chemoembolization (15). 
This could imply that patients undergoing radioembolization may be at risk of HFA 
nontarget irradiation, as DSA and 99mTc-MAA are the standard imaging modalities used 
for pre-treatment planning. However, complications as a result of inadvertent infusion 
of Y90 microspheres into the HFA appear to be uncommon with only a few reported 
cases in the literature (5,6,11). In our study, Y90 microspheres where released proximal 
to a patent HFA in 14 patients. In none of these 14 patients did the Y90 bremsstrahlung 
scintigraphy show suspicious activity along the anterior abdominal wall, or any symp-
toms that were thought to be due to non-target irradiation of the HFA vascular territory.
There could be several reasons why the majority of patients with a patent HFA did not 
develop symptoms of HFA non-target irradiation. All patients with a patent HFA in our 
study had HCC. HCCs generally are highly vascular and the preferential flow of Y90 
microspheres will have been towards the liver tumors. As the HFA is a small branch, the 
number of microspheres (and hence the Y90 activity) actually implanted along the HFA 
vascular territory may have been too small to deliver a clinically significant radiation 
absorbed dose. Second, contrast (i.e. soluble molecules) enhancement of the HFA on 
CTHA may not accurately predict the flow of Y90 microspheres, which are subject to 
many biophysical factors such as particulate mass and momentum (16). The terminal 
branches of the MHA and/or LHA may have a direct pathway to the HFA or create an 
anastomotic network with the internal thoracic or superior epigastric arteries through 
the ensiform artery (10). In patients with the latter variant, predominant blood flow to 
the anterior abdominal wall may be through the internal thoracic or superior epigastric 
arteries. In patients with HCC, the direction of flow through the ensiform artery may 
even be hepatopedal as a result of the recruitment of blood from extrahepatic arteries 
by the liver tumors (10). CTHA is performed with pump-injection of a relatively high 
volume of a contrast medium and as a result the competing flow from the internal tho-
racic or superior epigastric arteries may be cancelled out. Yet, the Y90 microspheres are 
released by means of slow infusion. Hence, during transarterial infusion of the spheres, 
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the anterior abdominal wall may receive blood mainly or entirely through the internal 
thoracic or superior epigastric arteries in patients with a patent ensiform artery.
In two patients, the HFA was prophylactically coiled prior to radioembolization. In both 
cases, a patent HFA was demonstrated on DSA, CTHA and 99mTc-MAA SPECT/CT. Our 
study shows that the risk of complications is low if Y90 microspheres are infused proxi-
mal to a patent HFA, but we feel coil embolization of a patent HFA should nevertheless 
be attempted prior to radioembolization, if considered technically feasible. However, 
based on our study findings, we do not recommend treatment cancellation in patients 
with an angiographically occult HFA or in cases of failed HFA coil embolization.
A limitation of our study is its retrospective nature. Further limitation of the study 
involves the lack of a validated gold standard for HFA patency. The imaging findings 
were not correlated with anatomical dissections. Despite this, we interpreted contrast-
enhancement of the HFA on CTHA as patency of the HFA. In individual patients with a 
patent anastomosis between the HFA and the internal thoracic or superior epigastric 
arteries, this may have led to what could be considered as false positives. Contrast may 
have been pushed into the HFA and anastomotic network by using pump-injections, 
whereas flow to the anterior abdominal wall would only have been through the internal 
thoracic or superior epigastric arteries under normal circumstances.
In conclusion, we found a significantly higher detection rate for the HFA with CTHA as 
compared to DSA and 99mTc-MAA SPECT/CT. However, even in patients with a patent 
HFA no symptoms occurred that could indicate radiation injury to the HFA vascular terri-
tory. We recommend prophylactic coil embolization of a patent HFA prior to radioembo-
lization if technically feasible, but do not recommend cancellation of radioembolization 
in patients with an angiographically occult HFA or in cases of failed HFA prophylactic 
coil-embolization.
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Compliance to radiobiological principles of radionuclide internal dosimetry is funda-
mental to the success of yttrium-90 (Y90) radioembolization. The artery-specific SPECT/
CT partition model is an image-guided personalized predictive dosimetric technique 
developed by our institution, integrating catheter-directed computed tomography 
hepatic angiography (CTHA), technetium-99m-macroaggregated albumin (99mTc-MAA) 
SPECT/CT and partition modeling for unified dosimetry. Catheter-directed CTHA accu-
rately delineates planning target volumes. SPECT/CT tomographically evaluates 99mTc-
macroaggregted albumin (99mTc-MAA) hepatic biodistribution. The partition model 
is validated for Y90 resin microspheres based on Medical Internal Radiation Dosimetry 
(MIRD) macrodosimetry.
Methods
This was a retrospective analysis of our early clinical outcomes for inoperable hepa-
tocellular carcinoma (HCC). Mapping hepatic angiography was performed according 
to standard technique with addition of catheter-directed CTHA. 99mTc-MAA planar 
scintigraphy was used for liver-to-lung shunt estimation, and SPECT/CT for liver dosim-
etry. Artery-specific SPECT/CT partition modeling was planned by experienced nuclear 
medicine physicians.
Results
From January to May 2011, 20 arterial territories were treated in 10 HCC patients. Median 
follow-up was 21 weeks (95% confidence interval (CI), 12-50). When analyzed strictly as 
brachytherapy, Y90 radioembolization planned by predictive dosimetry achieved index 
tumor regression in 8 of 8 patients, with median size decrease of 58% (95% CI, 40%-
72%). Tumor thrombosis regressed or remained stable in 3 of 4 patients with baseline 
involvement. Best alphafetoprotein reduction ranged from 32 to 95%. Clinical success 
was achieved in 7 of 8 patients, including 2 by sub-lesional dosimetry, one of which had 
radioembolization lobectomy intent. Median predicted mean radiation absorbed doses 
were 106 Gy (95% CI, 105-146 Gy) to tumor, 27 Gy (95% CI, 22-33 Gy) to non-tumorous 
liver and 2 Gy (95% CI, 1.3-7.3 Gy) to lungs. Across all patients, tumor, non-tumorous 
liver and lungs received predicted ≥91 Gy, ≤51 Gy and ≤16 Gy respectively via at least 
one target arterial territory. No patients developed significant toxicities within 3 months 
post-radioembolization. The median time to best imaging response was 76 days (95% CI, 
55-114 days). Median time to progression and overall survival were not reached. SPECT/
CT-derived mean tumor-to-normal liver (T/N) ratios varied widely across all planning 
target volumes (median 5.4; 95% CI, 4.1-6.7), even within the same patient.
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Conclusions
Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition 




As a form of arterial territory-specific point-source brachytherapy, yttrium-90 (Y90) 
radioembolization is always effective when delivered at the right location, in the right 
dose, and with the right intent. Y90 radioembolization failure is invariably due to one or 
a combination of these three factors being incorrectly addressed. Responsibility for this 
triad is shared among the interventional radiologist, the nuclear medicine physician, 
and the referring clinician. Y90 radioembolization is complex, and a lack of coordinated 
care risks sub-optimum outcomes.
Contemporary techniques, outcomes, and safety data of Y90 radioembolization are 
well-described in recent literature (1-8). Disregard for radiobiological principles of arte-
rial territory-specific Y90 radionuclide internal dosimetry risks toxicity and fatality (9-10). 
Since the 1980s, sectional imaging (e.g. computed tomography) has revolutionized the 
planning and delivery of external beam radiation therapy (EBRT). However to date, radia-
tion planning for Y90 radioembolization has yet to embrace modern imaging modalities 
such as catheter-directed CT hepatic arteriography (CTHA) and single photon emission 
computed tomography with integrated low-dose CT (SPECT/CT).
Catheter-directed CTHA delineates hepatic arterial territorial margins more accurately 
than digital subtraction angiography (1,11). SPECT/CT is superior to both planar scin-
tigraphy and SPECT for assessing intra-hepatic biodistribution of technetium-99m-
macroaggregated albumin (99mTc-MAA), and for estimating the tumor-to-normal liver 
(T/N) ratio (12-14). The partition model is a validated dosimetric method for Y90 resin 
microspheres, scientifically superior to the ‘body surface area (BSA)’ method (5,10).
Accurate assessment of target liver volumes is critical because it directly affects radiation 
absorbed dose estimates. This is especially important when planning for selective (lo-
bar) or super-selective (segmental or sub-segmental) Y90 radioembolization. Catheter-
directed CTHA refers to the acquisition of CT with direct intraarterial injection of dilute 
contrast media through an angiographic catheter or microcatheter introduced into a 
hepatic lobar, segmental or sub-segmental artery via a percutaneous transfemoral arte-
rial puncture (1,11). This provides superior delineation of arterial territories compared 
to digital subtraction angiography, enabling accurate estimation of artery-specific 
perfused liver volumes (1,11). Conventional Y90 radioembolization is planned on the in-
terventional radiologists’ assessment of each patient’s vascular anatomy (15). However, 
estimation of the perfused liver volume can be challenging. Hepatic vascular anatomy 
has many variations (13,15-16). A main hepatic artery may supply several liver segments 
via its branches; conversely a single segment may be supplied by more than one arterial 
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branch. Couinaud segments may be distorted by large tumors, previous liver surgery or 
locoregional therapy – for example, ablation cavities. Aberrant arteries due to neoplastic 
recruitment from extrahepatic sources further complicate hepatic vascular anatomy. 
These factors make it difficult to reliably estimate the target volume of a diseased liver 
based on digital subtraction angiography alone.
This problem may be overcome by catheter-directed CTHA. With the catheter tip placed 
in the target artery, CT performed at the time of intra-arterial contrast injection provides 
superior delineation of the perfused liver volume, as compared to that shown under 
digital subtraction angiography. Each ‘run’ of catheter-directed CTHA is specific for its 
catheter tip position. The use of catheter-directed CTHA shifts the planning emphasis 
away from a conventional lobe or segment-based approach to a more patient-specific 
arterial territory-based approach. Catheter-directed CTHA accurately delineates each 
target arterial territory regardless of arterial anatomy, variant vasculature, or tissue 
distortion by tumor, surgery, or locally ablative treatments.
The role of SPECT/CT in diagnostic imaging and internal dosimetry is well established in 
nuclear medicine (17-18). In the context of Y90 radioembolization, 99mTc-MAA SPECT/
CT for preradioembolization assessment has a higher detection rate for extrahepatic 
radiotracer activity and has greater impact on therapy planning compared to that un-
der planar scintigraphy (14,19-20). Hepatic intraarterial 99mTc-MAA scintigraphy is a 
validated means of simulating the Y90 radioembolization therapy field (13-14). SPECT/
CT-based dosimetry is superior to planar scintigraphy by tomographically resolving 
overlapping radiotracer activity, evaluating heterogeneous radiotracer uptake and 
detecting activity in small lesions (12,14,17). Phantom studies have shown that 99mTc-
MAA SPECT/CT volume measurements are accurate and reproducible (13). To date, no 
standardized technique exists for the calculation of SPECT/CT-based T/N ratios, although 
several methods have been described (21-23).
The partition model was developed and validated for Y90 resin microspheres by Ho et 
al. in the 1990s (24-25). It is one of several methods recommended by the manufacturer 
of Y90 resin microspheres to calculate the desired Y90 activity (26). Based on Medical 
Internal Radiation Dosimetry (MIRD) macrodosimetry, it partitions the lungs, tumor, and 
non-tumorous liver into separate compartments for radiation dose modeling (24,26). 
This model surpasses the commonly used BSA method by incorporating absolute tissue 
masses and patient-specific mean T/N ratios for personalized and scientifically sound 
estimates of mean radiation absorbed doses to each tissue compartment (5,10,27). 
Technical differences between BSA methodology and partition modeling discussed 
elsewhere, along with limitations and clinical implications (10).
118 Chapter 8
The artery-specific SPECT/CT partition model is a unified technique of personalized 
predictive dosimetry developed by our institution for Y90 radioembolization using 
resin microspheres. It integrates catheter-directed CTHA, 99mTc-MAA SPECT/CT and 
partition modeling for improved predictive radionuclide dosimetry. Its fundamental 
premise is to derive more accurate estimates of tissue masses and mean T/N ratios to 
optimize partition modeling. The underlying principles and limitations of MIRD mac-
rodosimetry remain unchanged. Through the use of artery-specific SPECT/CT partition 
modeling, predicted mean radiation absorbed doses specific to target arterial territories 
are independently calculated and physician-adjusted according to patient-specific 
circumstances (e.g. mean T/N ratio, liver-to-lung shunt, liver reserve, prognosis, treat-
ment intent and potential treatment benefit). The overall process yields a personalized 
image-guided predictive radiation plan for safe and effective Y90 radioembolization. 
This report provides a technical overview of this integrated dosimetric technique and 




The institutional review board waived the need to obtain informed consent for this ret-
rospective study. The technique for using artery-specific SPECT/CT partition modeling 
to plan Y90 radioembolization was implemented at our institution as a routine clinical 
service in January 2011. Five months post-implementation, we had treated 22 patients 
with inoperable HCC. Of these, 10 patients were embargoed under an ongoing clinical 
trial. Two patients were planned by BSA methodology due to morphologically diffuse 
and infiltrative tumors that were below 99mTc-MAA SPECT/CT resolution for reliable 
regions-of-interest (ROI) contouring. Both these patients were excluded (10). Treat-
ment of the remaining 10 consecutive patients was planned by artery-specific SPECT/
CT partition modeling, and these patients were eligible for inclusion into this report. 
Retrospective review of hospital medical records was performed for these 10 patients 
until August 2011, the time at which the manuscript was prepared.
Patient and baseline disease characteristics were highly heterogeneous (Tables 1 and 2). 
Median age was 59 years (range 48-65 years). There were 8 men and 2 women. Seven 
patients had chronic viral hepatitis. Five patients received prior therapy for HCC, includ-
ing 2 with previous Y90 radioembolization planned by conventional planar partition 
modeling. Eight patients were Child-Pugh A; the remainder were Child-Pugh B. Tumor 
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table 1. Patient characteristics
Patient No. Age Sex Tumor Risk factor Previous
Treatment
ECOG Child-Pugh
1 58 M HCC HCV Segmentectomy; sorafenib 1-2 A
2 63 M HCC HBV Y90 RE; segmentectomy 0 A
3 61 F HCC Cryptogenic No 3 A
4 48 M HCC HBV RFA 1-2 B
5 60 M HCC Cryptogenic No 0 A
6 56 M HCC HBV Right hemi-hepatectomy; TACE 0 A
7 61 F HCC Cryptogenic Y90 RE 1-2 A
8 65 M HCC HCV No 0 B
9 56 M HCC HBV No 0 A
10 52 M HCC HCV No 0 A
HCC: hepatocellular carcinoma; HBV: chronic hepatitis B; HCV: chronic hepatitis C; ECOG: Eastern coopera-
tive oncology group performance status; PV: portal vein; Y90 RE: Y90 radioembolization; RFA: radiofrequen-
cy ablation; TACE: transarterial chemoembolization









1 T4b C Bilobar; infiltrative Branch PV Right; left *
2 rT2 A Solitary recurrence at segment IV 
resection margin
No Right; left *
3 T3 D Central large dominant tumor; smaller 
satellite lesions
No Right; left *




5 T4b C Bilobar; multifocal; subcentimeter lesions 
present
Branch PV Right; accessory 
right; left *
6 T4b B Bilobar; multifocal; subcentimeter lesions 
present
No Right; left *
7 T4a B Right lobe; large necrotic tumor; satellite 
lesions with ill-defined margins
No Right; middle †
8 T4a B Bilobar; multifocal; subcentimeter lesions 
present
No Right; middle; 
left *
9 T4b C Bilobar; multifocal;subcentimeter lesions 
present
Branch PV Proper *
10 T4b C Large right lobe tumor with ill-defined 
margins; subcentimeter lesion present
Branch and main PV; 
right hepatic vein
Right †
UNOS: United Network for Organ Sharing staging system, all patients are N0 M0; BCLC: Barcelona Clinic 
Liver Cancer staging system; PV: portal vein; * Whole-liver 99mTc-MAA injection; † Selective lobar/segmen-
tal 99mTc-MAA injection
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extent varied widely across all patients and were mostly bilobar and multifocal. Eight 
patients had T4 disease by the United Network for Organ Sharing (UNOS) staging sys-
tem; none had nodal or distant metastases. Classification by the Barcelona Clinic Liver 
Cancer (BCLC) staging system was: 1 BCLC A; 3 BCLC B; 5 BCLC C; 1 BCLC D. Five patients 
had tumor vascular involvement.
technique overview
Mapping hepatic angiography and 99mTc-MAA injection were performed according to 
standard technique (1, 15). Prophylactic coil embolization of vessels at risk was performed 
either at mapping hepatic angiography or at Y90 radioembolization, at the discretion of 
the interventional radiologist. The catheter tip position for 99mTc-MAA injection was 
decided in consensus between the interventional radiologist and nuclear medicine 
physician during mapping hepatic angiography. 99mTc-MAA was slowly hand-injected 
non-selectively (whole liver), selectively (lobar) or super-selectively (segmental or sub-
segmental) depending on patient-specific circumstances. Patients were immediately 
transferred to the gamma camera suite for planar liver-to-lung shunt scintigraphy and 
SPECT/CT of the abdomen.
The following describes the essence of the technique of artery-specific SPECT/CT parti-
tion modeling. Catheter-directed CTHA guided volumes-of-interest (VOI) delineation 
on 99mTc-MAA SPECT/CT to obtain arterial territory-specific tissue volumes and SPECT/
CT-based mean T/N ratio estimates for improved partition modeling. The term planning 
target volume is used, adapted from EBRT. All treatments were planned by a team of expe-
rienced nuclear medicine physicians, and the final prescribed mean radiation absorbed 
doses were guided by published dose-response relationships (5). By partition modeling, 
the nuclear medicine physician had full control over predicted radiation absorbed dose 
estimates to tumor, non-tumorous liver and lungs within each planning target volume. 
The overall dosimetric aim was to balance the desired mean tumor radiation absorbed 
dose with collateral radiation injury, in accordance to the treatment intent.
Y90 radioembolization was performed using resin microspheres (SIR-Spheres®, Sirtex 
Medical Limited, New South Wales, Australia) within 2 weeks of mapping hepatic an-
giography. Catheter tip placement was the same as that of the 99mTc-MAA injections. 
All patients received prophylactic omeprazole, 20mg, twice daily prior to Y90 radioem-
bolization and this treatment continued for at least 6 weeks after radioembolization. 
In accord with our institutional protocol, after Y90 radioembolization all patients were 
observed overnight and discharged after bremsstrahlung planar scintigraphy of the 
lung and SPECT/CT of the abdomen the following day.
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terms and definitions
Postradioembolization bremsstrahlung SPECT/CT of the abdomen was used to de-
termine technical success. Technical success was achieved when all targeted tumors 
within planning target volumes showed satisfactory bremsstrahlung activity by visual 
assessment, in keeping with the radiation plan (28). The success of the technique was 
considered indeterminate when planning target volumes included subcentimeter 
tumors or tumors with ill-defined margins (e.g. infiltrative HCC), below bremsstrahlung 
SPECT/CT spatial resolution. A technical failure occurred when targeted tumors did not 
exhibit visually detectable focal bremsstrahlung activity, analogous to a geographical 
miss in the context of EBRT.
Clinical and biochemical toxicities within 3 months after radioembolization were classi-
fied according to Common Terminology Criteria for Adverse Events (CTCAE v4.03) (28-
29). The nadir in serum alphafetoprotein at any time post-radioembolization indicated 
the best biochemical response.
To evaluate the effectiveness of Y90 radioembolization strictly as a form of brachytherapy 
delivered at a single time-point, the best imaging response was defined as the greatest 
change in size of the targeted index (largest) tumor between baseline and follow-up 
diagnostic sectional imaging. Clinical success was defined as any degree of regression of 
targeted tumors on follow-up diagnostic sectional imaging within planning target vol-
umes, regardless of new tumors appearing within or outside planning target volumes 
(28).
Overall response by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 
1.1), World Health Organization (WHO), and 2-D European Association for the Study of 
the Liver (2D-EASL) guidelines were used to evaluate Y90 radioembolization as a part of 
comprehensive multi-modality therapy for inoperable HCC, without regard to planning 
target volumes (28,30).
statistical methods
Data are presented as median and 95% confidence intervals (CI), where applicable. Us-
ing Bland-Altman analysis, the total desired Y90 activities calculated by artery-specific 
SPECT/CT partition modeling were compared to that hypothetically derived by BSA 
methodology. The intra-class correlation coefficient (ICC) was calculated with values 0.8 
or more considered excellent; 0.6-0.8, good; 0.4-0.6, moderate; and less than 0.4, poor. 
Statistical analysis was performed on Microsoft® Office Excel 2003 (Microsoft Corpora-
tion) and SPSS version 17.0 (SPSS Inc., Chicago, USA).
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ResULts
The artery-specific SPECT/CT dosimetric plans of all 10 patients are summarized in Table 
3. There were a total of 20 radiation plans across 10 patients i.e. one planning target 
volume per target arterial territory. Two patients underwent Y90 radioembolization in 
a single arterial territory, 6 patients in 2 arterial territories and 2 patients in 3 arterial 
territories (Figure 1). 
Sublesional dosimetry was performed in 2 patients; 1 of which was planned with radio-
embolization lobectomy intent (Figures 2-3). Four patients underwent prophylactic coil 
embolization of arteries at risk: 3 gastroduodenal; 2 accessory left gastric; 2 right gastric; 
1 right inferior phrenic; 1 falciform; 1 pancreatico-duodenal arcade. Technical success 
was achieved in 2 of 10, indeterminate in 7 of 10, and technical failure in 1 of 10 patients. 
Patient 8 was classified as a technical failure due to the absence of visually detectable 
focal bremsstrahlung activity in a targeted caudate tumor.
Median predicted mean radiation absorbed doses by artery-specific SPECT/CT partition 
modeling were 106 Gy (95% CI, 105-146 Gy) to tumor, 27 Gy (95% CI, 22-33 Gy) to non-
tumorous liver and 2 Gy (95% CI, 1.3-7.3 Gy) to lungs. Across all patients, tumor, non-
tumorous liver and lungs were predicted to have received ≥91 Gy, ≤51 Gy and ≤16 Gy 
respectively to at least one target arterial territory. The median artery-specific tumor and 
non-tumorous liver masses were 156 g (95% CI, 117-436 g) and 752 g (95% CI, 513-833 
g) respectively. The median liver-to-lung shunt estimated by planar 99mTc-MAA scin-
tigraphy was 5.4% (95% CI, 4.3%-9.0%). The median Y90 activity injected into an arterial 
territory was 0.6 GBq (95% CI, 0.7-1.3 GBq). Patient 2 received a mean radiation absorbed 
dose of 93 Gy to the left lobe nontumorous liver for Y90 radioembolization lobectomy 
(Table 3; Fig. 2). There was good tumor response together with slow progressive atrophy 
of the left lobe 6 months post-radioembolization, in keeping with the dosimetric intent. 
The right lobe volume, which received a mean radiation absorbed dose of 27 Gy to non-
tumorous liver, remained stable over time (Figure 3).
SPECT/CT-based mean T/N ratios varied widely across all planning target volumes 
(median 5.4; 95% CI, 4.1-6.7), and even within the same patient (median intra-patient 
difference 1.9; 95% CI, 1.1-2.5). We could not find any predictive relationship between 
mean T/N ratios and liver tissue masses. In a sub-analysis, the total desired Y90 activities 
calculated by artery-specific SPECT/CT partition modeling were compared to that hypo-
thetically derived by BSA methodology. Bland-Altman analysis (Figure 4) showed a wide 
95% limit of agreement ranging from -1.12 to +1.41, with only moderate correlation (ICC 
0.59; 95% CI, -0.71 to 0.90).

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Y90 radioembolization was well tolerated in all patients. None developed postradio-
embolization syndrome. All patients were ambulating freely by the next day and dis-
charged within 24 hours post-radioembolization. In 8 patients, serum bilirubin, albumin, 
and alanine transaminase (ALT) were measured within 24 hours post-radioembolization; 
none developed significant biochemical toxicities.
Figure 1. Example of artery-specific SPECT/CT partition modeling of 3 arterial territories. A liver with mul-
tifocal HCC supplied by the right (A), middle (B) and left (C) hepatic arteries is depicted here in digital 
subtraction angiography and catheter-directed CTHA respectively. Regions-of-interest (ROI) are drawn on 
99mTc-MAA SPECT/CT transaxial slices representing the left (D, blue ROI), middle (D, orange ROI) and right 
(D, green ROI) hepatic artery planning target volumes, the implanted tumor (D, red ROI) and necrotic tumor 
(D, white ROI).
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At the time of this report, follow-up data was available for 8 patients. The median follow-
up duration was 21 weeks (95% CI, 12-50 weeks). The other 2 patients were non-residents, 
returned to their home country and were lost to follow-up. Patient 3 was excluded from 
biochemical and survival analysis due to confounding medical issues, but was included 
in imaging analysis.
With the exception of Patient 3, all 7 other patients remained clinically well. None 
developed gastrointestinal complications or radiation pneumonitis. There were no 
biochemical toxicities beyond CTCAE Grade 2 within 3 months postradioembolization. 
Postradioembolization serum alphafetoprotein was available in 5 patients. There was an 
Figure 2. Patient 2: Example of sub-lesional dosimetry with left radioembolization lobectomy intent. The 
patient had recurrent HCC at the segment IV resection margin. Left lobe hypodensity is a cyst (A, ‘C’). The 
tumor was supplied by the right and left hepatic arteries. Catheter-directed CTHA depicts the planning tar-
get volumes of the right (A) and left (B) hepatic arteries, dividing the dosimetric plan into two independent 
halves for sub-lesional dosimetry. 99mTc-MAA SPECT/CT showed good T/N ratio (6.1) of the lateral tumor 
portion supplied by the right hepatic artery (C, ‘R’), but poor T/N ratio (1.4) of the medial tumor portion sup-
plied by the left hepatic artery (C, ‘L’). The dosimetric plan of the left hepatic artery planning target volume 
was deliberately escalated beyond safe limits to achieve a predicted mean radiation absorbed dose of 133 
Gy to tumor and 93 Gy to non-tumorous liver, where progressive atrophy of the left lobe was the antici-
pated collateral effect i.e. left radioembolization lobectomy intent. Post-radioembolization bremsstrahlung 
SPECT/CT showed good tumoral activity in both lateral (D, ‘R’) and medial (D, ‘L’) tumor portions, indicating 
technical success.
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interval decrease in alphafetoprotein in 3 patients, ranging from 32 to 95%. The remain-
ing 2 patients had normal baseline alphafetoprotein levels, which remained un-elevated 
on follow-up.
Figure 3. Patient 2: Baseline triphasic CT liver shows the recurrent HCC at the segment IV resection margin 
(A). Follow-up triphasic CT liver at three (B) and six (C) months post-radioembolization showed good tumor 
(‘T’; 133 Gy) response with progressive atrophy of the left lobe (‘L’; 93 Gy), in keeping with left radioemboli-
zation lobectomy intent. Right lobe volume (27 Gy) remained stable.
Figure 4. Bland-Altman plot of Y90 activities derived by artery-specific SPECT/CT partition modeling versus 
that hypothetically derived by body surface area (BSA) methodology.
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Postradioembolization best imaging response was available in 8 patients. Median 
time-to-best imaging response was 76 days (11 weeks; 95% CI 55-114 days). When Y90 
radioembolization was analyzed strictly as a brachytherapy, all 8 of 8 patients showed 
regression of the index tumor, with a median size decrease of 58% (95% CI, 40%-72%). 
None developed new tumors within planning target volumes. Seven of 8 patients 
achieved clinical success at the time of best imaging response. Patient 1 was a case of 
infiltrative HCC classified as clinical failure due to progression of existing portal vein 
tumor thrombosis despite significant regression of the index tumor. Otherwise, tumor 
thrombosis regressed or remained stable in 3 of 4 patients with baseline tumor vascular 
involvement.
At the time of best imaging response, extrahepatic metastases were discovered in 3 
of 8 patients, involving the lungs and adrenal gland. When Y90 radioembolization was 
analyzed as part of a comprehensive multi-modality treatment plan, partial response 
was achieved in 3 of 8, stable disease in 1 of 8, and progressive disease in 4 of 8 patients; 
consistent across all three classifications (RECIST 1.1, WHO and 2D-EASL). Median imag-
ing time-to-progression (TTP) and median overall survival were not reached at the time 
of this report. Patient 1 died 13 weeks postradioembolization and had an overall survival 
of 95 weeks (22 months) under comprehensive multi-modality care; all 7 other patients 
are still alive.
DIsCUssIon
The aim of personalized predictive dosimetry is to guide decisions on radionuclide 
therapy in order to avoid the use of futile therapy and achieve the maximum tumor 
radiation absorbed dose while minimizing collateral radiation injury to normal tissue. 
Precise radionuclide predictive dosimetry has the potential to yield many benefits for 
cancer therapy, and the need to further research into internal dosimetry has recently 
been emphasized (31). To our knowledge, the artery-specific SPECT/CT partition model 
is the first to integrate catheter-directed CTHA, 99mTc-MAA SPECT/CT and partition 
modeling (MIRD) into a unified, accurate, and practical form of image-guided personal-
ized predictive dosimetry for Y90 radioembolization.
Our results show that a 100% tumor response rate can be achieved when the predicted 
mean tumor radiation absorbed dose was at least 91 Gy to a planning target volume. 
There were no significant toxicities with predicted mean radiation absorbed doses to 
non-tumorous liver and lungs of ≤51 Gy and ≤16 Gy, respectively. This highlights the 
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power of predictive radionuclide dosimetry to achieve desired outcomes when planned 
in accordance to dose-response relationships. The capability of artery-specific SPECT/CT 
partition modeling is best exemplified by patient 2, in whom sub-lesional dosimetry was 
successfully planned with Y90 radioembolization lobectomy intent (Figs. 2-3).
Y90 radioembolization is point-source, continuous low dose-rate brachytherapy deliv-
ered at a single time-point. Hence, its true therapeutic efficacy can only be revealed by 
analyzing outcomes in the context of planning target volumes and technical success. 
Therefore, postradioembolization appearance of new tumors within a planning target 
volume should not be misconstrued as clinical failure. Such lesions may represent new 
metastases, pre-existing micro-metastases that have enlarged, or de novo tumors aris-
ing from cirrhotic liver; all of which have little or no bearing on Y90 radioembolization as 
brachytherapy delivered at a single time-point. It follows that when applying standard 
response evaluation criterion (e.g. RECIST), which takes into account new tumors and 
distant metastases, one should analyze Y90 radioembolization brachytherapy as part of 
comprehensive multi-modality care and not in isolation.
The application of Y90 radioembolization without due regard for radiobiological prin-
ciples is akin to flying an aircraft without guidance from air traffic control. Since most 
patients with inoperable HCC have limited prognosis, Y90 radioembolization should 
be carefully planned using scientifically sound methods (e.g. MIRD) to achieve the 
maximum desired effect for optimal, personalized cancer therapy. Our dosimetric data 
showed wide inter- and intra-patient variations in SPECT/CT-based mean T/N ratios 
(Table 3), emphasizing the importance of having a personalized dosimetric approach to 
Y90 radioembolization. The assumption of a standard T/N ratio for the sake of dosimet-
ric simplification may result in over- or undertreatment, and confounds data analyses 
because reliable dose-response relationships cannot be established or verified (10). 
Despite its popularity, the BSA method has questionable radiobiological basis and is 
scientifically inferior to MIRD methodology (5,10). One must be cognizant that the BSA 
method was first published by van Hazel et al. for whole-liver Y90 radioembolization to 
previously untreated colorectal liver metastasis, not HCC (32). These patients did not 
have chronic liver disease, prior liver resection, local ablation, or selective/super-selective 
Y90 radioembolization. Furthermore, colorectal liver metastases are rarely bulky enough 
to distort liver anatomy. These features are often present in HCC, and therefore they 
cast doubt on the validity, safety, and efficacy of the BSA methodology for use in HCC. 
Our data showing a lack of agreement in total Y90 activities derived by artery-specific 
SPECT/CT partition modeling versus BSA method is further evidence against the routine 
use of BSA methodology (Figure 4).
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In this report, postradioembolization bremsstrahlung SPECT/CT was used to determine 
technical success. This was indeterminate in 7 of 10 patients, all of whom have either 
sub-centimeter tumors or tumors with ill-defined margins. This finding highlights the 
low spatial resolution of bremsstrahlung SPECT/CT as a technical limitation by indirectly 
imaging Y90 biodistribution using scatter radiation. It may be possible for positron emis-
sion tomography to overcome this limitation by co-incidence imaging of yttrium-90 
internal pair production (33). This is currently under investigation at our institution.
Y90 microspheres once implanted, remain permanently in place and decays to infin-
ity in situ. This simplifies the dosimetric process because time-activity curves need 
not be obtained, unlike systemic radionuclide therapy. Future Y90 radioembolization 
dosimetric techniques must improve accuracy in several areas: delineation of arterial 
territory target volumes, microparticle simulation and biodistribution assessment, and 
predictive radiation dose-response modeling. For example, future development of 
positron-labeled microspheres in place of 99mTc-MAA may increase the accuracy of 
liver-to-lung shunt calculation, simulation of hepatic microsphere biodistribution, and 
improve predictive radiation modeling by voxel- or Monte-Carlo-based techniques (34-
35). Y90 radioembolization will also benefit from a wealth of experience if EBRT radiobio-
logic models (e.g. linear quadratic model, normal tissue complication probability model) 
and radiation planning techniques (e.g. dose-volume histogram) can be meaningfully 
translated into radionuclide dosimetry models (e.g. MIRD) and vice versa. Application of 
the biologically effective dose (BED) concept into Y90 radioembolization dosimetry may 
achieve this aim (36).
In conclusion, compliance to radiobiological principles of radionuclide internal dosim-
etry is fundamental to Y90 radioembolization success. Image-guided personalized pre-
dictive dosimetry by artery-specific SPECT/CT partition modeling achieves high clinical 
success rates for safe and effective Y90 radioembolization.
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ABstRACt
Liver malignancies are a major burden of disease worldwide. The long-term prognosis 
for patients with unresectable tumors remains poor, despite advances in systemic che-
motherapy, targeted agents and minimally-invasive therapies such as ablation, chemo- 
and radioembolization. Thus the demand for new and better treatments for malignant 
liver tumors remains high. Surgical isolated hepatic perfusion (IHP) has been shown to 
be effective in patients with various hepatic malignancies, but is complex, associated 
with high complication rates and not repeatable. Percutaneous isolated liver perfusion 
(PHP) is a novel minimally-invasive, repeatable and safer alternative to IHP. PHP is rapidly 
gaining interest and the number of procedures performed in Europe now exceeds 200. 
This review discusses the indications, technique and patient management of PHP and 
provides an overview of the available data. 
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IntRoDUCtIon
The liver is frequently affected by cancer. Primary liver cancer is the sixth most common 
cancer in the world and the third cause of cancer-related death (1). The liver is also a 
predilection site for metastases from various malignancies (1,2). Surgery or ablation 
offers the best chance of a cure in most liver malignancies, but this is often not feasible 
due to the extend or location of the disease.  Liver malignancies have a dominant or 
exclusive vascular supply from the hepatic artery, whereas 70-80% of the supply of the 
non-tumorous liver parenchyma is derived from the portal vein (3,4). This difference in 
perfusion is utilized in liver-directed therapies, such as trans-arterial (chemo-) emboliza-
tion or radioembolization. The unique hepatic anatomy also allows vascular isolation 
of the liver to deliver high doses of cytotoxic agents with minimal systemic toxicity. 
Isolated hepatic perfusion (IHP) is a complex surgical technique that involves clamp-
ing of the inferior vena cava (IVC) and portal vein (PV), ligation of IVC tributaries and 
arterial hepatico-enteric anastomoses with subsequent infusion of a high dose of che-
motherapy into the proper hepatic artery (5-10). Promising results have been obtained 
with IHP in treating liver tumors from different histology. Response rates of 37-52% have 
been reported for metastatic ocular melanoma patients (11-14). In patients with liver 
metastases from colorectal carcinoma, response rates of 50-60% have been obtained 
(15-17). Despite the good response rates, the complexity and duration (up to 9 hours) 
of the procedure have prevented for IHP to gain wide acceptance (12). Furthermore, IHP 
is generally not repeatable and is associated with high morbidity and mortality rates 
(16,18-20). 
Percutaneous isolated hepatic perfusion (PHP) is a novel alternative to IHP that enables 
vascular isolation and perfusion of the liver with the use of endovascular techniques 
(21). The minimally-invasiveness as well as the repeatability of PHP offers an important 
advantage over IHP. This review will describe this highly innovative technique and pro-
vide an update of current literature on PHP.
PHP PAtIent seLeCtIon 
PHP has been performed in patients with primary tumors and various hepatic metasta-
ses (Table 1). Patients that best qualify for PHP are those that have disease of the liver 
only or predominantly. For obvious reasons, systemic treatment is the more appropriate 
therapy for patients with more extensive extra-hepatic disease, if available. As significant 
hemodynamic perturbations occur during PHP, patients should have a normal to high 
functional capacity and have no or limited cardio-pulmonary co-morbidity. Although 
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the most commonly used chemotherapeutic agent, melphalan chloride, has limited liver 
toxicity, patients with insufficient liver function are generally excluded from treatment. 
Portal hypertension, especially with concomitant hepatofugal portovenous blood flow, 
is a contra-indication for treatment. During the procedure adequate anti-coagulation 
with heparin is required to prevent intravascular thrombosis and clot formation in the 
extracorporeal circulation system. Therefore, patients with intolerance to heparin do not 
qualify for treatment nor do patients with an increased risk of bleeding (recent history of 
spontaneous internal bleeding or uncorrectable coagulation disorder). Women that are 
pre-menopausal should not be treated during the menstruation period or receive hor-
monal suppression therapy to prevent intra-procedural vaginal bleeding. It is generally 
recommended to perform computed tomography (CT) or magnetic resonance imaging 
(MRI) of the brain prior to treatment, as brain metastases with a propensity to bleed 
are a contra-indication to PHP. Patients should undergo arterial phase and portovenous 
phase contrast-enhanced abdominal CT to confirm patency of the portal vein and 
screen for vascular anomalies that may render PHP difficult of impossible. Variants of the 
hepatic arteries are usually not a contra-indication to PHP, but may require pre-emptive 
coil-embolization to either re-distribute hepatic flow or prevent inadvertent leakage of 
chemotherapeutics to the systemic circulation.
HePAtIC VAsCULAR MAPPInG 
Prior to PHP, angiography of the celiac trunk and hepatic arteries should be performed 
to delineate the arterial supply of the liver (Figure 1). Angiography of the superior mes-
enteric artery may provide additional information and is always performed in patients 
with an aberrant right hepatic artery or to obtain an indirect portogram if hepatofugal 
or compromised portovenous flow is suspected. After mapping of the hepatic arterial 
circulation, a strategy for chemotherapy infusion is formulated. Infusion into the com-
mon or proper hepatic artery allows whole-liver treatment without repositioning of the 
catheter, but carries a higher risk of inadvertent flow of chemotherapeutic drugs into 
branches with supply to the gastrointestinal tract. To prevent this, coil-embolization 
may be indicated of arteries at risk, such as the gastroduodenal and right gastric artery. 
The use of cone-beam CT is recommended as this improves the detection of vascular 
variants, extra-hepatic enhancement and extra-hepatic vascular tumor supply (22-26). 
Embolization of aberrant hepatic arteries has been proven to be an effective strategy to 
redistribute flow in transarterial liver therapies such as radioembolization (27). Hepatic 
vascular mapping is generally performed several days to a week prior to PHP.
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PHP PRoCeDURe 
At present, only one PHP system is commercially available (Chemosaturation Hepatic 
Delivery System, Delcath Systems Inc, New York, USA) and therefore some of the tech-
niques described are specific to this system. In Japan, another double balloon catheter 
(4L/2B, Fuji System Co. Ltd, Tokyo, Japan) is currently used in clinical studies. 
The procedure is performed under general anesthesia by a team consisting of a dedi-
cated interventional radiologist, anesthesiologist and an extracorporeal perfusionist. A 
cannula is placed in the radial artery for continuous arterial pressure monitoring and a 
Figure 1. Hepatic vascular mapping in a 63-year old female with bilateral hepatic metastases from ocular 
melanoma. a. Angiographic images from the celiac trunk show a right gastric artery (asterisk) originating 
from the left hepatic artery (white arrow). b. In the late arterial phase, two hypervascular metastases in the 
right liver lobe (white arrows) are seen as well as the falciform artery (arrowheads). A treatment plan was 
made to perform PHP with selective infusion of melphalan chloride into the left hepatic artery (LHA) and right 
hepatic artery (dotted arrow in a) with pre-emptive coiling of the right gastric (RGA) and falciform artery (FA). 
c. Selective angiography from the LHA shows the FA (white arrowheads) to be originating from the segment 
4 artery (white arrows). The RGA is also depicted (black arrowheads). d. Selective angiography of the FA (long 
white arrow) shows opacification of the right internal thoracic artery (black arrow) through the ensiform ar-
tery (dotted arrow) and of anterior abdominal wall arteries (short white arrows). e. Antegrade catheterization 
of the RGA was unsuccessful and therefore, retrograde catheterization was performed via the LGA using a 
2.4F micro-catheter (arrow). Angiography shows the RGA (white arrowheads) and LHA (white arrow). f. Angi-
ography of the LHA (white arrow) after successful coiling of the FA (dotted arrow) and RGA (black arrow) with 
2mm detachable micro-coils. Some reflux of contrast is seen in right hepatic artery branches (short white ar-
rows). g. Axial CT image in portovenous phase before treatment demonstrates two hepatic metastases (white 
arrowheads). A third metastasis was seen in segment 4B (not shown). In the left liver lobe a cyst is seen (black 
arrowhead) as well as a hypodensity caused by previous laparoscopic excisional biopsy (black arrow). h. CT in 
portovenous phase after two cycles of PHP shows marked reduction in size of the right liver lobe metastasis. 
The other two metastases showed a complete radiological response after treatment.
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urinary bladder catheter inserted. A triple-lumen line is placed in the left internal jugular 
vein (IJV) for central venous pressure monitoring and infusion of sympathomimetics and 
fluids. Access to the right IJV is created with a 10F vascular sheath, to the right common 
femoral vein (CFV) with an 18F sheath and to the left common femoral artery (CFA) with 
a 5F sheath (Figure 2). After all lines and sheaths have been placed, heparin is adminis-
tered at an initial dose of 300 U/kg and the activated clotting time (ACT) is maintained 
above 400 sec during the entire procedure. Hepatic angiograms are obtained and the 
tip of a micro-catheter is then placed into the hepatic artery at the intended location of 
infusion. In a selective lobar approach, the dose of chemotherapy is split and infused 
Figure 2. Schematic display of the set-up of percutaneous hepatic perfusion.  Chemotherapeutic drugs 
are infused through a catheter placed in the hepatic artery (arrowhead) and the effluent chemosaturated 
blood returning through the hepatic veins is aspirated through the side-holes of the double-balloon cath-
eter. An extracorporeal system with carbon activated filters is used to separate the chemotherapeutics from 
the blood, before the blood is returned through a sheath in the internal jugular vein. 
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into the right and left hepatic artery separately. In most patients, the ratio of the two 
lobes is such that 60% of total dose is to be injected into the right hepatic artery and 
40% into the left hepatic artery. The disadvantage of consecutive lobar infusions is that 
it prolongs the time of extracorporeal circulation, as the chemotherapy infusion has to 
be interrupted to reposition the catheter. After placement of the infusion-catheter in 
the hepatic artery, a 16F double-balloon catheter (Isofuse Isolation Aspiration Catheter, 
Delcath Systems Inc, New York, NY) is inserted via the right CFV and positioned with its 
tip in the right atrium. The catheter is then connected to an extracorporeal circulation 
system consisting of a centrifugal pump and two drug filtration activated carbon filters. 
Blood is aspirated through catheter fenestrations in a segment between the two bal-
loons, actively pumped through the filtration system and returned through the sheath 
in the IJV. The cranial balloon of the catheter is then inflated in the right atrium and 
retracted into the inferior caval vein (ICV) until the shape of the balloon resembles that 
of an acorn. The caudal balloon is inflated in the inferior vena cava below the level of the 
hepatic veins and above the level of renal veins. With both balloons inflated, a venogram 
is obtained by hand-injection of a contrast medium through the injection port of the 
double-balloon catheter (Figure 3). With adequate positioning of the double balloon 
catheter, flow of the effluent hepatovenous blood back to the systemic circulation is 
prevented by the cranial balloon at the atriocaval junction and by the caudal balloon at 
the level of the retrohepatic ICV. 
Figure 3. Same patient as in figure 1. Postero-anterior (a) and lateral (b) images during venography per-
formed by hand-injection of non-diluted contrast medium through the size-holes of the double-balloon 
catheter. The cranial balloon (dotted white arrow) was positioned at the atriocaval junction to prevent flow 
to the right atrium (white arrowheads). The caudal balloon (white arrow) prevented retrograde flow to the 
infrarenal inferior vena cava. A micro-catheter (black arrow) was placed through a 5F celiac catheter and 
into the left hepatic artery for the infusion of melphalan chloride. Both the right hepatic vein (open white 
arrow) and middle hepatic vein (black arrowhead) were opacified. Also, a nasogastric tube is seen (dotted 
black arrow).
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Once correct positioning of the two balloons is confirmed, a step-wise approach is used 
to start filtration of blood by the two cartridges. A centrifugal pump is used to achieve a 
flow rate between 0.40 and 0.75 L/min. The maximal flow rate should not exceed 0.8 L/
min and pre-pump pressures should not exceed -250 mmHg to avoid the catheter to col-
lapse or kink. The hemofiltration filters are brought online one by one, by removing the 
clamps. Once the cartridges are completely filled with blood, the bypass line is closed. 
When the hemofiltration circuit is running sufficiently and hemodynamic stability is 
achieved (see below), intra-arterial infusion of chemotherapeutic drugs may be started 
using a pump-injector and a flow rate of 0.4 ml/sec. Before and during the infusion, 
hepatic angiograms are obtained to ensure that hepatic blood flow is not compromised. 
If the angiograms show arterial spasms, this may be treated with nitroglycerine boluses 
of 100-200 micrograms. After the infusion, extracorporeal filtration is continued for 30 
minutes (‘washout period’) to allow clearance of chemotherapeutics from the liver. At the 
end of the procedure, the effects of heparin are reversed by administration of protamine 
sulphate on a 1:1 basis (1 mg of protamine sulphate to antagonize 1 mg of heparine). 
The vascular sheaths are left in place until coagulation is sufficiently corrected, although 
a vascular closure device may be placed immediately after the procedure to achieve 
hemostasis at the arterial puncture site. The duration of the procedure is generally 3-4 
hours.
AnestHesIoLoGY AnD PeRFUsIonIst sUPPoRt 
PHP is associated with hemodynamic and metabolic changes that require monitoring 
and management by an experienced anesthesiologist. In early studies, the conduct of 
PHP under local anesthesia and sedation has been described but nowadays procedures 
are generally performed under general anesthesia (28,29). PHP results in significant 
decreases in mean arterial and central venous pressures and increases in heart rate 
compared to baseline (29,30). Decreases in blood pressures generally occur at two 
stages: upon occlusion of the IVC and when blood flow is diverted through the filters. 
Inflation of the balloons of the double-balloon catheter results in a decrease of central 
venous return and right atrium pre-load. This first drop in blood pressure is corrected by 
administration of fluids and norepinephrine and/or phenylephrine to maintain a mean 
arterial pressure above 60 mmHg. A second drop in blood pressure may be attributed 
to the depletion of sympathomimetics by the activated carbon filters. Infusion rates as 
high as 0.2-1.5 μg/kg/min for norepinephrine and 0.4-3.0 μg/kg/min for phenylephrine 
are generally required during the perfusion period as 67-95% of the sympathomimetics 
are cleared from the blood by the filters (29). A decrease in patient’s body temperature is 
also commonly encountered during PHP and is a result of the blood flowing through the 
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non-heated extracorporeal circuit. In general, the hypothermia is not severe and may be 
reduced by using an air-warming system (30).  
CHeMotHeRAPeUtIC AGent 
The majority of studies have used melphalan chloride as the chemotherapeutic agent 
of choice, for it has pharmacological properties to make it suitable for PHP. It can eas-
ily be administered intra-arterially, has limited liver toxicity, a high hepatic extraction 
rate, a very short half-life and an immediate effect on tumor cells (31,32). The currently 
available filtration system (Delcath hemofiltration cartridges) is specific for melphalan 
chloride.
Melphalan chloride is an alkylating agent of the nitrogen mustard group. Its binding to 
deoxyribonucleic acid (DNA) can result in cross-linking between bases on complemen-
tary strands leading to double-stranded DNA breaks and eventually cell death (8,10,33-
38). In a phase I dose-escalating study with percutaneous administration, the maximum 
tolerated dose (MTD) of melphalan chloride was 3.0 mg/kg body weight (39). The maxi-
mum total dose is generally limited to 220 mg. Because of the short-life of melphalan 
chloride, the drug should be prepared in the pharmacy just prior to administration.
Several studies have used doxorubicin as the chemotherapeutic agent, mainly in patients 
with hepatocellular carcinoma (HCC) (29,40-43). Doxorubicin has some disadvantages 
over melphalan chloride as an agent for PHP. Firstly, it has a first-pass hepatic extraction 
fraction that is only around 60% (44). Secondly, doxorubicin is associated with consider-
able liver toxicity. Studies on PHP with doxorubicin have reported chemical hepatitis 
rates of >70% (29,40-43). The chemical hepatitis was generally mild to moderate and 
self-limiting. Thirdly, with the currently available filters the doxorubicin infusion time, 
and consequently the administrated dose, is limited as prolonged infusion may lead 
to increased systemic exposure. In a study by Ku et al., a mean doxorubicin extraction 
rate of 91% was found, but the filtration rated dropped to 55% at 20 minutes (40). Nev-
ertheless, very promising results have been obtained with doxorubicin in patients with 
advanced HCC with PHP as either the primary treatment or as an adjunct to surgery (see 
results section). The hemofiltration cartridges (DHP-1; Kuraray Co., Ltd., Osaka, Japan) 
used in this study differ from those in studies with melphalan chloride.
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Post-PRoCeDURAL CARe 
Patients are monitored in a medium or intensive care unit (ICU) 12-24 hours after the 
procedure and are generally discharged after 2-3 days. This compares favorably to IHP for 
which admission to the ICU is generally several days and a mean hospital stay has been 
reported of 10-29 days (45). Anemia, neutropenia and thrombocytopenia may be seen 
early after the procedure and may (in part) reflect dilution as a result of peri-procedural 
fluid administration. Transfusion with fresh frozen plasma, packed red blood cells or plate-
lets may occasionally be needed. PHP is associated with transient metabolic acidosis, but 
infrequently to such a degree that correction with sodium bicarbonate is required (32).
CoMPLICAtIons 
Table 1 provides an overview of the type and frequency of common and serious com-
plications as reported in the literature. The most common adverse effects result from 
bone marrow suppression leading to neutropenia, thrombocytopenia, and/or anemia. 
Mild to moderate bone marrow suppression is seen in half tot three-quarters of patients. 
The nadir of cytopenia is generally 10–14 days after PHP. It is generally recommended 
to administer granulocyte colony-stimulating factor analogues (pegfilgastrim) within 48 
hours after PHP to anticipate bone marrow depression. Symptomatic anemia and severe 
thrombocytopenia (<20.000/mm3) may require transfusions. Regular blood tests in the 
first two weeks after PHP are recommended.  
Complications related to multiple vascular accesses and vessel catheterization might 
occur. Patients are at an increased risk of puncture site bleeding as high doses of heparin 
are administrated during the procedure to prevent clot formation in the extracorporeal 
circuit. Bleeding other than from the puncture site is uncommon, but may have severe 
consequences (29,30,46). The hypotension associated with PHP may results in compli-
cations such as organ ischemia, but these have not been reported to date. In general, 
the hypotension is of short duration and responds well to administration of fluids and 
sympathomimetics.
The reported mortality rate of PHP is 0-13.3% (Table 1). Most of the published deaths 
occurred in early studies at the beginning of the learning curve and with a system that 
was different from the kit that is currently used. The reported IHP-related death rate is 
much higher than that of PHP: 5-27% (45). 
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LeAkAGe to tHe sYsteMIC CIRCULAtIon
Bone marrow depression is a result of leakage of melphalan chloride to the sys-
temic circulation. Increased systemic exposure to melphalan chloride may be a result 
of incomplete filtration of the chemotherapeutic agent by the hemofiltration filters. In a 
phase I dose-escalating study, pharmacological blood samples were obtained during 74 
procedures in 28 patients with unresectable hepatic malignancies (38). Perfusions were 
performed with Hemosorba drug filtration cartridges (Asahi Medical Co, Tokyo, Japan) 
for which the filter extraction percentages ranged from 58.2% to 94.7%, with a mean of 
77%. A 2nd generation filter system is available since 2012 and this filter was reported to 
have an efficiency rate of 99% in pre-clinical studies (47). Initial experiences with the 2nd 
generation filter seem to indicate that the degree of bone marrow depression with this 
filter is lower compared to that associated with previous filter systems (46).   
There may be causes of melphalan chloride leakage other than through the filter sys-
tem. The fact that, even with the 2nd generation filter, mild to moderate bone marrow 
depression is not infrequently seen seems to suggest that leakage other than through 
the hemofiltration system indeed occurs (46). One potential cause of leakage may be 
insufficient sealing of the balloon at the atriocaval junction with consequent leakage 
alongside the balloon. Furthermore, leakage to the systemic circulation could also be a 
result of the presence of collateral pathways between the IVC and azygos, hemiazygos, 
accessory hemiazygos, thoracolumbar and/or diaphragmatic veins. Small interconnect-
ing veins between the aforementioned structures are not uncommon and may cause 
the melphalan chloride to bypass the extracorporeal filter system. Another possible 
mechanism may be the uptake of melphalan chloride by the hepatobiliary system and 
storage until the balloons are deflated, after which melphalan chloride is released sys-
temically. However, IHP is associated with lower rates of leakage of chemotherapeutic 
drugs than PHP (48). Furthermore, the half-life of melphalan chloride is very short. It 
therefore seems less plausible that post-procedural release of chemotherapeutics by the 
liver is the cause of systemic toxicity.
In IHP, leakage can be monitored by injection of human serum albumin (HSA) or erythro-
cytes labelled with iodine-31 or technetium-99 (45,49,50). A closed, recirculating system 
is used in IHP and detection of labelled HSA or erythrocytes in the systemic circulation 
is an indication of leakage. Unfortunately, this method cannot be applied in PHP as the 
perfusion circuit is not a closed system and the activated carbon filters allow passage 
of both HSA and erythrocytes. Leakage can be quantified by measurement of systemic 
drug levels during PHP, but this does not provide real-time information as laboratory 
tests to determine melphalan plasma levels are rather complex and time-consuming.
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table 1. Summary of conducted studies on percutaneous hepatic perfusion. 
Author Year no. pts 
(no. PHPs)
type of hepatic malignancy 
(n)





2015 93 (max 6 
per pt)
Melanoma (ocular 83; 
cutaneous 10)
melphalan RCT PHP u
Vogl (46) 2014 14 (18) Melanoma (ocular 8; cutaneous 
3), Gastric/Breast/CA (1)
melphalan retrospective PHP u
Fitzpatrick 
(57)
2014 5 (15) Melanoma
(ocular 4; cutaneous 1)
melphalan case-series PHP u
Fukumoto 
(42)









2013 10 (27) Melanoma (ocular 5; cutaneous 
3, unknown 1). Sarcoma (1)
melphalan retrospective PHP u
Pingpank 
(58) 
2011° 23 (68) NET (23) melphalan prospective PHP u
Miao (30) 2008 51 (136) Melanoma (ocular 12, 
cutaneous 4), NET (12), CRC (7), 
HCC (5), RCC (4), AdrC/Breast/
CA (2), Ewing (1)
melphalan prospective PHP u
Pingpank 
(39)
2005 28 (74) Melanoma (ocular 10, 
cutaneous 3), CRC (2), 
Hepatobiliary (3), NET (4), RCC 
(2), AdrC/Breast/Sarcoma/PA (1)
melphalan phase I PHP u
Ku (59) 2004 22 (40) HCC (22) doxorubicin prospective; resection 
+ PHP 
Savier (48) 2003 4 (10) Breast/CRC/Gastric/CA (1) melphalan prospective 
study
IHP + PHP
Ku (56) 1998 28 (39) HCC, TNM III (1) or IV-A (27) doxorubicin prospective PHP 
Ku (60) 1997 16 (16) HCC (11), CRC (1), Breast CA (1), 
Melanoma (1)
doxorubicin prospective PHP
Ku (40) 1995 15 (15) HCC, unresectable (15) doxorubicin phase I PHP
Ravikumar 
(29)
1994 21 (58) HCC (5), CRC (8), Melanoma 
(2), Sarcoma (4), Adrenal/
Pancreatic/SCLC/CA (n=1)
5-FU, doxorubin phase I PHP
ORR = objective response rate (complete plus partial resspone). NET = neuroendocrine tumor. HCC = hepa-
tocellular carcinoma. CRC = colorectal carcinoma.RCC = renal cell carcinoma. AdrC = Adrenalcortical carci-
noma. CA = cholangiocarcinoma. SCLC = small cell lung carcinoma. PA = periampullary carcinoma. BCLC = 
Barcelona Clinic Liver Criteria.
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(vs 1.6 in 
controls)
10.6 months 
(vs 10.0 in 
controls) W
neutropenia (85.7%), thrombocytopenia (80.0%), 
anemia (62.9%), self-limiting hyperbilirubinemia 








 n.r.  n.r.  n.r. transient mild hypothermia and metabolic acidosis
response 70.6 (48) n.r. 25 months leukopenia (44.1%), serum AST gr. 3-4 (77.9%), hair 
loss (72%), gastroduodenal ulcer (4.4%)
response and 
toxicity
50 (5)  240 
days
n.r. bone marrow suppression; mild elevation serum 
troponin (70%)
response (ORR) 79 39 
months
n.r. acute transaminitis gr 3-4 (22%); neutropenia 47%, 









29.6 (8) n.r. n.r. neutropenia gr 3-4 (73.6%); thrombocytopenia gr 
3-4 (36.8%); aneamia (21.1%)
efficacy 86 (19) n.r. 1 & 5 yr OS: 86 
& 47%
leukopenia (45.5%), hair loss (63.6%)
feasibility; 
pharmacokinetics
 n.r.  n.r.  n.r. neutropenia grade 3-4 (50%)
response and 
survival
63 (17) n.r. 16 months chemical hepatitis (71%), leukopenia (54%), hair 
loss (43%), thrombocytopenia (18%), hemolysis/
hematuria (57%), gastroduodenal ulcer (7%), death 




n.r. n.r. n.r. chemical hepatitis (75%), leukopenia (43.7%), 





64 (9) n.r. 12 months for 
responders 
(vs 5 for non-
responders)
chemical hepatitis (71%), leukopenia (67%), alopecia 
(33%), thrombocytopenia (40%), hemolysis/
hematuria (87%), gastroduodenal ulcer (14%), death 
13.3% due to pancreatisis (7%) and HAT (7%)
MTD, feasibility 9.5 (2)  n.r.  n.r. hematologic, primarily leukopenia/neutropenia; 
transient hypotension (78.5%)
n.r. = not reported. hPFS = hepatic progression-free survival. MTD = maximum tolerated dose. HAT = he-
patic artery thrombosis. ° Only presented as an abstract. u Delcath System. ¶ List is not extensive, mortality 
and common complications are reported. Ω 57.1% of patients in control group crossed over to PHP.  
Complication rates are quoted per PHP at MTD 
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Figure 4.
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ResULts oF PHP to DAte 
The data of the efficacy of PHP is limited, and only one randomized controlled trial has 
been published to date. Table 1 provides an overview of PHP studies, excluding case-
reports and small case-series. The number of procedures per patients varies from 1 to 
3 between the different studies as the optimal treatment schedule and indications for 
re-treatment have not yet been established. Most studies on PHP have been conducted 
in patients with liver metastases from ocular melanoma (Figure 4). Patients with liver 
metastases from ocular melanoma are evident candidates for liver-directed locoregional 
therapy because of the remarkable metastatic pattern of this tumor. Metastases occur 
in approximately 50% of patients with ocular melanoma. In those patients with metas-
tases, the liver is affected in 95% of patients and in 80% the disease has only spread to 
the liver (2,51). Ocular melanoma has a high sensitivity to melphalan chloride and there 
are currently no systemic therapies with proven long-term efficacy for this tumor type.
In 2005, Pingpank et al. published results of a phase I dose escalation study on PHP 
with melphalan chloride in 28 patients with primary and metastatic hepatic disease, 
establishing a MTD of 3mg/kg (39). Response and survival rates were not primary end-
points, but were reported. In the 10 patients with metastases from ocular melanoma, 
an objective response rate (ORR) of 50% was observed: 2 complete responses (CR) and 
3 partial responses (PR). In the total study group, 6 PRs were documented (21.4%). The 
duration of CR was 10 and 12 months and duration of PR included two patients with 
ongoing responses at 9 and 11 months. 
← Figure 4. Hepatic vascular mapping and PHP in a 44-year old female with bilateral hepatic metastases 
from ocular melanoma. a. Angiography from the celiac trunk showed the gastroduodenal artery (GDA) 
(dotted black arrow), the right gastric artery (RGA) (dotted white arrow), a segment 3 artery (S3) (black 
arrowhead) originating from the left hepatic artery and a segment 2 artery (S2) (black arrow) originating 
from the left gastric artery. b. After coil-embolization of the GDA (black arrow), RGA (asterisk) and aberrant 
left hepatic artery (open white arrow), redistribution of flow to S2 (arrowheads) was established through 
intrahepatic collaterals. c. Multiple hypervascular tumors aren in both lobes (arrowheads). d. After inflation 
of the cranial (black arrow) and caudal (white arrow) balloon of the double-balloon catheter, the inferior 
caval vein (open black arrow) and right hepatic vein (white open arrow) were opacified during venography. 
No leakage was demonstrated alongside the balloons. e. Angiography with a micro-catheter positioned 
in the proper hepatic artery showed opacification of all hepatic arteries, including the right hepatic artery 
(white arrow), S2 (open black arrow) and S3 (open white arrow), just prior to infusion of melphalan chloride. 
f. At the start of the second PHP 6 weeks later, angiography shows complete disappearance of staining of 
the liver metastases. Follow-up CT and PET/CT (not shown) after two PHP procedures revealed three small 
residual tumors that were subsequently treated with RFA. The patient remained without evidence of dis-
ease until 1 year after the first PHP.
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In a retrospective study by Forster et al., including 10 patients with hepatic metastases 
from ocular melanoma (n=5), cutaneous melanoma (n=3), melanoma from unknown 
origin (n=1) or sarcoma (n=1), nine patients (90%) had stable disease or PR on follow-
up imaging (52). The median percent decrease in hepatic tumor volume was 48.6% for 
patients with ocular melanoma compared to 33.3% for the entire cohort. At a median 
follow-up of 11.5 months (range 4-55 months), median hepatic free survival was 240 
days and median overall survival from the time of first PHP was 8.7 months. 
A retrospective two-center study reported the results of PHP in 14 patients treated with 
18 PHP procedures (46). The majority of patients (n=11; 78.5%) had liver metastases 
from melanoma (ocular (n=8) or cutaneous (n=3)). A 50% ORR was reported (one CR in a 
patient with cholangiocarcinoma and 6 PRs in patients with metastases from melanoma) 
and 38% patients had stable disease. 
In 2016, the results were published of a multi-center, randomized controlled study com-
paring PHP with best alternative care (BAC) in patients with hepatic metastases from 
melanoma (53). The study included 93 patients with unresectable hepatic metastases 
from melanoma (either ocular (n=83) or cutaneous (n=10)). Patients with limited extra-
hepatic disease were allowed to enter the study, although most patients (59.1 %) had 
metastases confined to the liver. Patients in the PHP arm (n=44) underwent a maximum 
of 6 isolated liver perfusions with melphalan at 4 weekly intervals. Patients in the control 
group (n=49) received best alternative care (BAC) with the majority of patients (81.6%) 
receiving active treatment such a systemic chemotherapy, chemoembolization, radio-
embolization and surgery. A statistically significant improvement in hepatic progres-
sion-free survival (hPFS) and overall progression-free survival (oPFS) was demonstrated 
in patients treated with PHP compared to BAC. The hPFS and oPFS were 7.0 and 5.4 
months respectively for the PHP group compared to 1.6 and 1.6 months respectively for 
the BAC group (p<0.0001). No statistically significant difference in overall survival (OS) 
was found between the PHP and BAC group (10.6 and 10.0 months respectively), but this 
was confounded by a large proportion of the patients in the BAC group (57.1 %) crossing 
over to receive PHP after progression of disease.
A Japanese group has published several studies on PHP in patients with HCC using a 
different double balloon catheter and hemofiltration system (see above). Some overlap 
between the patient groups in the different studies exists (42,54-56). In a prospective 
study, 28 patients with advanced HCC (TNM III or IV-A) underwent an average of 1.4 PHP 
with doxorubicin. The ORR was 63% and the OS was 16 months. The 1-, 3- and 5-year 
survival rates were 67.5%, 39.7% and 39.7% respectively (41). In a recent publication, the 
results were reported of combined reductive surgery and PHP with mitomycin C and/
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or doxorubicin in 68 patients with intermediate or advanced stage HCC (42). An ORR of 
70.6% was achieved with a median OS of 25 months. 
FUtURe DIReCtIons
PHP holds promise as a locoregional therapy for patients with hepatic malignancies. 
The ability to deliver high doses of chemotherapy with limited systemic exposure is 
appealing and the minimally invasive nature of the procedure offers great advantages 
over IHP. In phase I studies, the feasibility and toxicity profile of the procedure have been 
well established. Data on the efficacy of PHP is limited, but initial results are promising, 
especially in the treatment of liver metastases from ocular melanoma. A recent phase III 
trial showed superiority of PHP over BAC in patients with hepatic metastases from either 
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ocular (89.2 %) or cutaneous (10.8 %) melanoma (53). Further studies are needed to 
establish the role of PHP in treatment of different types of hepatic malignancies, define 
the optimal treatment frequency and interval and compare treatment outcomes with 
currently available locoregional and systemic therapies. Prospective studies on the ef-
ficacy of PHP for primary liver tumors as well as hepatic metastases from various origins 
are currently being conducted (Table 2).
The most frequent toxicity associated with PHP is bone marrow depression as a result of 
leakage of melphalan chloride. With the introduction of the 2nd generation hemofiltra-
tion system, the rate and severity of bone marrow depression appear to be reduced. 
To further reduce the systemic toxicity rates, further studies are needed to analyze 
the causes of systemic leakage of chemotherapeutics and improve the technique and 
hemofiltration system of PHP. Currently, melphalan chloride is the most commonly che-
motherapeutic agent used for PHP. In studies using either fluorouracil or doxorubicin 
the affinity of the filters used was either limited or the extraction rated dropped after 
prolonged chemotherapy infusion (29,40). New detoxification filters factory tuned to 
high affinity for specific chemotherapeutics may enable more effective treatment with 
other drugs than melphalan chloride in the future. 
In conclusion, PHP is a novel, minimally invasive and repeatable alternative to IHP. Phase 
I studies have demonstrated PHP to be feasible and safe. A recently published random-
ized controlled trial has shown improved control of liver disease compared to standard 
available therapy in patients with hepatic metastases from (ocular) melanoma. Further 
phase II and III studies are needed to define the role of PHP in the clinical management 
of patients with different hepatic malignancies.
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Percutaneous hepatic perfusion (PHP) with melphalan is an effective treatment for 
patients with hepatic metastases, but associated with high rates of bone marrow de-
pression. To reduce systemic toxicity, improvements have been made to the filtration 
system. In pre-clinical studies, the Delcath System’s GEN2 filter was superior to the first 
generation filters. In this clinical study, we analysed the pharmacokinetics and toxicity 
of PHP using the new GEN2 filter. 
Methods
Starting February 2014, two prospective phase II studies were initiated in patients with 
hepatic metastases from ocular melanoma or colorectal cancer. In 10 PHP procedures 
performed in the first 7 enrolled patients, blood samples were obtained to determine 
filter efficiency and systemic drug exposure. PHP was performed with melphalan 3mg/
kg with a maximum of 220 mg. Complications were assessed according to CTCAE v4.03. 
Response was assessed according to RECIST 1.1.
Results
Pharmacokinetic analysis of blood samples showed an overall filter efficiency of 86% 
(range 71.1 - 95.5%). The mean filter efficiency decreased from 95.4% ten minutes after 
the start of melphalan infusion to 77.5% at the end of the procedure (p=0.051). Bone 
marrow depression was seen after up to 80.0% of 10 procedures, but was self-limiting 
and mostly asymptomatic. No hypotension-related complications or procedure related 
mortality occurred. 
Conclusions
The GEN2 filter has a higher melphalan filter efficiency compared to the first generation 
filters and a more consistent performance. PHP with the GEN2 filter appears to have an 
acceptable safety profile, but this needs further validation in larger studies.
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IntRoDUCtIon
Percutaneous hepatic perfusion  (PHP)  is an innovative, minimally invasive procedure 
that is gaining interest as a therapeutic option for patients with hepatic malignancies. A 
recently published randomized controlled trial (RCT) has shown superiority of PHP over 
best alternative care in patients with hepatic metastases from ocular and cutaneous 
melanoma (1). Furthermore, small prospective cohort studies have shown promising 
results in patients with secondary liver tumours as well as primary liver tumours (2-7).
Wide acceptance of PHP in clinical practice has been halted due to concerns about the 
safety profile of PHP. The most notable complication of PHP is bone marrow depression 
resulting in anaemia, neutropenia and/or thrombocytopenia. Reported rates of com-
plications related to bone marrow depression vary from 43.7% to 85.7% (8). In PHP, the 
liver vasculature is isolated from the systemic circulation using percutaneously inserted 
catheters. A micro-catheter is placed in the hepatic artery to deliver a high dose of the 
chemotherapeutic agent melphalan. Prior to the start of infusion of the chemotherapeu-
tic drug, a double-balloon catheter is placed in the inferior caval vein (ICV). The balloons 
prevent leakage of chemotherapeutics to the systemic circulation by occluding the ICV 
at the level of the atrio-caval junction and infra-hepatic ICV. Through catheter side-holes 
located in between the two balloons, the chemosaturated blood returning through the 
hepatic veins is aspirated and the blood is then pumped through an extra-corporeal 
filtration system. After filtration, the blood is returned to the patient through a catheter 
in the  internal  jugular vein  (8). The high rate of bone marrow depression associated 
with PHP indicates that systemic exposure to chemotherapeutic drugs does occur. This 
may result from failure to achieve complete isolation of the liver vasculature or from 
incomplete extraction of chemotherapeutics by the hemofiltration system. In a phase I 
trial including 28 patients treated with PHP, pharmacological analyses of blood samples 
demonstrated a mean filter extraction rate of 77% (range 58.2% - 94.7%) (9). In this study, 
and most of the other published studies, PHP was performed using a first generation he-
mofiltration system. In 2012, a second generation detoxification cartridge (GEN 2 filter; 
Delcath Systems, New York, NY, USA) was made commercially available. Compared to the 
first generation hemofiltration system, the GEN 2 filter has been modified in several ways 
to improve the filter extraction rate. The activated carbon particles have been changed 
in shape (from granular to spherical), density (from 0.600 – 0.560g/ml to 0.195 - 0.185 g/
mL), size (mean ± standard deviation from 1363 ± 457 μm to 720 ±102 μm) and volume 
per cartridge (from 500ml to 550ml). In a porcine study, the extraction rate of the GEN 2 
filter was 99 ± 0.4% (10). Initial clinical experiences seem to indicate that the use of the 
GEN 2 filter may indeed reduce systemic toxicity (7). In 2014, we initiated two phase II 
trials investigating PHP with the GEN 2 filter in patients with hepatic metastases from 
either ocular melanoma or colorectal carcinoma. As part of these trials, we obtained 
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blood samples in a subset of patients to investigate the pharmacokinetics of PHP with 
the GEN 2 filter. Our hypothesis was that the use of the GEN 2 filter would result in a 
higher filter extraction rate and lower incidence of bone marrow depression compared 
to those reported after PHP with the first generation filter. The primary objective of this 
pharmacological study was to determine the melphalan filter efficiency of the GEN 2 
filter. The objective of the phase II studies was to analyse the safety and efficacy of PHP 
with melphalan.
MetHoDs
study design and patients
In this pharmacological study the first consecutive seven patients treated with PHP 
were included as part of the aforementioned phase II studies. In the first three patients, 
pharmacological samples were also obtained during the second PHP procedure. 
Thus, pharmacological data of 10 PHP procedures in 7 patients was analysed. The phase 
II studies and the presented pharmacological study were approved by the Local Medi-
cal Ethics Committee of the Leiden University Medical Centre. Patients were potential 
candidates for one of the two phase II studies, if they had histologically proven, unre-
sectable metastases confound to the liver from either ocular melanoma or colorectal 
carcinoma. Patients were ineligible for surgical resection because of diffusely spread 
of liver disease or a metastasis not accessible for surgical resection or radiofrequency 
ablation, as evaluated by a multidisciplinary liver team of hepatic surgeons, medical 
oncologists and interventional radiologists. 
Both phase II studies had similar inclusion criteria: life expectancy > 4 months, resection 
of the primary tumour > 4 weeks prior to PHP, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT) and alkaline phosphatase ≤ 5 times upper limit of normal, leuco-
cyte count ≥ 3,0 ×109/l, platelet count ≥ 100 × 109/l and estimated GFR ≥ 40 ml/min. Exclu-
sion criteria were a World Health Organization (WHO) performance status of ≥ 2, age <18 
and > 65 years, less than 40% healthy liver tissue based on computed tomography (CT) 
or magnetic resonance imaging (MRI), evidence of extrahepatic disease or coagulation 
disorders: activated partial thromboplastin time (APTT) > 32,5 seconds and prothrombin 
time (PT) > 13,7 seconds. Contrast-enhanced CT of chest, abdomen (arterial and venous 
phase) and brain were performed to exclude extra-hepatic disease and detect vascular 
variants precluding PHP. All patients underwent pre-procedural angiography with cone-
beam CT. The later was used to exclude extrahepatic enhancement and vascular tumor 
supply from extrahepatic collaterals. All patients provided written informed consent for 
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the study. Patients were routinely scheduled to undergo two PHP procedures with a 
six-week interval, in case there was no progression of disease after the first PHP.
PHP procedure
Details of the PHP procedure have been described previously (8). The following de-
scription is a summary of the most relevant parts of the procedure. Procedures were 
performed under general anesthesia in the angiography room by a dedicated team of 
an interventional radiologist, anesthesiologist and perfusionist. After creation of vas-
cular accesses to both internal jugular veins, the right common femoral vein and left 
hepatic artery, heparin was administrated to achieve an activated clotting time (ACT) 
of > 400 sec. A 2.7F microcatheter (Progreat, Terumo, Tokyo, Japan) was placed in the 
hepatic artery to deliver melphalan. A double balloon catheter (Isofuse Isolation Aspira-
tion catheter, Delcath Systems Inc., New York, USA) was positioned in the ICV and the 
balloons were inflated to prevent the flow of chemosaturated blood to the systemic 
circulation (Figure 1). During set-up and initiation of the extracorporeal filtration circuit, 
sufficient blood pressure was maintained by the anesthesiologist by administration of 
fluids and intravenous infusion of norepinephrine and/or phenylephrine. All PHP pro-
cedures were performed with the GEN 2 filtration system. Melphalan (Alkeran, Aspen, 
Dublin, Ireland) was infused at a dose of 3mg/kg (with a maximum of 220mg) at a rate of 
0.4 ml/sec in about 30 minutes. After melphalan infusion, extracorporeal circulation of 
blood returning through the hepatic veins was maintained for an additional 30 minutes 
(‘wash-out’ period). At the end of the procedure, protamine sulphate was administrated 
to reverse the effects of heparin. Patients were monitored in a medium or intensive care 
unit 12-24 hours after the procedure. Patients were discharged from the hospital at day 
3 after PHP.
Pharmacological sampling
Blood samples were taken simultaneously from the median cubital vein as well as of the 
tubing before and after the filter of the extracorporeal system starting 10 minutes after 
commencement of melphalan infusion (T10), at the end of melphalan infusion (Tend infusion) 
and at the end of the wash-out period (Tend wash-out) (Figure 1). In addition to this, venous 
(systemic) blood samples were obtained 10 and 20 minutes after the start of the wash-
out period, at the end of the wash-out period and 5, 30, 60 and 120 minutes after the 
end of the wash-out period. Blood was drawn in 10 mL sodium heparin tubes and placed 
in ice immediately after collection. Directly after the PHP procedure, the blood samples 
were centrifuged for 10 minutes  at 1000G  at room temperature. After centrifugation, 
the plasma was split into two aliquots and stored in cryovials at -70ºC until analysis. All 
samples were analysed  for melphalan by a high-performance liquid chromatographic 
analysis with ultraviolet detection as previously described (11). The detection limit of 
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melphalan in plasma was 0.5 µg/ml. The intra-assay coefficients of variation were 2,5% 
for melphalan in plasma in the concentration range of 0.5 -5.0 µg/ml and the inter-
assay coefficients of variation were 12.4% for melphalan in plasma in the concentration 
range of 0.5 µg/ml, and 3.6% for melphalan in plasma in the concentration range of 5.0 
µg/ml.
safety and efficacy of PHP
Blood tests were performed on each patient prior to treatment, on day 1, 2, 3, 9, 12, 15 
and 18 after PHP and then weekly, until both blood cell count and liver function tests 
were normalized or reduced to grade I-II toxicity according to the common terminology 
criteria for adverse events v4.03 (CTCAE v4.03). Routine study blood tests included: full 
blood count, APTT, PT, international normalized ratio (INR), glucose, creatinine, sodium, 
potassium, bilirubin, amylase, alkaline phosphatase, ALT, AST, lactate dehydrogenase 
(LDH), γ-glutamyl transferase, protein, albumin, bicarbonate. Routine follow-up included 
visits to the outpatient clinic at 1 and 6 weeks and then every three months as well as 
telephonic consultation at day 9, 12, 15 and 18. Patients underwent CECT of the abdo-
men and chest (including arterial phase of the liver) 4 and 12 weeks after the first PHP 
procedure and every 3 months thereafter. In patients with poor visibility of metastases 
Figure 1. Schematic overview of PHP circuit. Indicated are the pharmacokinetic sampling points
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on CT, multiphase MRI of the liver was performed instead of CECT of the abdomen. If the 
CECT at 4 weeks post-PHP did not demonstrate disease progression and no complica-
tions occurred during the first PHP that contra-indicated repeated treatment, patients 
underwent a second PHP procedure as per protocol.
outcome assessment
Technical success was defined as the successful delivery of the prescribed dose of mel-
phalan. 
The mean filter efficiency  of the GEN 2 filters was determined by calculation of the 
difference between the areas under the plasma melphalan concentration-time curves 
(AUC) before and after the filter. The AUCs were calculated with the trapezoidal rule. The 
overall mean filter efficiency was calculated as follows: ((prefilter AUC) – (postfilter AUC)/
(prefilter AUC)) x100.  For the filter efficiency at a specific time point, the filter efficiency 
was calculated using the pre- and post filter concentrations ((prefilter  concentration 
Tx) – (postfilter concentration Tx)/(prefilter concentration Tx)) x100. The maximum con-
centration (Cmax) was defined as the peak systemic concentration of melphalan during 
a PHP procedure. Post-procedural blood test abnormalities, toxicity and adverse events 
were assessed according to CTCAE v4.03. Haematological laboratory disorders occurring 
within 3 days after PHP were categorized as ‘early’ and those occurring more than 3 days 
after PHP as ‘late’. Early haematological complications were considered to be related to 
the procedure itself, i.e. to the dilution of blood as a result of fluid administration and/
or to haemolysis by the hemofiltration system. Late haematological complications were 
most likely attributable to bone marrow depression as a result of melphalan toxicity. CT 
and MRI scans were assessed by an independent abdominal radiologist according to 
Response Evaluation Criteria for Solid Tumors version 1.1 (RECIST 1.1). Time to progres-
sion and overall survival were assessed.
statistical analysis
The filter extraction rates for all perfusions at different time points are expressed as mean 
± standard deviation (SD). The mean filter efficiency rates and mean melphalan plasma 
concentration were compared using a paired t-test. Time-to-progression and overall sur-
vival was expressed in months as mean and median ± SD. All data were analysed using 
SPSS software for Windows version 20 (SPSS, Chicago, Illinois, USA). Graphs were created 
using GraphPad Prism 6 Software for Windows (GraphPad Software, La Jolla California 




Patients and tumour characteristics of the 7 patients are listed in Table 1. Median age at 
time of treatment was 57 years (range 42-64 years); 5 patients were males. All patients re-
ceived previous treatment for their hepatic metastases, such as systemic chemotherapy, 
radiofrequency ablation (RFA) or immunotherapy in a clinical trial. Four out of the seven 
patients underwent two technically successful PHP procedures as per protocol, however 
not all these procedures were included in this pharmacological study. Three patients 
underwent only one PHP procedure. One  patient was reluctant to undergo a second 
PHP as the first procedure was complicated by pancytopenia with severe bacterial phar-
yngitis. In another patient, the CT 6 weeks after the first procedure showed progression 
of colorectal hepatic metastases and this patient did therefore not undergo a second 
PHP procedure. The third patient developed a pulmonary embolus three weeks after 
the procedure and was reluctant to undergo a second PHP. All ten PHP procedures were 
technically successful. Median duration of infusion for all procedures was 45  minutes 
(range 39 – 55 minutes). The overall mean duration of the entire PHP procedure was 4:02 
hours (range 3:26 – 4:45h). The perfusion parameters are listed in Table 2. All patients 
were successfully treated with the planned dose of 3 mg/kg body weight, with a maxi-
mum dose of 220 mg of melphalan. The median follow-up was 24 months (interquartile 
range 9.0-26.5 months).
Pharmacokinetic analysis
Heparinized blood samples were successfully obtained during all ten PHP procedures as 
per protocol. A summary of the Cmax, Area Under the Curve (AUC) and filter efficiency is 
shown in Table 3. The overall mean filter efficiency during 10 PHP procedures was 86.0% 
(range 71.1 %–95.5%). No significant differences were observed in filter efficiency and 
systemic concentrations between the first and second procedure in the patients that 
underwent two procedures. Figure 2 illustrates the changes in filter efficiency during 
the 10 PHP procedures. The mean filter efficiency at specific time points decreased from 
95.4% (range 82.7-100%) at T10 to 77.5% (range 30-100%) at Tend washout (p=0.051).
Figure 3 displays the mean plasma concentration of melphalan of all patients during the 
PHP procedure. The systemic concentration increases rapidly during the infusion period. 
The mean peak melphalan plasma (Cmax) was 1.1 µg/ml  (range 0,5-1,8 µg/ml). In the 
majority of the procedures (67%), Cmax occurred at Tend infusion. The melphalan  plasma 
concentration decreased rapidly after cessation of infusion and was undetectable in the 
blood samples in all patients 2 hours after the start of the infusion.
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safety of PHP
Procedure-related adverse events in all 10 PHP procedures are summarized in Table 
3. This excludes peri-procedural transient hypotension, which was seen and managed 
successfully by the anesthesiologist in all patients and did not result in any hypotension-
related complications. Haematological laboratory disorders were the most common 
post-procedural complication. Early (<3 days) anaemia and thrombocytopenia grade III 
occurred after 10% of the procedures. No early grade III or IV leukopenia or neutropenia 
were observed, but asymptomatic early grade III (40%) or IV (10%) lymphocytopenia 
occurred after half of the perfusions. Late haematological complications, indicative of 
bone marrow depression, were observed in the majority of patients in our study. Late 
grade III/IV leukopenia, neutropenia and thrombocytopenia were observed after 80.0%, 
80.0% and 40.0% of perfusions respectively. After the first two procedures, pancytope-
nia occurred: the first patient was asymptomatic, but the second patient was admitted 





























Figure 2. Filter efficiency per pa-
tient at different time-points during 
the procedure. 
The mean filter efficiency was calcu-
lated at three time points during the 
10 procedures. First at ten minutes 
after the start of the melphalan infu-
sion, than at the end of the melpha-































Figure 3. Mean systemic concen-
tration of melphalan of all patients 
over time.
A mean concentration of systemic 
melphalan was calculated at dif-
ferent time points, for all ten pro-
cedures, the bars indicate the stan-
dard deviation (SD). The horizontal 
dotted line at 0.5 µg/ml indicates 
the detection limit of melphalan in 
plasma. 
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ing subsequent procedures 6 mg of granulocyte colony-stimulating factor (GCSF) was 
administered 48 hours after the treatment. Four patients received blood transfusion to 





































1 M, 57 UM 105 34 2 PR 28 Liver Alive 28†
2 F, 62 UM 36 6 1 PR 9 Liver Dead 11
3 M, 42 UM 36 3 1 PR 11 Bone, liver Alive 26
4 M, 58 CRC 34 34 1 SD 1 Lymph node, LTR Dead 7
5 M, 46 CRC 28 27 2 PR 5 Lung Alive 27
6 F, 43 UM 40 16 2 PR 14 Liver Alive 25‡
7 M, 64 CRC 30 30 2 SD 5 Lung Alive 24
Abbreviations: PT = patient; PHP = percutaneous hepatic perfusion; UM = uveal melanoma; CRC = colorectal 
cancer; LTR = local tumor recurrence at colonic anastomosis
† 2nd perfusion was followed by radiofrequency ablation (RFA) of 6 small residual tumors.
‡2nd perfusion was followed by RFA of 3 small residual tumors. Because of hepatic progression another 2 
perfusions were performed.













(min) Location of infusion
1 220 3:58 NR 75 PHA
2 180 3:26 51 88 RHA






LHA (180mg) and RHA 
(40mg) 
5 165 3:54 40 82 PHA






Anterior branch RHA 







PHA (110 mg) and 
replaced RHA (110mg)






PHA (110 mg) and 
replaced RHA (110mg)
NR = not recorded. PHA = proper hepatic artery. LHA = left hepatic artery.
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correct post-procedural blood cell abnormalities. No relation was found between the 
occurrence of grade III-IV haematological complications and the administered  mel-
phalan dose. In all patients haematological laboratory values had returned to baseline 
within 3 weeks. Mean time for blood cell count to return to normal was 8.3 days (range 
3-20) for thrombocytes (normal lab value 150-400 ∙109/L) and 13 days (range 5-18) for 
leukocytes (normal lab value 40-10 ∙109/L).
efficacy of PHP
Although response and survival rates were not the primary endpoints of this pharma-
cological study, all patients were assessable for response evaluation. The results are dis-
played in Table 1. A partial response was achieved in all patients with ocular melanoma 
liver metastases (n=4). The mean TTP in these patients was 15.5 months (range: 9-28 
months). In the patients with CRC metastases (n=3), partial response was achieved in one 
patient (33.3%) and the mean TTP of this patient was 4.3 months (range: 1-5 months). 
DIsCUssIon
In our study, we demonstrated an overall mean filter efficiency of 86.0% in patients 
undergoing PHP with the GEN 2 filter. The efficacy of this filter compares favorably to 
that of first generation PHP-filters. As mentioned in the introduction, the mean filter ex-
traction rate of the first generation filter (Hemosorba; Asahi Medical, Tokyo, Japan) was 
found to be 77% in a phase I study (9). Apart from a better filter efficiency, also a more 
consistent performance of the GEN 2 filter was observed. The filter extraction rate varied 
from 71.1% to 95.5%, whereas a considerably wider range has been reported with the 







efficiency* Filter efficiency at time tx (%) ± 
Mean Pre-filter  Post-filter  overall  t10$  tend infusion$  tend washout$ 
Mean  1,13  4,29  0,57  86,0  95,4  85,9  77,5  86,3 
seM  0,13  0,28  0,0  2,5  2.1  3.6  8.1  3,7 
Median  1,15  4,55  0,49  87,2  100  86,3  84.4  86,2 
Minimum  0,50  2,20  0,23  71,1  82.7  63,6  30,0  68.2 
Maximum  1,80  5,20  1,30  95,5  100  100  100  100 
Range  1,30  3,00  1,07  24,4  17.2  36.4  70  31.8 
SEM = standard error of the mean 
*((AUCprefilter- AUCpostfilter)/AUCprefilter) x 100 
±((prefilter concentration) – (postfilter concentration)/(prefilter concentration)) at time Tx
$ t10 versus t30: p=0,013; t30 versus t60: p=0,290; t10 versus t60: p=0,051. (p for significance is p<0.017)
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Hemosorba filter (range 58.2% - 94.7%). The mean filtration rate in our study was lower 
than that obtained in in-vivo, pre-clinical studies. In a study including 6 pigs treated 
with PHP with the first generation filter, the filter extraction rate was 99% (10). Clearly, 
table 4. Main procedure-related adverse events by severity in all perfusions (n=10), categorized as early 
phase (day 0-3) and late phase (day 4-6 weeks after perfusion).
CtCAe* All grades (n) Grade 3 (n) Grade 4 (n)
Hematologic events
Anemia Early 9 1 -
Late 9 1 -
Thrombocytopenia Early 9 1 -
Late 9 - 4
Leukopenia Early 3 - -
Late 8 1 7
Neutropenia Early - - -
Late† 8 - 8
Lymphocytopenia Early 8 4 1
Late† 9 6 1
Hepatic events
Elevated AST level Early 5 - -
Late† 3 - -
Elevated ALT level Early 3 - -
Late† 2 - -
Elevated serum bilirubine level Early 1 - -
Late† 2 - -
other
Fever 2 - -
Thromboembolic event‡ 1 1 -
Post-procedural hemorrhage± 2 - -
Pharyngitis≠ 1 1 -
Alopecia 1 - -
Nausea 2 - -
Edema limbs€ 1 - -
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase.
* Grades of adverse events were defined according to CTCAE (version 4.0). 
† Not determined in 1 perfusion. 
‡ Pulmonary emboli (PE) was diagnosed in one patient 17 days after PHP. Symptoms resolved in after treatment 
with low-molecular weight heparin. 
± Bleeding from puncture site groin, managed conservatively. 
≠ Sepsis based on bacterial pharyngitis for which intravenous antibiotics and immunoglobulins were given, 
followed by aspiration of retropharyngeal abscess. 
€ As a result of administration of intravenous fluid during procedure.
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outcomes of a well-controlled laboratory animal experiment may differ from PHP in 
a clinical setting. Furthermore, the lower filter efficacy in our study may be related to 
differences between pigs and humans in liver volume and hepatic blood flow rates and 
volumes. In our study the mean efficiency dropped from 95.4% at T10 to 77.5% at Tend infu-
sion, although the difference did not reach statistical significance. Pre-clinical studies have 
also shown that the filter efficiency decreases during the perfusion (10). We hypothesize 
that the filter is more saturated at the end of the procedure. Based on this study finding, 
we recommend shortening the time that a patient is on the extracorporeal filtration 
system. This requires optimal coordination between members of the team performing 
the procedure and timely ordering of melphalan, as the short half-life of the drug man-
dates preparation shortly before the start of infusion. Furthermore, infusion time can 
be shortened by coil-embolization of variant hepatic arteries during the pre-procedural 
angiography. By this so-called consolidation of hepatic arterial inflow, the locations of 
infusion can be reduced and thus the need for repositioning of the catheter during the 
procedure. This strategy has been well established in the treatment of liver tumors with 
radioembolization (12,13). The low percentage of early grade III/IV anaemia, leukope-
nia, neutropenia and thrombocytopenia indicates that the modified activated carbon 
of the GEN 2 filter does not cause significant haemolysis. After half of the perfusions 
early grade III /IV lymphocytopenia occurred. As decreases in number were much less 
frequent for other blood cells, the observed early lymphocytopenia may also be related 
to causes other than haemolysis by the filter. Factors such as pre-procedural fasting, 
peri-procedural stress or administration of corticosteroids and fluids may play in role in 
causing lymphocytopenia. 
Late haematological complications, indicative of bone marrow depression related to 
systemic exposure to melphalan, were observed in the majority of patients in our study. 
The rates of bone marrow depression in our study are comparable to those reported 
after PHP with the first generation filter (8). Our study findings thus indicate that the 
improved filtration rate of the GEN 2 filter does not translate to lower rates of grade 
III/IV haematological complications. It is important to note though, that grading of 
leukopenia, neutropenia and thrombocytopenia according to CTCAE v4.03 is based on 
laboratory investigations, not on symptoms. The second patient included in our study, 
developed pancytopenia complicated by bacterial pharyngitis. All consecutive patients 
received gCSF and none experienced symptoms related to bone marrow depression. 
Furthermore, in all patients haematological disorders were transient. There has been 
some speculation over the cause of systemic exposure to melphalan in patients under-
going PHP. It has been suggested that systemic toxicity may be related to causes other 
than incomplete filtration by the hemofiltration system (8). In a small prospective study 
by Savier et al, 4 patients underwent surgical isolated liver perfusion followed by one or 
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two consecutive percutaneous liver perfusions (2). For the percutaneous procedures, a 
closed circuit was created using thread-occlusion of the hepatic artery and portal vein 
occlusion with a transhepatic occlusion-balloon. Blood returning from the hepatic veins 
was pumped into the hepatic artery and no hemofiltration system was used. In all percu-
taneous liver perfusions, leakage of melphalan was seen and grade III or IV neutropenia 
occurred after two-thirds of the procedures. In the surgical procedures, systemic levels 
of melphalan were almost undetectable and no grade III or IV hematological complica-
tions occurred. The authors postulated that leakage may occur alongside the balloons 
or though veins around the common bile duct or the diaphragmatic veins. In our study, 
systemic exposure to melphalan may have been caused by either incomplete filtration 
and/or leakage due to incomplete isolation of the hepatic circulation. Unfortunately, we 
were unable to differentiate between these two different causes of systemic exposure 
to melphalan.
Clearly, the toxicity of PHP with melphalan has to be balanced against the potential 
benefits. To date, there are limited treatment options for patients with metastatic ocular 
melanoma. No standard systemic therapy is available and chemotherapy, immunother-
apy or targeted therapies have not yet been able to show improved survival (14). Radio-
embolization and transarterial chemoembolization are effective locoregional therapies 
for patients with primary and secondary liver tumors, but the results in patients with 
liver metastases from ocular melanoma has only been described in retrospective, small 
cohort studies (15,16). The superiority of PHP with melphalan over best alternative care 
(BAC) has been demonstrated in a multi-center RCT including 93 patients with unresect-
able hepatic metastases from either ocular (n = 83) or cutaneous (n = 10) melanoma (1). 
The hepatic progression-free survival (hPFS) and overall progression-free survival (oPFS) 
in the PHP group were 7.0 and 5.4 months respectively, compared to 1.6 and 1.6 months 
respectively for the BAC group (p < 0.0001). Given the potential benefit, we consider the 
safety profile of PHP to be acceptable in patients with hepatic metastases from ocular 
melanoma and PHP should therefore be considered as a first line therapy for these 
patients. For patients with colorectal cancer metastases several other treatment options 
are available, such as chemotherapy, radio-embolisation or targeted therapy. Therefor 
the place of PHP as treatment option for these patients has yet to be determined.
The small sample size is the most important limitation of our study. Another limitation is 
related to the difficulties of melphalan analysis, which precluded immediate assessment 
of melphalan levels during the procedure and only allowed detection of melphalan 
above a threshold of 0.5 µg/ml. The inability to detect melphalan levels below 0.5 µg/ml 
may have led to overestimation of the filter efficiency at the different time-points. Yet, 
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this limitation had little influence on determination of the overall filter efficiency as this 
was measured as area under the curve using the trapezoid method.
In conclusion, our study demonstrates that the filtration rate of the GEN 2 hemofiltration 
system performs better than the first generation filtration system. The filter efficiency 
decreases during the PHP procedure. Despite the improved filtration rate, haemato-
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Interventional radiology (IR) procedures are associated with high rates of preparation 
and planning errors. In many centers, pre-procedural consultation and screening of 
patients is performed by referring physicians. Interventional radiologists have better 
knowledge about procedure details and risks, but often only get acquainted with the 
patient in the procedure room. We hypothesized that patient safety (PS) and patient 
satisfaction (PSAT) in elective IR procedures would improve by implementation of a pre-
procedural visit to an outpatient IR clinic. 
Methods
IRB approval was obtained and informed consent was waived. PS and PSAT were mea-
sured in patients undergoing elective IR procedures before (control group; n=110) and 
after (experimental group; n=110) implementation of an outpatient IR clinic. PS was 
measured as the number of process deviations. PSAT was assessed using a questionnaire 
measuring Likert scores of three dimensions: interpersonal care aspects, information/
communication and patient participation. Differences in PS and PSAT between the two 
groups were compared using an independent t-test. 
Results
The average number of process deviations per patient was 0.39 in the control group 
compared to 0.06 in the experimental group (p<0.001). In 9.1% patients in the control 
group, no legal informed consent was obtained compared to 0% in the experimental 
group. The mean overall Likert score was significantly higher in the experimental group 
compared to the control group: 2.68 (SD 0.314) versus 2.48 (SD 0.381) (p<0.001). 
Conclusions
PS and PSAT improve significantly if patients receive consultation and screening in an IR 
outpatient clinic prior to elective IR procedures.
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IntRoDUCtIon
In 1964 Charles Dotter performed the first percutaneous transluminal angioplasty (PTA) 
in a patient with a superficial femoral artery stenosis (1). This was the beginning of a new 
medical specialty: interventional radiology (IR). For years, transarterial therapies such 
as PTA and stent placement have been the hallmark of IR. Over the past two decades, 
many new IR procedures have been introduced for indications other than atheroscle-
rotic occlusive disease. Thanks to technological innovations, the realm of IR now offers 
a wide variety of minimally invasive treatments such as uterine artery embolization, 
biliary stenting, percutaneous ablation, transarterial (chemo)embolization, radioembo-
lization, vertebroplasty, and etcetera. In contrast to the technological revolution of IR, 
organization of patient care in many IR departments has seen limited change since the 
days of Charles Dotter. Many IR centers have not taken full responsibility for the care of 
patients and still rely on the referring physician to organize aspects of care other than 
the procedure itself. Such practice is questionable in a time where procedure complexity 
and indications have expanded to such an extent that few physicians other than the 
interventional radiologist will have sufficient insight into the potential benefits and 
harms of a procedure. 
Studies have shown that IR procedures are associated with high rates of preventable 
errors related to pre-planning and patient preparation (2,3). Such errors may result in 
treatment delay or last-minute postponement and could jeopardize patient safety (2,3). 
Also, the way informed consent is currently obtained for many IR procedures raises legal 
concerns. In many centers, patients will only get acquainted with the interventional 
radiologist performing the procedure once they have arrived at the procedure room (4). 
Improvements have been made in many hospitals by the introduction of IR safety check-
lists, as it has in our institution (2,5). Yet, we hypothesized that further improvements 
could be made if patients undergoing elective IR procedures would be screened and 
consented preoperatively in an IR outpatient clinic. We therefore conducted a prospec-
tive study with the aim to compare patient safety and patient satisfaction between 
patients who were subjected to a pre-procedural visit to an IR outpatient clinic (experi-




The study was conducted in accordance with the ethical standards of the institutional 
review board (IRB) and with the 1964 Helsinki declaration and its later amendments. 
Informed consent was waived by the IRB.
The study was designed as a single center, non-randomized, and prospective study. Pa-
tient safety and patient satisfaction were assessed prospectively in patients undergoing 
elective IR procedures. Outcomes were assessed in a group of patients before imple-
mentation of the IR outpatient clinic (control group) and then compared to those in a 
group of patients who were treated after implementation of the IR outpatient clinic and 
had made a visit to the clinic. The primary purpose of the study was to compare patient 
safety associated with elective IR procedures between the experimental group and the 
control group. The secondary purpose was to compare patient satisfaction between the 
two groups. 
Power-analysis (Medclac version 12.4.0.0; Medcalc software) was based on a type 1 error 
of 0.05, a power of 80% and the assumption that implementation of an IR outpatient 
clinic would lead to a 14% reduction in the number of process deviations. This resulted 
in a calculated sample size of 220 patients with 110 patients in each group.
Particpants
Patients undergoing an elective IR procedure during the study period were eligible if 
they were older than 16 years and mentally capable to fill out the Dutch questionnaire. 
Patients undergoing one of the following procedures were excluded: peripheral vascular 
interventions and endovascular aortic repair (EVAR), cerebral interventions, non-elective 
interventions, change of drainage catheter or contrast injection through a drainage 
catheter, combined surgical and IR procedure, ultrasound-guided biopsy, or bone biopsy 
(Figure 1). At the time of commencement of the study a close collaboration existed in our 
institution between interventional radiologists and vascular surgeons. Interventional ra-
diologists were already involved in screening and consenting of patients in the vascular 
clinic, vascular surgeons were participating in peripheral vascular interventions in the 
angiography room and all EVARs were performed by a team of interventional radiologists 
and vascular surgeons. We therefore excluded patients undergoing peripheral vascular 
interventions or EVAR. The second category of patients was not included as cerebral 
interventions in our institution were already routinely preceded by outpatient consul-
tation by a neuro-interventionalist. Ultrasound-guided biopsy and bone biopsy were 
excluded in order not to cause any diagnostic delay. Our institution is committed to a 
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national program that guarantees a diagnosis within 48 h for 80 % of patients suspected 
to have one of 23 pre-defined cancer types.
Prior to their appointment for an elective IR treatment, patients were informed of the 
details and intent of the study by letter. Patients in the experimental group were invited 
for a visit to the outpatient clinic. All patients were asked to fill out a questionnaire after 
the procedure at a voluntary basis. If patients indicated that they were unwilling to visit 
the IR outpatient clinic or fill out the questionnaire, they were excluded from the study 
(Figure 1).
Figure 1. Flow diagram showing total number of patients screened, exclusion numbers and reasons, and 
per group analysis. RA research assistant, PA physician assistant
Intervention
Patients in the experimental group were scheduled for an appointment in the IR outpa-
tient clinic 2-14 days prior to the IR-procedure. During the appointment patients would 
be screened for risk factors and provided with information about the procedure by an 
interventional radiologist or physician assistant. In the same setting informed consent 
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would be obtained. A key point list was used to ensure screening and consenting was 
performed adequately (Table 1). All relevant matters discussed were recorded in the 
electronic patient records (EZIS, Chipsoft, The Netherlands). 
Patients in the control group were not routinely screened or consented by medical IR 
staff prior to the procedure. Before the procedure, one of two IR administrative assistants 
would perform a pre-procedural check to verify whether blood tests had been taken 
in accordance with IR protocols and whether anesthesiological support and specific 
tools were ordered as requested by the interventional radiologist. If the administrative 
assistant felt that blood tests were abnormal or missing, they would inform the interven-
tional radiologist who would then contact the referring physician. The administrative 
assistant would also check whether the patient was using anti-coagulants and contact 
the patient by telephone to verify that instructions were given to temporarily stop the 
medication if deemed necessary. Prior to the procedure both the IR technician and inter-
ventional radiologist would assess different items of an IR safety checklist to ensure that 
the procedure could commence safely. Upon arrival at the procedure room, patients 
were asked whether the procedure and complication risks had been explained to them 
sufficiently. If a patient or the interventional radiologist felt that insufficient information 
had been provided, additional information was given. If the referring physician had 
recorded in the patient records that informed consent had been obtained, the informed 
consent was considered to be sufficient (written informed consent is not mandated in 
the Netherlands).
outcome assessment
Baseline characteristics that were recorded included age, sex and the type of procedure.
The primary outcome patient safety was assessed by measurement of the number of 
process deviations. A process deviation was defined as ‘an aspect of healthcare not 
executed correctly or not in accordance with IR protocols’. Process deviations were 
assessed using an IR safety checklist containing sections related to ‘pre-procedural plan-
ning’ and ‘sign-in’ (Figure 2). The checklist was derived from the IR patient safety checklist 
of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) (5). Each 
section of the checklist was assessed by an independent research assistant or physician 
assistant at the time of the IR procedure. When there was some overlap between process 
deviations in two sections, only one process deviation could be scored in one of both 
sections. For example, a patient not having fastened before the procedure may have 
been a result of either a lack of information (Fasting Order Given in ‘Pre-procedural plan-
ning’) or the wrong instructions being given (Patient Fasting in ‘Sign-in’).
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The secondary endpoint patient satisfaction was assessed by means of a validated 
questionnaire. The design and content of the questionnaire was based on the Consumer 
Quality Index (CQI)-measurement instruments on outpatient care (6). The questionnaire 
included 19 questions in Dutch measuring three dimensions: interpersonal aspects 
of care (5 items; α=0.82; 1 factor), information and communication (7 items; α=0.85; 1 
factor) and patient participation (3 items; α=0.63; 1 factor). Examples of the question-
naire were: “Did the doctor listen carefully to you?” and “Did the doctor explain things 
table 1. Key point information and outpatient screening list
Information Discussed
Procedure
Indication □ Yes □ No
Method of anaesthesia □ Yes □ No
Procedure details explained □ Yes □ No
Procedure length discussed □ Yes □ No
Expected treatment outcome explained □ Yes □ No
Complications
Bleeding □ Yes □ No □ N.A.
Infection □ Yes □ No □ N.A.
Thrombus/embolus □ Yes □ No □ N.A.
Neurogenic complications □ Yes □ No □ N.A.
Non-Target □ Yes □ No □ N.A.
Allergy □ Yes □ No □ N.A.
Pneumothorax □ Yes □ No □ N.A.
Other □ Yes □ No □ If yes, specify:
Post-procedure
Puncture site care □ Yes □ No □ N.A.
Drain management □ Yes □ No □ N.A.
Suture management □ Yes □ No □ N.A.
Pain management □ Yes □ No □ N.A.
Admission Time □ Yes □ No □ N.A.
Other □ Yes □ No □ If yes, specify:
Screening Checked
Contra-indications □ Yes □ No
Contrast allergy □ Yes □ No
Renal function □ Yes □ No
Anti-coagulation □ Yes □ No
Other medication □ Yes □ No
Other allergy □ Yes □ No
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in an understandable way?”. The items were assessed on a 4-point Likert scale (strongly 
disagree, somewhat disagree, somewhat agree, and strongly agree). Four questions 
did not correlate with these three dimensions and were measured separately (Table 4). 
The answers of individual patients were anonymized for interventional radiologists and 
referring physicians.
Figure 2. IR patient safety checklist
statistical analysis
Data from the PS checklists and the questionnaires was analyzed using IBM SPSS Statis-
tics 20 software (Chicago, IL, USA). Differences in baseline characteristics between the 
two groups were compared using a Chi-Square test. For patient safety, differences in the 
mean process deviations between the two groups were tested using an independent 
t-test.
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Patient satisfaction scores were calculated for each dimension. The total Likert score for 
the three dimensions were calculated by adding up the score of each dimension (α > 
0.60). The scores of the separate questions were assessed per question. Differences in 
the mean scores between the two groups were tested using an independent t-test. All 
statistical analyses were two-tailed and values of p<0,05 were considered significant.
ResULts
Participants
The study was conducted from April 2013 till January 2014. After inclusion of patients 
in the control group, a 4-week period was used to implement the IR outpatient clinic. 
Inclusion of patients in the experimental group commenced after these 4 weeks. The 
patient characteristics are listed in Table 2. 
The number of female patients in the experimental group was significantly lower than in 
the control group: 33 versus 47 (p=0.050). Also, there was a significant difference in the 
type of procedure between the groups (p = 0.011).
Patient safety
The differences in patient safety between the two groups are listed in Table 3 and 4. The 
number of process deviations per patient was significantly lower in the experimental 
group compared to the control group: 0.06 versus 0.39 (p < 0.001). Significant differ-
ences in the number of process deviations were seen between the two groups in both 










Questionnaires response (N %) 88 (80.0%) 77 (70.0%)
Type of procedure (N %) 0.011
Ablations 27 (24.5%) 29 (26.5%)
Biopsy 33 (30.0%) 43 (39.1%)
Drainages 15 (13.5%) 4 (3.6%)
Embolization 15 (13.5%) 24 (21.8%)
Central venous access 15 (13.5%) 5 (4.5%)
Stents / PTA non -arterial 5 (4.5%) 5 (4.5%)
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sections of the IR safety checklist, ‘pre-procedural planning’ and ‘sign-in’. No process de-
viations were seen in ‘pre-procedural planning’ in the experimental group, whereas 0.22 
process deviations per patient occurred in this section in the control group (p < 0.001). 
All patients in the experimental group had given legal informed consent, whereas 9.1% 
(n=10) of patients in the control group had not been consented adequately. Significant 
differences between the two groups were also seen in the section ‘sign in’: 0.06 process 
deviation per patient in the experimental group versus 0.17 in the control group (p = 
0.021). Most process deviations in the section ‘sign in’ were related to the administra-
tion of antibiotics. Four patients in the experimental group and 7 patients in the control 
group received prophylactic antibiotics prior to ablation of a liver tumor, while this was 
deemed unnecessary according to IR protocols. The doctors prescribing the antibiotics 
had followed the preoperative protocol used for surgical liver resection. Five patients 
in the control group arrived at the angiography room for a percutaneous gastrostomy 
without administration of prophylactic antibiotics as mandated by IR protocols.
In the experimental group, there were no delays in treatment and 3 (2.7 %) postpone-
ments. In 2 of the 3 procedures that were postponed, the coagulation profile was 
unknown and blood tests had to be ordered before the procedure could be safely com-
menced. In the third patient, the creatinin or estimated glomerular filtration rate had 
not been determined prior to the procedure. In the control group, 19 (17.3 %) of the 
procedures where delayed to allow time to correct for process deviations. In 17 (15.5 
%) procedures, the process deviation could not be corrected with the patient in the 
procedure room and the procedure was postponed to a later time or date. The causes for 
the postponement were: indication insufficiently discussed with the referring physician 
or in a multidisciplinary team (n = 2), missing relevant medical history (n = 2), absence 
of specific tools or material (n = 4), failure to stop anticoagulation medication (n = 2), 
fasting order not given (n = 3) or not correctly executed (n = 3), unknown coagulation 
profile (n = 1).
Patient satisfaction
The results of the questionnaires are summarized in table 5. Total patient satisfaction 
showed a significance difference between the two groups in favor of the experimental 
group (p<0.001). Significant improvement in patient satisfaction was seen after imple-
mentation of the IR outpatient clinic in all dimensions. The largest difference between 
the two groups occurred in the dimension ‘Information and communication’: an increase 
in the Likert scale score of 0.26 was seen after implementation of the IR outpatient clinic 
(p<0.001).
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Items process deviations (N)
Pre-procedural planning
Discussed referring Physician / MDT 2 0
Imaging studies reviewed 1 0
Relevant Medical history 2 0
Informed Consent/ complications discussed 10 0
CIN prophylaxis 0 0
Specific Tools present/ordered 4 0
Fasting Order Given 3 0
Relevant lab test ordered 0 0
Anaesthesiologist necessary 0 0
Anticoagulation medication stopped 2 0
Post interventional (ICU) bed required 0 0
Treatment limitation checked 0 0
Total Pre-procedural planning 24 0
Sign In
All records with patient 0 0
Correct patient/side/site 0 0
Patient fasting 3 0
IV access 3 0
Coagulation checked 1 1
CIN checked 0 2
Other lab tests checked 0 0
Allergies and/or prophylaxis checked 0 0
Antibiotics/ other drugs administered 12 4
Total Sign In 19 7
Total Pre-procedural planning and Sign in 43 7






Process deviations (Mean ± SD) 
Pre-Procedural planning 0.22 ± 0.531 0.00 ± 0.000 < 0.001
Sign In 0.17 ± 0.425 0.06 ± 0.245 0.021
Pre-Procedural + Sign In 0.39 ± 0.779 0.06 ± 0.245 < 0.001
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DIsCUssIon
In our study, we investigated the impact of implementation of a pre-procedural visit to 
an IR outpatient clinic for patients undergoing an elective IR procedure. The results show 
that patient safety and patient satisfaction improve significantly when patients receive 
preoperative screening and consultation in such a clinic. 
In patients who were not seen in the clinic, a high rate of process deviations occurred: 
0.39 per patient. After implementation of the clinic the number of process deviations 
was reduced to 0.06 per patient.
A study by Koetsier et al. has shown that the number of process deviations associated 
with IR procedures decreases when an IR safety checklist is used (2). Such a checklist was 
used for all patients in our study. The use of the checklist allowed detection and correc-
tion of process deviations prior to commencement of the procedure in most patients 
in our study. Yet, it did not prevent delay and postponement of procedures in 17.3% 
and 15.5% of patients, respectively. After implementation of an IR outpatient clinic the 
table 5. Questionnaire outcomes: average score per dimensions of patient satisfaction, for separate ques-








Dimensions of patient satisfaction
Interpersonal Aspects 2.73 ± 0.402 2.89 ± 0.291 0.005
Information and communication 2.57 ± 0.571 2.83 ± 0.262 < 0.001
Participation 2.38 ± 0.754 2.59 ± 0.613 0.067
Separate questions (Mean ± SD)
Interpersonal aspect 
Was Doctor knowledgeable? 2.88 ± 0.357 2.87 ± 0.380 0.770 
Information and communication
Information was consistent with the actual treatment? 2.57 ± 0.770 2.75 ± 0.520 0.075
Information about duration of the treatment in accordance with 
the actual treatment?
2.34 + 0.887 2.53 ± 0.644 0.120
Properly informed about preparation of the treatment 2.51 ± 0.919 2.65 ± 0.762 0.262
Overall Patient Satisfaction
Patient satisfaction without separate questions 2.45 ± 0.398 2.67 ± 0.301 < 0.001
Patient satisfaction 2.48 ± 0.381 2.68 ± 0.314 < 0.001
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percentage of delays and postponements was reduced to 0% and 2.7% respectively. The 
results of this study thus indicate that an IR outpatient clinic has additional value to IR 
safety checklists and implementation of such a clinic may lead to further improvements 
in patient safety.
Furthermore, implementation of the clinic resolved another important matter. Adequate 
informed consent had not been obtained prior to arrival of the patient at the procedure 
room in 9.1% (n=10) of patients in the control group. This high rate of inadequate in-
formed consent in patients undergoing IR procedures is consistent with other reports. 
A survey by O’Dwyer et al. revealed that in 56% of patients consent or re-consent for IR 
procedures is obtained in the procedure room and only 22% of patients are consented 
in an outpatient clinic (4). Requirements for legal informed consent vary per country, but 
the following three concepts of legal medical informed consent are widely accepted (7). 
Medical treatment can only be started after a patient’s permission. Secondly, in order for 
the patient to make a decision, information about the patient’s medical condition, the 
treatment purposed and alternatives should be given in lay terms. Finally, the expected 
benefits and potential harms of the treatment should be explained to the patient. 
Legislation is usually not very specific on how these matters should be achieved, but 
obviously consent should be given in a proper manner, in an appropriate environment 
and in the presence of appropriate and relevant information (7). Most people would 
affirm that consent for elective procedure should be obtained some time before the 
procedure and in an outpatient setting. Patients should be given time to think about the 
information provided to them and to read additional information from booklets or any 
other accessible medium. It seems reasonable to assume that interventional radiologists 
have better knowledge about details of an IR procedure than referring physicians and 
should therefore be the ones discussing relevant details with a patient. In our study, the 
number of patients without timely and adequate informed consent decreased to zero 
percent after implementation of an IR outpatient clinic.
Patient satisfaction is of paramount importance in building a good relationship between 
doctors and patients. In our study, patient satisfaction improved significantly by the 
implementation of an IR outpatient clinic. All aspects of patient care that were investi-
gated (interpersonal aspects of care, information and communication and participation) 
improved after the IR clinic was implemented. The largest improvement in patient satis-
faction was perceived in matters related to ‘patient information and communication’. The 
provided information on pre-procedural preparation, procedural details and the length 
of the procedure was also perceived to be more accurate in patients in the experimental 
group compared to the control group. This may not only have a positive effect on the 
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relationship between doctors and patients, but may also have consequences for the 
legitimacy of the informed consent.
Over the last decades, IR has ridden the tidal wave of technological innovation to be-
come a well-recognized medical specialty offering treatment for a variety of indications. 
Long gone are the days when interventional radiologists were the plumbers of the hu-
man vascular system with vascular surgeons being their main contractors. IR now caters 
to many different medical specialists offering a variety of therapies for many different 
indications. Despite the evolution of IR, in many centers the interventional radiologist 
has retained the traditional role between the stage scenes as a technician applauded 
for his catheter skills. A growing number of radiologists are now urging interventional 
radiologists to enter the stage as clinicians (8-10). Our study shows that indeed both 
patient safety and patient satisfaction improve when IR takes on the responsibility to 
perform screening and provide information for patients undergoing IR procedures. It 
was Charles Dotter who said that the radiologist ‘who enters into treatment …can now 
play a key role, if he is prepared and willing to serve as a true clinician’ (1). It is time for 
interventional radiologists to pay tribute to the father of IR by following his advice. This 
will also require diagnostic colleagues and hospital administrators to recognize the role 
of interventional radiologists as clinicians, allocating them time to perform the duties 
that come with it.
Our study has some limitations. Firstly, we were not able to account for the Hawthorne 
effect (11). IR staff may have enhanced their efforts to reduce process deviations or to 
satisfy patients, knowing that they were being observed. Secondly, regression-to-the-
mean may have had impact on the study results. Thirdly, the impact of the IR outpatient 
clinic was assessed in a quasi-experimental experiment. Thus, it is possible that the ob-
served changes were to some extend affected by changes in time. Yet, the study period 
was only 7 months during which only minimal changes in policy and IR staff occurred. 
Fourthly, we measured a surrogate outcome, process deviations, to assess patient safety. 
A study comparing the complication rate between the experimental and control group 
would have required a much larger sample size. The majority of process deviations in 
the control group could be corrected before commencement of the procedure, but 
not without causing delay or postponement in many patients. Finally, we excluded 
patients undergoing peripheral vascular interventions, EVAR or neuro-interventions 
from our study for reasons explained above. These patients make up a large portion of 
all IR patients. Although our study results cannot automatically be extrapolated to these 
patients, it seems reasonable to assume that similar principles apply in these subgroups 
of patients. We acknowledge the fact that practices may vary from country to country 
and even from institution to institution. It may therefore not be possible to extrapolate 
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our study findings to all institutions, but we believe the outcomes of our study to be 
applicable to many IR centers.
In conclusion, our study shows that the number of process deviations associated with 
elective IR procedures can be significantly reduced when patients are consulted in an 
IR outpatient clinic prior to the procedure. Also, by providing pre-procedural patient 
consultation in an outpatient setting IR can improve the satisfaction of patients. More 
patients will perceive the pre-procedural information provided by them as adequate 
and the number of patients in whom informed consent is inadequate can be reduced to 
zero. After the completion of our study, we have implemented a visit to the IR outpatient 
clinic for patients undergoing elective IR procedures of moderate to high complexity. 
Patients undergoing elective procedures of low complexity, such as routine biopsies, 
venous catheters or drainages, are receiving telephone consultation.
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IntRoDUCtIon
When thinking about ways to cure cancer, the human brain is tempted to oversimplify. 
The idea that we will one day find the perfect solution to treat cancer is appealing and 
conceivable, but unlikely given the historical facts. In the past, doctors (mostly sur-
geons) believed we might be able to eradicate cancer by radical surgery. Yet, despite the 
tremendous contribution surgery has made to improve the life-expectancy of cancer 
patients on a whole, even aggressive surgery provides little chance of a cure in meta-
static cancer. For long, people have been hopeful that chemotherapy would provide 
a definitive solution to metastatic cancer. In the past century, a multitude of clinical 
trials have been conducted in many different cancer types, often with ever-intensified 
regimes of combination chemotherapy. We now know that chemotherapy provides a 
cure in some and palliation in many patients, but there still are many cancer patients 
that are desperately in need of better therapies. Over recent years we have turned our 
hopes on targeted molecular therapies, propelled by the successes in unraveling the 
genetics of oncogenesis. Despite the many promising trials that have been conducted 
over recent years, there is a lesson to be learned from the past. It is very likely that we 
will see some spectacular breakthroughs in cancer treatment in the coming years, but 
it is unlikely that targeted or molecular drugs will solve it all. The battle against cancer 
will need to be fought along many lines of medical research. Some inventions will have a 
tremendous impact on the life of cancer patients, whereas other research will only have 
limited effect. Yet, the only way we stand a chance to defeat cancer is by trying in many 
different ways. By bringing together the ingenuity and efforts of many, we will change 
the perspective of cancer patients of the future. This thesis is a contribution, albeit small, 
to the fight against cancer. This thesis focuses on patients with hepatic malignancies. 
PARt 1. RADIoFReQUenCY ABLAtIon
Improvements in outcomes after percutaneous ablation may be achieved in different 
ways. Identifying and selecting those patients that will benefit most from RFA is an im-
portant first step. The study presented in Chapter 2 demonstrates that the survival rate 
between patients from distinct geographical regions may differ as a result of differences 
in baseline parameters and patient selection. As demonstrated in this study, tumor 
size >3cm and tumor number >1 are independent risk factors for recurrence (csHR = 
1.568; 95% CI: 1.083-2.271 and 1.494; 95%CI: 1.031-2.163 respectively). This finding is 
consistent with previous reports in the literature (1-3). As shown in our study, patients 
from a Northern-European country have a higher cumulative incidence of death despite 
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lower recurrence rates. This underlines the importance of factors such as the etiology of 
underlying liver disease and disease stage at the time of treatment. 
Further advances in the field of RFA may be achieved through improvements in tumour 
targeting. As discussed in Chapter 3, co-registration of US and CT/MRI images can be 
performed using manual, semi-automatic or automatic co-registration. Our phantom 
study with the GE Logiq E9 navigation software demonstrated that the accuracy of 
automatic co-registration is inferior to manual co-registration and semi-automatic co-
registration. The mean registration mismatch was ≤ 2.5mm for both manual and semi-
automatic co-registration in our study. This is consistent with other phantom studies 
using similar image fusion technology (4). Unfortunately, the accuracy of co-registration 
is lower in a clinical setting as a result of factors such as the deformability of tissue, 
breathing and movement. New image fusion technology should compensate for such 
factors as well as provide ways to obtain easier and faster image fusion.
A third way to improve the outcome after RFA is through the combination of ablation 
with other therapies, such as TACE, radioembolization or systemic treatment (see below). 
Also, other ablation techniques may prove to be a solution to the limitations of RFA, as 
they are less (microwave ablation) or non-dependent (irreversible electroporation) on 
thermal conductivity of tissue.
In Chapter 4, we investigated the use of TACE as an adjuvant treatment to RFA in HCC 
>3cm. Unfortunately, the combination of RFA with adjuvant drug eluting bead-TACE was 
associated with low rates of local tumor control and survival. The 3-year local tumor 
progression free-survival and overall survival after combined treatment was 17.9% and 
59.4% respectively. This compares unfavorable with results obtained with RFA with neo-
adjuvant TACE, but comparison of results is problematic, as the different studies have 
been conducted in distinctly different patient cohorts.
PARt 2. tRAnsARteRIAL LIVeR tHeRAPIes
TACE is generally considered as a palliative treatment, as complete tumor necrosis is 
often not achieved. Incomplete tumor necrosis may be a result of incomplete tumor 
treatment or incomplete response to treatment. Better imaging techniques have led to 
lower rates of incomplete tumor treatment. The use of cone-beam computed tomogra-
phy (CBCT) and computed tomography hepatic arteriography (CTHA) enable improved 
identification of all arteries with blood supply to a tumor. Previous studies have shown 
that the use of these imaging modalities results in improved outcomes (5-7). In Chapter 
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5, we demonstrated that catheter-directed contrast-enhanced ultrasound (CCEUS) 
provides similar multi-planar information on tumor enhancement as CTHA without 
exposing a patient to iodinated contrast media or additional radiation. Unfortunately, 
practical limitations have hampered the implementation of CCEUS into routine clinical 
practice. 
Radioembolization is generally used to treat patients with advanced stages of disease. In 
large tumors, delivering a tumoricidal radiation dose to the entire tumor is challenging. 
As demonstrated in Chapter 6, in patients with unresectable hepatocellular carcinoma 
up to 37% of patients may have extra-hepatic vascular tumor supply. Identifying extra-
hepatic feeders is essential to ensure complete tumor treatment and improve outcomes. 
Other studies have reported extrahepatic arterial tumor supply in 17-30.8% (8-11). In 
these studies, angiography and CBCT were used to identify extrahepatic tumor supply. 
In our study, we used CTHA and this may have led to better detection of extrahepatic 
feeders as CTHA has better spatial resolution and a larger field of view. Furthermore, the 
superior image quality of CTHA proved to be essential in enabling safe radioemboliza-
tion through the right inferior phrenic artery. In Chapter 7, we demonstrated the supe-
riority of CTHA over angiography and Tc99m-macroaggregated albumin single photon 
emission computed tomography with integrated computed tomography (Tc99m-MAA 
SPECT/CT) in the detection of the falciform artery. Despite this and other studies on the 
superior image quality of CTHA, this imaging modality has not been widely adopted 
outside of Japan, mainly because of the higher costs compared to CBCT. Further studies 
will need to investigate whether the higher costs of CTHA are counterbalanced by the 
superior image quality. 
CTHA was also used to develop artery-specific SPECT/CT partition modeling in radioem-
bolization, as described in Chapter 8. This technique allows individualized patient treat-
ment with a reduced risk of under-treatment of tumor areas. Based on dose calculations 
using integrated CTHA, we estimated that a target volume dose of >90 Gy is associated 
with complete radiological response. Other studies have suggested that radiation doses 
of at least 100-120 Gy are required for complete response. Yet, estimating the relation-
ship between radiation dose and response is complicated by the fact that distribution 
of microspheres in inhomogeneous and tissue radiation dose can only be measured 
indirectly. Better insight in dose-response relationships in radioembolization may be 
provided by post-treatment imaging with positron emission tomography (PET) or with 
the use of new generation microspheres. 
PHP is a novel minimally invasive treatment for patients with hepatic malignancies. 
Chapter 9 provides an overview on the currently available literature on PHP. The rec-
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ognition of PHP as a first line therapy for patient with hepatic metastases from ocular 
melanoma is growing, but further research is needed in order to optimize treatment 
protocols and reduce systemic toxicity. In Chapter 10, we demonstrated that the 
second generation Delcath hemofiltration system has a higher and more consistent 
chemotherapy filtration rate compared to earlier generation filters. In the future, new 
detoxification filters factory tuned to high affinity for specific chemotherapeutics may 
further reduce systemic exposure to chemotherapeutic drugs or enable more effective 
treatment with other drugs than melphalan chloride.
PARt 3. PAtIent MAnAGeMent
New biochemical drugs and technological discoveries with great promise for the future 
are often at the center of the attention of researchers and funding agencies. This may 
divert the attention away from research projects that may seem less innovative and ex-
citing. Nevertheless, projects that investigate everyday practise may have an important 
impact on the wellbeing of patients. In Chapter 11, we demonstrated that both patient 
safety and satisfaction improve significantly when patients are seen in an interventional 
radiology outpatient clinic prior to an intervention. With the increasing number and 
complexity of procedures, it is important that interventional radiologists take greater 
responsibility over the peri-procedural management of patient undergoing minimally 
invasive image-guided therapies.
FUtURe PeRsPeCtIVes
Percutaneous RFA offers important advantages over surgery. It is associated with lower 
morbidity and mortality rates, shorter hospital stays and lower costs. Yet, recurrence 
rates after RFA tend to be higher than after surgery, especially in larger tumors. Future 
research should aim to reduce recurrence rates after percutaneous ablation to make it 
a therapy that is as effective as surgery. Other ablation techniques, such as microwave 
ablation or irreversible electroporation, have been developed in order to overcome the 
limitations of RFA, but so far studies have failed to provide evidence that these newer 
ablation methods are superior to RFA. Limitations that apply to RFA often also apply to 
other percutaneous ablation techniques.
An important limitation of percutaneous ablation is the absence of histological con-
firmation of treatment success. Whereas the surgeon will get confirmation from the 
pathologist whether a tumor has been removed successfully with sufficient margins, the 
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interventional radiologists relies on post-procedural imaging. We therefore need better 
ways to assess tumor necrosis and ablation margins with medical imaging. Our research 
team is currently investigating post-processing software that allows fusion of pre- and 
post-ablation cross-sectional images to better define ablation margins. With the use of 
such software, we may be able to identify patients that are likely to have microscopic 
residual tumor. Patients with increased risk of incomplete tumor ablation may then be 
re-ablated before recurrence actually occurs.
Another important cause of recurrence after percutaneous ablation may be the presence 
of micro-metastases. These frequently occur in close proximity to the primary tumor, but 
may not be coagulated during the ablation. Our research group has initiated a research 
project to investigate segmental radioembolization as an adjuvant treatment to RFA. 
Findings in experimental animal studies have demonstrated increased tumor necrosis 
and improved animal survival after combined treatment with RFA and radiation therapy 
when compared with either therapy alone (12,13). Preliminary clinical studies in primary 
lung malignancies have confirmed the synergistic effects of these therapies (14). Poten-
tial causes for the synergy include the sensitization of viable tumor cells to subsequent 
radiation owing to the increased oxygenation resulting from hyperthermia-induced 
increased blood flow to the tumor (15). Another possible mechanism, which has been 
seen in animal tumor models, is a radiation-induced inhibition of repair and recovery 
and increased free radical formation (16). It is unknown what radiation dose should be 
used when combining RFA with adjuvant radioembolization. This will be investigated 
in a dose-finding study that is financially supported with a research grant from Health 
Holland and the Maag Lever Darm stichting.
Conclusions
1. Midterm recurrence and death rates after radiofrequency ablation (RFA) differ be-
tween hepatocellular carcinoma (HCC) patients in South-East Asian and Northern-
European populations as a result of differences in baseline patient characteristics 
and patient selection.
2. The accuracy of manual and semi-automatic co-registration of ultrasound (US) and 
computed tomography (CT) images is better than that of automatic co-registration, 
based on experiments with the General Electric Logiq E9 navigation platform in a 
phantom.
3. Local tumor progression-free survival rates after combined RFA and drug-eluting 
bead transarterial chemoembolization (DEB-TACE) for HCC >3 are low compared to 
the results reported after combination therapy of conventional transarterial chemo-
embolization (TACE) followed by RFA.
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4. Catheter-directed CEUS is a potentially valuable imaging tool in adjunction to DSA 
when performing TACE and may provide similar information as catheter-directed 
computed tomography hepatic arteriography (CTHA).
5. Delivery of Y90 microspheres through the right inferior phremic artery (IPA) is fea-
sible and safe with the use of CTHA in addition to digital subtraction angiography 
and Tc-99m macroaggregated albumin (MAA) single photon emission computed 
tomography/integrated computed tomography (SPECT/CT).
6. The hepatic falciform artery detection rate of CTHA is superior to that of DSA and 
99mTc-MAA SPECT/CT.
7. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT parti-
tion modeling achieves high clinical success rates for safe and effective Y90 radioem-
bolization.
8. Percutaneous hepatic perfusion should be considered as a first line treatment in 
patients with liver metastases from ocular melanoma
9. The Delcath Systems’ second generation (GEN2) hemofiltration system has a higher 
melphalan filter efficiency compared to the first generation filters and a more consis-
tent performance. 
10. Patient safety and satisfaction improve significantly if patients receive consultation 
and screening in an interventional radiology (IR) outpatient clinic prior to elective IR 
procedures.
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Interventie oncologie is een deelspecialisme van de interventieradiologie dat sterk in 
opkomst is. Bij oncologische interventies wordt gebruik gemaakt van moderne beeld-
vormende technieken, zoals angiografie, computer tomografie (CT) of magnetische 
resonantie imaging (MRI). Die beeldvormende technieken maken het mogelijk heel 
gericht een gezwel te behandelen en de schade aan de rest van het lichaam beperkt te 
houden. Een ander kenmerk van oncologische interventies is dat ze minimaal invasief 
zijn. Er is doorgaans niet meer nodig dat een klein prikgaatje om een behandeling uit te 
voeren. Oncologische interventies bieden belangrijke voordelen voor patiënten boven 
chirurgische ingrepen en systemische chemotherapie. Omdat de behandelingen gericht 
en minimaal-invasief zijn, is de kans op complicaties beperkt, het herstel doorgaans 
sneller en zijn de kosten lager. 
Technologische ontwikkelingen hebben in de voorbije twee decennia verschil-
lende nieuwe behandelingen mogelijk gemaakt en bestaande therapieën verbeterd. 
Dit proefschrift is een bundeling van wetenschappelijk onderzoek dat is verricht naar 
verschillende nieuwe radiologische interventies bij de behandeling van patiënten met 
kanker in de lever. De meeste studies in dit proefschrift zijn verricht bij patiënten met 
kanker welke is ontstaan uit levercellen, zogenaamd hepatocellulair carcinoom (HCC). 
Jaarlijks overlijden circa 800.000 mensen in de wereld aan leverkanker en de kansen op 
genezing zijn klein voor personen bij wie de ziekte wordt geconstateerd. 
Deel 1 Radiofrequentie ablatie
In dit deel staat radiofrequentie ablatie (RFA) centraal. Bij radiofrequentie ablatie wordt 
onder beeldgeleide een naald geplaatst in een gezwel. De naald wordt vervolgens aan-
gesloten op een stroombron en door middel van een wisselstroom worden moleculen 
in het gezwel in trilling gebracht. Door de trilling van de moleculen ontstaat wrijvings-
warmte en zo kan de tumor worden verhit tot temperaturen die de tumorcellen niet 
overleven. Een gezwel kan zo als het ware worden weggebrand. Deze techniek is met 
name bij patiënten met HCC een aantrekkelijk alternatief voor een operatie. Circa 90% 
van de patiënten met HCC hebben een onderliggende leverziekte, zoals chronische 
leverontsteking (hepatitis) of cirrose. Als gevolg daarvan is het operatief verwijderen 
van een leverkankergezwel risicovol en soms zelfs onmogelijk. RFA is acht keer veiliger 
dan het operatief verwijderen van een HCC, maar met name bij grotere gezwellen is de 
kans na een operatie groter dat het gezwel in totaliteit is verwijderd. 
In hoofdstuk 2 worden de resultaten besproken van een onderzoek naar RFA in een 
groep patiënten met HCC in Singapore en Nederland. Hoewel in beide landen eenzelfde 
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internationale richtlijnen worden gehanteerd en dezelfde techniek en apparatuur wordt 
gebruikt, werden duidelijk verschillen gezien in uitkomsten tussen de Aziatische en 
Europese groep. Risicofactoren voor het terugkomen van de ziekte in de lever waren 
een gezwelgrootte van meer dan 3 centimeter en het hebben van meer dan 1 gezwel. 
De kans dat opnieuw een leverkankergezwel uitgroeide was 1.3 maal groter bij de Azi-
atische patiënten, maar toch was de sterfte na 5 jaar onder Aziatische patiënten bijna 
driemaal lager (4.9% versus 21.0% in de Europese groep). Mogelijke verklaringen voor 
de verschillen in uitkomst waren een hoger percentage in de Europese groep met een 
verder gevorderd ziektestadium, alcoholmisbruik als oorzaak voor de onderliggende 
leverziekte en verschillen in patiëntenselectie. 
In hoofdstuk 3 beschrijft een studie naar fusie-imaging, een techniek die helpt om met 
grotere precisie een RFA naald in een gezwel te plaatsen. Echografie is het best bruikbaar 
om een RFA naald op de juiste plaats te brengen, maar soms is een gezwel niet of slecht 
zichtbaar op echografie beelden. Er kan dan gebruik gemaakt worden van zogenaamde 
fusie-imaging. De beelden van een eerder gemaakte CT of MRI scan kunnen worden 
gekoppeld met de echografie beelden zodat toch kan worden bepaald waar de naald 
moet worden geplaatst. In een fantoom studie werden drie verschillende methoden van 
fusie imaging onderzocht: handmatige fusie, semi-automatische fusie en automatische 
fusie. De eerste twee methoden bleken meer accuraat dan de automatische fusie en 
de meest betrouwbare fusie werd verkregen door handmatige identificatie van multi-
pele overeenkomstige anatomische locaties op echografie beelden enerzijds en CT/MRI 
beelden anderzijds.
Zoals in hoofdstuk 2 werd aangetoond, is het risico dat een HCC terugkomt groter bij 
gezwellen groter dan 3 centimeter. In hoofdstuk 4 wordt combinatie behandeling van 
RFA en transarteriële chemoembolisatie (TACE) onderzocht bij patiënten met een HCC 
groter dan 3 cm. TACE is een behandeling waarbij via het slagaderlijk bloedvatstelsel 
een weg wordt gezocht naar de leverslagader en lokaal bolletjes met chemotherapie 
worden geïnjecteerd. Deze behandeling heeft op twee verschillende manieren effect op 
het gezwel: de bolletjes sluiten de bloedtoevoer van het gezwel af en geven geleidelijk 
het chemotherapeuticum af zodat de kankercellen gedurende dagen tot weken hieraan 
worden blootgesteld. In een retrospectieve studie vergeleken we de resultaten van RFA 
bij patiënten met een HCC ≤3 centimeter met die van RFA + TACE bij patiënten met een 
HCC > 3 centimeter. Ondanks de toevoeging van TACE bleken patiënten met een groter 
HCC een duidelijk slechtere prognose te hebben. Er is derhalve een blijvende noodzaak 
tot verbetering van de minimaal invasieve behandelmogelijkheden van patiënten met 
een HCC van >3 centimeter. 
215Nederlandse samenvatting
Deel 2 transarteriële therapieën
In dit deel van het proefschrift staan TACE, radioembolisatie en percutane leverperfusie 
centraal. Hierboven werd al TACE genoemd, waarbij bolletje geladen met chemothe-
rapie via het slagaderlijk bloedstelsel tot in een gezwel worden gebracht. TACE is de 
therapie van keuze bij patiënten met meerdere HCCs in de lever zonder uitzaaiingen 
buiten de lever. Hoofdstuk 5 beschrijft de resultaten van een pilot studie bij HCC 
patiënten die TACE ondergingen met een nieuwe beeldvormende methode. Digitale 
subtractie angiografie (DSA) is de standaard beeldvormende techniek om de bolletjes 
chemotherapie op de juiste plek te krijgen. Bij DSA wordt gebruik gemaakt van röntgen-
stralen en worden de bloedvaten zichtbaar gemaakt door contrastmiddel te injecteren. 
Een nadeel van DSA is dat de verkregen beelden alleen tweedimensionale informatie 
geven. Driedimensionale informatie kan wel verkregen worden door een CT scan te 
maken tijdens de injectie van contrastmiddel in de slagaderen. Deze techniek heet 
catheter-directed computed tomography hepatic arteriography (CTHA). Een nadeel is 
dat het gepaard gaat met relatief hoge dosis röntgenstraling. In de beschreven pilot 
studie werd aangetoond dat vergelijkbare driedimensionale informatie kon worden ver-
kregen met behulp van echografie en injecties van echo-contrastmiddel. Deze techniek, 
catheter-directed contrast-enhanced ultrasound (CCEUS) genoemd, gaat niet gepaard 
met schadelijke röntgenstraling. Bovendien geeft het echografie contastmiddel geen 
risico op nierfunctieverlies, in tegenstelling tot het jodium-houdend contrastmiddel dat 
gebruikt wordt bij DSA en CTHA.
Radioembolisatie is een andere en nieuwere transarteriële therapie  Hierbij wordt via 
het slagaderlijk bloedvatstelsel een dunne katheter geplaatst in de leverslagader om 
vervolgens bolletjes te laten inlopen welke zijn geladen met het radiotherapeutisch 
middel yttrium-90. Enkele dagen voor de eigenlijke behandeling ondergaat een patient 
angiografie waarbij een eiwit aggregaat wordt geïnjecteerd dat is gekoppeld aan tech-
netium-99. Dit eiwit aggregaat, technetium 99m-macro-aggregated albumin (Tc99m-
MAA), heeft een vergelijkbare grootte als yttrium-90 bolletjes. Wanneer na injectie van 
Tc99m-MAA een scan wordt gemaakt, kan de verdeling van yttrium-90 bolletjes worden 
voorspelt en de benodigde dosis radiotherapeutisch materiaal worden berekend. De 
scantechniek die hierbij wordt gebruikt heet single photon emission computed to-
mography with integrated computed tomography (SPECT/CT). Wanneer de verdeling 
van de ‘test’-dosis Tc99m-MAA zichtbaar wordt gemaakt, wordt de scan aangeduid als 
Tc99m-MAA SPECT/CT.
Een gevreesde complicatie van radioembolisatie is dat de bolletjes met yttrium-90 
buiten de lever terecht komen en zo stralingsschade veroorzaken aan de darmen of 
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longen. Er is veel informatie over hoe radioembolisatie veilig kan worden verricht via 
de leverslagader. Het is echter niet ongewoon dat een levergezwel ook bloed ontvangt 
via andere slagaders dan de leverslagader. In hoofdstuk 6 wordt aangtoond dat bij 
grote HCC gezwellen er in ruim eenderde van de gevallen ook een bloedvoorziening 
is van buiten de lever. Meest voorkomend bleek bloedtoevoer via de slagader van het 
middenrif, de arteria frenica inferior. In hoofdstuk 6 wordt in een kleine patientengroep 
aangetoond dat injectie van yttrium-90 bolletjes via de slagader van het middenrif veilig 
kan als in aanvulling op DSA ook gebruik gemaakt wordt van hoog geavanceerde beeld-
vormende technieken, zoals de hierboven genoemde CTHA en Tc99m-MAA SPECT/CT.
Ook in hoofdstuk 7 spelen DSA, CTHA en Tc99m-MAA SPECT/CT een belangrijke rol. 
In een retrospectieve studie bij HCC patienten wordt onderzocht hoe goed elk van de 
genoemde beeldvormende techniek in staat is om de arteria falcifome te identificeren. 
De arteria falciforme is een heel kleine slagader die verloopt van de lever naar de buik-
wandhuid. Als bij injectie van yttrium-90 in de leverslagader een deel van de bolletjes 
via deze slagader in de buikwand terecht komen kan dat leiden tot bestralingsschade 
aan de huid. Aangetoond wordt dat CTHA veel beter in staat is de arteria falciforme 
te identificeren dan DSA en Tc99m-MAA SPECT/CT: met CTHA werd bijna vier keer zo 
vaak een arterie falciforme gevonden. Uit deze studie bleek evenwel ook dat het zelden 
noodzakelijk is om extra voorzorgsmaatregelen te nemen bij patiënten met een kleine 
arteria falciforme.
Hoofdstuk 8 onderzoekt een nieuwe methode voor de planning van radioembolisatie 
en bepaling van de benodigde stralingsdosis yttrium-90. Meestal wordt een leverge-
zwel van bloed voorzien door verschillende aftakkingen van de leverslagader. Wanneer 
bolletjes yttrium-90 worden geïnjecteerd op een positie stroomopwaarts van de vertak-
kingen, is moeilijk te voorspellen hoeveel bolletjes elk afzonderlijk bloedvat instromen. 
Het kan dan zijn dan een deel van het gezwel een hoge stralingsdosis ontvang en een 
ander deel (te) weinig. De methode die onderzocht wordt in hoofdstuk 8 maakt het mo-
gelijk een meer voorspelbare en gelijkmatige verdeling van de yttrium-90 bolletjes te 
verkrijgen. De voedende slagaderen worden afzonderlijk gekatheteriseerd waarna met 
behulp van CTHA en Tc99m-MAA SPECT/CT de optimale dosis voor de elk stroomgebied 
apart wordt bepaald.
De laatste twee hoofdstukken van deel 2 handelen over onderzoeken naar percutane 
geïsoleerde leverperfusie, ookwel aangeduid met de engelse naam percutaneous he-
patic perfusion (PHP). Bij deze therapie wordt de bloedvoorziening van de lever als het 
ware gescheiden van die van de rest van het lichaam met behulp van verschillende 
katheters. Op die manier wordt het mogelijk een hoge dosis chemotherapie te geven 
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aan levergezwellen zonder de rest van het lichaam bloot te stellen aan die hoge dosis 
toxische medicatie.
Hoofdstuk 9 geeft een overzicht van de techniek van PHP, de huidige indicaties en 
gepubliceerde wetenschappelijke studies. Op basis van beschikbare studies kan worden 
geconcludeerd dat PHP een effectieve therapie is bij de behandeling van leveruitzaaiin-
gen van oogmelanoom. Bij de meerderheid van de patiënten treedt beenmergdepressie 
op veroorzaakt door een (beperkte) mate van blootstelling van het lichaam aan chemo-
therapie. De beenmergdepressie leidt in veel gevallen niet tot symptomen en zelden 
tot ernstige complicaties. In hoofdstuk 10 worden de eerste resultaten beschreven van 
twee klinische studies naar PHP. In genoemde studies werd gebruik gemaakt van een 
vernieuwd filter, waarmee het bloed uit de lever wordt gezuiverd alvorens het bloed te-
rug gepompt wordt naar de centrale bloedsomloop. Het nieuwe filter bleek effectiever 
en betrouwbaarder dan eerder gebruikte filtratiesystemen. Desondanks kwam toch een 
deel van de chemotherapie terecht in de centrale bloedsomloop en trad bij 80% van 
de patiënten beenmergdepressie op. Ook in deze studie hadden patiënten veelal geen 
klachten van de beenmergdepressie en waren ernstige complicaties zeldzaam.
Deel 3 Patiëntenzorg
Deel 3 van dit proefschrift bevat slechts één hoofdstuk, hoofdstuk 11, en betreft geen 
onderzoek wat zich specifiek richt op behandelingen van kanker in de lever. Vanwege 
het belang van het onderwerp is het toch in dit proefschrift opgenomen. De radiologie 
heeft zich in de voorbije decennia geconcentreerd op het leveren van efficiënte en kwa-
litatief hoogstaande diagnostiek en het verlenen van peri-procedurele zorg is niet gaan 
behoren tot haar kerntaken. Ondanks de toename in aantal en complexiteit van radio-
logische interventies, beschikken de meeste afdelingen radiologie niet over een eigen 
polikliniek en opnameafdeling. In de meeste centra is de zorg rondom radiologische 
interventies grotendeel uitbesteed aan verwijzend specialisten. In 2013 is de afdeling 
radiologie in het Leids Universitair Medisch Centrum (LUMC) gestart met een polikliniek 
interventieradiologie. In een observationele studie werd gedurende 3 maanden voor 
en na implementatie van de polikliniek de zorg rondom radiologische interventies 
geëvalueerd. De polikliniek interventieradiologie bleek een positief effect te hebben op 
de verleende zorg. Er werden na invoering van de polikliniek minder fouten gemaakt in 
de voorbereiding op de ingreep en patiënten waren tevredener over de behandeling 
omdat ze zich beter geïnformeerd en gehoord voelden.
slotwoord
RFA wordt veelvuldig ingezet bij de behandeling van HCC, maar wordt veelal gezien 
als alternatief voor patienten waarbij een operatie niet haalbaar is. RFA biedt evenwel 
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belangrijke voordelen (lagere kosten, minder complicaties en sneller herstel) en zou 
derhalve bij bepaalde patienten moeten gelden als eerste keus therapie. Op basis van 
gepubliceerd wetenschappelijk onderzoek is het aannemelijk dat RFA even effectief 
is als operatieve verwijdering bij patienten met een HCC kleiner dan 2 centimer, maar 
goede vergelijkende studies ontbreken nog. De resultaten van RFA bij grotere gezwellen 
dienen te worden verbeterd om het te maken tot een eerste keus therapie. Inmiddels is 
in het LUMC een start gemaakt met de HORA EST HCC studie. Hierbij worden patiënten 
met grotere HCCs behandeld met een combinatie van RFA en radioembolisatie met 
Holmium-166. Verder is gestart met onderzoek dat is gericht op verbeteringen in het 
evalueren van de zogenaamde ablatie marge, hetgeen een maat is voor hoe ruim een 
gezwel is weggebrand. 
De transarteriële therapieën TACE en radioembolisatie worden frequent ingezet als pal-
liatieve therapie bij patiënten met HCC. De in dit proefschrift opgenomen onderzoeken 
zijn er met name op gericht geweest met betere beeldvormende technieken te komen 
tot betere resultaten. Het gebruik van CTHA bij de planning en dosisberekening voor 
radioembolisatie heeft bewezen meerwaarde, maar er zijn nog weinig centra die de be-
nodigde apparatuur tot hun beschikking hebben. Mogelijk biedt cone-beam computed 
tomography (CBCT) een goed alternatief voor CTHA. Deze techniek is wel beschikbaar in 
de meeste centra en dankzij technologische verbeteringen benadert de beeldkwaliteit 
van CBCT inmiddels die van CTHA. De in het LUMC verrichtte onderzoeken naar PHP 
hebben geleid tot een acceptatie van PHP als eerste lijns palliatieve behandeling bij 
patiënten met leveruitzaaiingen van oogmelanoom. In een volgende studie hopen 
we PHP te combineren met immunotherapie om zo te komen tot betere lange termijn 
resultaten. 
Het is vrijwel ondenkbaar dat een patiënt voor een operatie verschijnt in de operatie-
kamer zonder vooraf gezien te zijn door een chirurg (in opleiding). Het is echter aan 
de orde van de dag dat een patiënt pas in de behandelkamer kennis maakt met de 
interventieradioloog. De studie in hoofdstuk 11 van dit proefschrift heeft aangetoond 
dat het voeren van een polikliniek interventieradiologie leidt tot een vermindering van 
fouten in de voorbereiding van een ingreep en tot meer patienttevredenheid. Deson-
danks behoort een polikliniek interventieradiologie in de meeste centra niet tot de 
gangbare praktijk en is er geen eenduidige vergoedingssystematiek voor een consult 
interventieradiologie. Het is aan de huidige generatie interventieradiologen om daar 
verandering in te brengen.
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